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Elimination of Endogenous toxin Creatinine from Blood Plasma 
such specificity in inhibitory potency, we carefully examined the relationship between the drug 
binding site(s) and the uremic toxin binding sites. In summary, accumulation of creatinine in 
patients with renal failure appears to account for a substantial portion of the impaired serum 
protein binding of drug especially at site I. Consequently, interactions of toxin and drug with 
respect to serum protein binding and renal excretion may increase the free fraction of drug in 
serum of patients with renal insufficiency (Sun et al. 2006). These findings lend further 
support to the hypothesis that a retained ligand(s) was responsible for impaired plasma binding 
associated with uremia and suggests a role for CTN known to accumulate in renal failure. 
Site I bound uremic toxin 
Site II bound uremic toxin 
Site I bound drug 




Scheme 3.1 Mechanism showing possible cascade displacement model in uremic toxin- drug system 
depicts allosteric effect of toxin when binding to site I and site II. Red colour: CTN 
binding to its high-affinity site, site I as shown by solid arrows: blue colour: CTN 
binding to its low-affinity site, site II as shown by dashed arrows. Hemodialytic reaction 




Ligand Binding Strategies of Human Serum Albumin: How can the Cargo Be Utilized? 
Human serum albumin (HSA), being the most abundant carrier protein in blood and a modem 
day clinical tool for drug delivery, attracts high attention among biologists. HSA binds a wide 
variety of drugs and a number of relatively insoluble endogenous and exogenous compounds, 
and then it facilitates their transport throughout the body. Depending on the drug and the 
target, high affinity for plasma proteins may consequently be a benefit or a drawback for 
efficacy. As far as lipophilic drugs are concerned, their binding to HSA results in improved 
solubility, and sometimes in decreased toxicity. Once administered, the free drug 
concentration can change because of interactions with other drugs and endogenous factors 
binding to HSA, or due to significant alterations of the serum carrier concentration upon 
illness. In particular, the competition between two drugs for their binding to albumin can 
significantly affect the disposition of both drugs, with possibly serious physiological 
consequences. These phenomena are very important if the drug is tightly bound (over 90%) to 
HSA. As an example, the concurrent administration of warfarin with phenylbutazone results 
in an enhanced risk of hemorrhage in patients due to higher concentration of the free 
anticoagulant drug because of its displacement from the shared binding site on albumin. In 
addition, enantioselective binding can be observed if the drug is chiral, because the two 
diastereomeric adducts formed between the single enantiomers and the protein can have 
different stability. When this is the situation, the single enantiomers act as distinct 
compounds, with their metabolism, distribution, and elimination being, in principle, different. 
Hence, its unfolding/refolding strategies and exogenous/endogenous ligand binding 
preference are of immense use in therapeutics and clinical biochemistry. Among its fellow 
proteins albumin is known to carry almost every small molecule. Thus, it is a potential 
contender for being a molecular cargo/or nanovehicle for clinical, biophysical and industrial 
purposes. Nonetheless, its structure and function are largely regulated by various chemical 
and physical factors to accommodate HSA to its functional purpose. This multifunctional 
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protein also possesses enzymatic properties which may be used to convert prodrugs to active 
therapeutics. This work aims to highUght current overview on the binding strategies of protein 
to various ligands that may be expected to lead to significant clinical applications. 
Comparative Studies of Unfolding and Binding of Ligands to Human serum albumin in 
the presence of Fatty Acid: Spectroscopic Approach 
This study was undertaken to investigate the influence of fatty acid binding on the unfolding 
of HSA and how the fatty acid molecules can influence and/or compete with other ligand 
molecules bound to the protein. The equilibrium unfolding of fatted and fatty acid free HSA 
was measured by overlapping of unfolding transition curves monitored by different probes for 
secondary and tertiary structure and determining changes in free energy of unfolding. Proteins 
stability was studied by fluorescence spectroscopy, whereas conformational changes were 
detected by circular dichroism techniques. We have suggested a "molten globule" like 
intermediate state of HSA at a fairly high concentration of GnHCl (3.2 M for fatty acid free 
and 3.6 M for fatted). The fi-ee energy of stabilization (AGH2O) in the presence of fatty acid 
was found to be 900 cal moFV We also analyze the effects of fatty acid on binding of ligands 
using spectroscopic technique and reported the equilibrium constants and free energies 
obtained fi-om the binding and unfolding experiments. On the basis of results obtained, the 
present study revealed how binding of fatty acids modulates the binding of diazepam (an 
anesthetic), bilirubin (increased concentration in jaundice) and hemin (a product of bilirubin). 
Nevertheless, the present study successfiiUy provides insights on the secondary and tertiary 
structure of HSA-FA complex as a step towards elucidating HSA under normal physiologic 
conditions. Specifically, making an important contribution to understanding the effect of the 
binding of fatty acids on conformational changes of HSA and its impact on ligand binding. 
Synopsis 
Elimination of Endogenous Toxin, Creatinine from Blood Plasma depends on Albumin 
Conformation: Site specific Uremic Toxicity & impaired drug binding 
Uremic syndrome results from a malfiinctioning of various organ systems due to the retention 
of compounds which, under normal conditions, would be excreted into the urine and/or 
metabolized by the kidneys. If these compounds are biologically active, they are called uremic 
toxins. The aim of this study was to elucidate the mechanisms underlying the renal 
elimination of uremic toxin creatinine that accumulate in chronic renal failure. Creatinine is 
the specific marker of renal function. The increase in serum creatinine is the result of uremic 
retention, but also can be due to muscle breakdown. Morbidity and mortality in hemodialyzed 
patients are positively correlated with serum creatinine. Quantitative investigation of the 
plausible correlations between uremic toxin and serum were performed by spectroscopy, 
calorimetry, molecular docking and accessibility of surface area. Alkalinization of normal 
plasma from pH 7.0 to 9.0 produced a small increase in binding of uremic toxin which 
becomes more abrupt under uremic conditions. This may modify its distribution in the body 
and therefore may affect both the accumulation and the rate of toxin elimination. Furthermore, 
the uremic abnormality supports the concept that a competing toxin, tightly bound at pH 9.0, 
was responsible for impaired drug binding. The accumulation of creatinine was presumably 
the known progressive decline of kidney function. The major amino acid residue being 
involved in the interaction was Arg257 which provides the guanidino group to the toxin. The 
evaluation of the degree of ligand loading of HSA with uremic toxin predicts several key side 
chain interactions of site I that presumably define the specificity between the toxin and plasma 
protein ligation pathways to maintain functional integrity of their signaling. Thus, 
accumulation of uremic toxin in body can be due to conformational change caused by neutral 
to basic transition which in turn may affect the site-site interactions between domain IIA and 
domain IIIA such that site interactions between domains will disappear. The findings obtained 
here will provide useful information for elucidating the complicated mechanism of drug and 
toxin disposition in renal disease state. 
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Heavy environmental Pollutants are carcinogenic: Probing the binding of drug having 
combating effect on Human Serum Albumin 
Environmental and occupational exposure to heavy metals is known to cause severe health 
hazards including prenatal and developmental defects. The interest in biological functions 
(benefits or toxic effects) of metal species has grovm enormously in recent years. In this 
work, different spectroscopic methods were applied to study the effects of the interaction of 
heavy metal ions in presence of anticancerous drug ganciclovir (GA2) with human serum 
albumin (HSA), considered as the most abundant plasma protein. Ganciclovir (GA2) is an 
important, pharmacologically active chemo preventive drug, but its interaction with potential 
macromolecular targets is completely unexplored. The binding of anticancer drug GA2 to 
HSA was investigated by using spectroscopic, calorimetric and molecular docking studies. 
The temperature-dependent ITC and fluorescence results indicate the interaction of one 
molecule of ganciclovir with protein molecule and suggest appreciable conformational 
changes as a result of binding. A predominance of hydrophobic interaction was observed. 
Thus, the results provide a quantitative understanding of the binding of ganciclovir to HSA, 
which is important in understanding their effect as therapeutic agents individually and in 
combination therapy. Molecular docking studies have probed the binding site of ganciclovir 
in domain II i.e. sudlow site I. Here, we report an as yet undescribed mode of heavy metal 
toxicity. Zn^* and Cd^ "^  proved to affect efficiently the spontaneous binding of ganciclovir 
inspite of different sites of binding to HSA. Albumin is the major transport protein in blood 
for Zn^* and Cd^ "^ , especially for Zn^^ a metal ion required for physiological processes and 
recruited by various drugs and toxins. Intriguingly, this site is located at the interface 
between two domains, and involves two residues from each of domains I and II. 
Comparisons of docked structures of free and ganciclovir bound human serum albumin 
suggest that zinc and cadmium binding to this site and ganciclovir to one of the drug site may 
be interdependent. Interactive binding of metal ions and drug to albumin may therefore have 
physiological implications. 
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PREFACE 
Albumin is one of the longest known and probably the most studied of all proteins. Its 
manifold diverse functions have attracted the interest of scientists and physicians for 
generations. Its applications are many, both in clinical medicine and in basic research. Yet, 
until now, no monograph has been published that brings together the fiill scope of albumin: its 
history, structure, physical and biological properties, genetics, metabolism, clinical 
applications, and its preparations and uses in the laboratory. As a nonglycosylated single chain 
of 585 amino acids tightly folded into three domains by 17 intrachain disulfide bonds, 
albumin offers a revealing model for study of the processes of expression, secretion, and 
intramolecular folding to produce the mature protein. Prompted by its multiple functions, 
many investigators have analyzed the mechanism and rate of biosynthesis and the catabolism 
of albumin, as well as its distribution in the serous fluids of the body. 
The repeating pattern of largely helical domains stabilized by multiple disulfide bonds is 
unique to the albumin family of proteins. Albumin itself is unique in its myriad affinities. 
How a protein with only two major binding sites can exhibit such diverse affinities is a puzzle 
to the protein chemist and a predicament for the pharmacologist. Crystallographic study of the 
binding of ligands has elucidated the complex nature of the sites in some instances, but many 
cases remain to be explained. 
The structure, properties, and ligand binding of albumin, described in chapter 1, are 
intimately cormected and constitute the prime interest of protein chemists, biochemists, and 
pharmacologists. The overview on the binding strategies of protein to various 
endogenous/exogenous ligands and clinical aspects of human serum albumin are interrelated 
but are described separately in this part of work highlighting it as a potential contender for 
being a molecular cargo/or nanovehicle for clinical, biophysical and industrial purposes. 
The reversible binding of endogenous fatty acids appears to improve the cytoprotective effect 
of S-nitrosylated HSA by facilitating S-transnitrosation from HSA to cellular target proteins. 
The second chapter deals with the unfolding mechanisms in denaturing condition induced by 
guanidine hydrochloride for the defatted form (HSA) and for the palmitic acid:albumin 
Preface 
(fHSA) complex. The palmitic acid ligand strongly stabilizes the protein, which remains in the 
native form up to high denaturant concentrations, characterized by a multiple-step 
mechanism.The palmitic acid induces local conformational changes that perturb the 
immediate environment of Trp-214.These observations suggest that the fatty acid binding site 
is located in the interior of domain II. 
Changes in serum albumin concentration in disease, typically the marked decline in 
malnutrition and in renal and liver disease, have long served as diagnostic and prognostic 
criteria, the third chapter of thesis highlights elimination of uremic toxin creatinine 
(conventional biomarker), an important therapeutic goal in clinical analytic domain. The 
accumulation of creatinine was presumably the known progressive decline of kidney function 
and predicts several key side chain interactions of site I that presumably define the specificity 
between the toxin and plasma protein ligation pathways to maintain functional integrity of 
their signaling. 
Acute and chronic toxicoses caused by heavy metal ions mainly involving zinc, cadmium, 
mercury and lead are known for all forms of life. Human serum albumin is useful as a model 
system for studying the metal binding properties of other vertebrate serum proteins. The last 
part of my thesis i.e. fourth chapter provides a strategy that could combat the hazardous and 
toxic effects of complex formation against environmental pollutants. Crosstalk between metal 
ions and anticancerous drug status could provide a strategic approach to fight against the 
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Ligand Binding Strategies of Human Serum Albumin: How can the Cargo Be 
Utilized? 
Human serum albumin (HSA), being the most abundant carrier protein in blood and a 
modern day clinical tool for drug delivery, attracts high attention among biologists. HSA 
binds a wide variety of drugs and a number of relatively insoluble endogenous and 
exogenous compounds, and then it facilitates their transport throughout the body. 
Depending on the drug and the target, high affinity for plasma proteins may consequently 
be a benefit or a drawback for efficacy. As far as lipophilic drugs are concerned, their 
binding to HSA results in improved solubility, and sometimes in decreased toxicity. Once 
administered, the free drug concentration can change because of interactions with other 
drugs and endogenous factors binding to HSA, or due to significant alterations of the 
serum carrier concentration upon illness. In particular, the competition between two drugs 
for their binding to albumin can significantly affect the disposition of both drugs, with 
possibly serious physiological consequences. These phenomena are very important if the 
drug is tightly bound (over 90%) to HSA. As an example, the concurrent administration of 
warfarin with phenylbutazone results in an enhanced risk of hemorrhage in patients due to 
higher concentration of the free anticoagulant drug because of its displacement from the 
shared binding site on albumin. In addition, enantioselective binding can be observed if 
the drug is chiral, because the two diastereomeric adducts formed between the single 
enantiomers and the protein can have different stability. When this is the situation, the 
single enantiomers act as distinct compounds, with their metabolism, distribution, and 
elimination being, in principle, different. Hence, its unfolding/refolding strategies and 
exogenous/endogenous ligand binding preference are of immense use in therapeutics and 
clinical biochemistry. Among its fellow proteins albumin is known to carry almost ever\ 
small molecule. Thus, it is a potential contender for being a molecular cargo/or 
nanovehicle for clinical, biophysical and industrial purposes. Nonetheless, its structure and 
function are largely regulated by various chemical and physical factors to accommodate 
HSA to its functional purpose. This multifunctional protein also possesses enzymatic 
1 
Abstract 
properties which may be used to convert prodrugs to active therapeutics. This work aims 
to highlight current overview on the binding strategies of protein to various ligands that 
may be expected to lead to significant clinical applications. 
Comparative Studies of Unfolding and Binding of Ligands to Human serum 
albumin in the presence of Fatty Acid: Spectroscopic Approach 
This study was undertaken to investigate the influence of fatty acid binding on the 
unfolding of HSA and how the fatty acid molecules can influence and/or compete with 
other ligand molecules bound to the protein. The equilibrium unfolding of fatted and fatty 
acid free HSA was measured by overlapping of unfolding transition curves monitored by 
different probes for secondary and tertiary structure and determining changes in free 
energy of unfolding. Proteins stability was studied by fluorescence spectroscopy, whereas 
conformational changes were detected by circular dichroism techniques. We have 
suggested a "molten globule" like intermediate state of HSA at a fairly high concentration 
of GnHCI (3.2 M for fatty acid free and 3.6 M for fatted). The free energy of stabilization 
(AGH2O) in the presence of fatty acid was found to be 900 cal mofV We also anahze the 
effects of fatty acid on binding of ligands using spectroscopic technique and reported the 
equilibrium constants and free energies obtained from the binding and unfolding 
experiments. On the basis of results obtained, the present study revealed how binding of 
fatty acids modulates the binding of diazepam (an anesthetic), bilirubin (increased 
concentration in jaundice) and hemin (a product of bilirubin). Nevertheless, the present 
study successfully provides insights on the secondary and tertiary structure of HSA-FA 
complex as a step towards elucidating HSA under normal physiologic conditions. 
Specifically, making an important contribution to understanding the effect of the binding 
of fatty acids on conformational changes of HSA and its impact on ligand binding. 
Abstract 
Elimination of Endogenous Toxin, Creatinine from Blood Plasma depends on 
Albumin Conformation: Site specific Uremic Toxicity & impaired drug binding 
Uremic syndrome results from a malfunctioning of various organ systems due to the 
retention of compounds which, under normal conditions, would be excreted into the urine 
and/or metabolized by the kidneys. If these compounds are biologically active, they are 
called uremic toxins. The aim of this study was to elucidate the mechanisms underlying 
the renal elimination of uremic toxin creatinine that accumulate in chronic renal failure. 
Creatinine is the specific marker of renal function. The increase in serum creatinine is the 
result of uremic retention, but also can be due to muscle breakdown. Morbidity and 
mortality in hemodialyzed patients are positively correlated with serum creatinine. 
Quantitative investigation of the plausible correlations between uremic toxin and serum 
were performed by spectroscopy, calorimetry, molecular docking and accessibility of 
surface area. Alkalinization of normal plasma from pH 7.0 to 9.0 produced a small 
increase in binding of uremic toxin which becomes more abrupt under uremic conditions. 
This may modify its distribution in the body and therefore may affect both the 
accumulation and the rate of toxin elimination. Furthermore, the uremic abnormality 
supports the concept that a competing toxin, tightly bound at pH 9.0, was responsible for 
impaired drug binding. The accumulation of creatinine was presumably the known 
progressive decline of kidney function. The major amino acid residue being involved in 
the interaction was Arg257 which provides the guanidino group to the toxin. The 
evaluation of the degree of ligand loading of HSA with uremic toxin predicts several key 
side chain interactions of site I that presumably define the specificity between the toxin 
and plasma protein ligation pathways to maintain functional integrity of their signaling. 
Thus, accumulation of uremic toxin in body can be due to conformational change caused 
by neutral to basic transition which in turn may affect the site-site interactions between 
domain IIA and domain IIIA such that site interactions between domains will disappear. 
The findings obtained here will provide useful information for elucidating the complicated 
mechanism of drug and toxin disposition in renal disease state. 
Abstract 
Heavy environmental Pollutants are carcinogenic: Probing the binding of drug 
having combating effect on Human Serum Albumin 
Environmental and occupational exposure to heavy metals is known to cause severe 
health hazards including prenatal and developmental defects. The interest in biological 
functions (benefits or toxic effects) of metal species has grown enormously in recent 
years. In this work, different spectroscopic methods were applied to study the effects of 
the interaction of heavy metal ions in presence of anticancerous drug ganciclovir (GA2) 
with human serum albumin (HSA), considered as the most abundant plasma protein. 
Ganciclovir (GA2) is an important, pharmacologically active chemo preventive drug, but 
its interaction with potential macromolecular targets is completely unexplored. The 
binding of anticancer drug GA2 to HSA was investigated by using spectroscopic, 
calorimetric and molecular docking studies. The temperature-dependent ITC and 
fluorescence results indicate the interaction of one molecule of ganciclovir with protein 
molecule and suggest appreciable conformational changes as a result of binding. A 
predominance of hydrophobic interaction was observed. Thus, the results provide a 
quantitative understanding of the binding of ganciclovir to HSA, which is important in 
understanding their effect as therapeutic agents individually and in combination therapy. 
Molecular docking studies have probed the binding site of ganciclovir in domain II i.e. 
sudlow site 1. Here, we report an as yet undescribed mode of heavy metal toxicity. Zn^ "^  
emd Cd^ ^ proved to affect efficiently the spontaneous binding of ganciclovir inspite of 
different sites of binding to HSA. Albumin is the major transport protein in blood for 
Zn^ * and Cd^^ , especially for Zn^ * a metal ion required for physiological processes and 
recruited by various drugs and toxins. Intriguingly, this site is located at the interface 
between two domains, and involves two residues from each of domains I and 11. 
Comparisons of docked structures of free and ganciclovir bound human serum albumin 
suggest that zinc and cadmium binding to this site and ganciclovir to one of the drug site 
may be interdependent. Interactive binding of metal ions and drug to albumin may 
therefore have physiological implications. 
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List of Figures Pg.No. 
Figure 1.1 Summary of the ligand binding capacity of HSA as defined by 9 
crystallographic studies to date. The domains are colour coded as follows: I, magenta; II, 
green; III, blue. The A and B subdomains are depicted in light and dark shades, 
respectively. Inset shows binding location of prototypical ligands (bilirubin, PDB ID, 
2VUE; thyroxine, PDB ID, IHKI; diazepam, PDB ID, 2BXF and propofol, PDB ID, 
1E7A) on respective domains. 
Figure 1.2 Crystal Structures of HSA complexed with three different fatty acids. Bound 11 
fatty acids are shown in yellow colour space filling representation. This colour scheme is 
maintained throughout. (A) myristic acid complexed with thyroxine (blue colour) [PDB 
ID, 1HK4]; (B) stearic acid [PDB ID, 1E7I]; (C) palmitic acid [PDB ID, 1E7H] ; (D) the 
protein secondary structure is shown schematically with the domains colour-coded as 
follows: I, magenta; II, green; III, blue. The dashed line shows GA module binding site at 
domain IIA. All Figures were prepared using Pymol software (version 0.99). 
Figure 1.3 (a) Sudlow Site I binding cavity (HSA), (b) hydrophobic cavity (CAV-I) 15 
inside site I, (c) hydrophilic cavity (CAV-2) located inside site I, (d) Sudlow Site II. 
Figure 1.4 Electrostatic potential surface representations of GA binding interfaces. Red 17 
indicates negatively charged surface areas and blue indicates positively charged surface 
areas. Key interface residues are iridicated with text. The binding surfaces are marked 
with yellow borders. (A) Chain A of the crystal GA dimer. (B) Chain B of the crystal GA 
dimer. (C) The binding site for HSA on the GA module. (D) The GA-binding surface on 
HSA. 
Figure 1.5 Correlations between conformational transitions and domain isomerization 21 
Figure 2.1 Guanidine hydrochloride denaturation profile of fatted ( • ) and fatty acid free 33 
HSA (O) as monitored by measurements of MRE at 222 nm. The shapes (a) and (A) 
represent the reversibility points for fatted and fatty acid free HSA obtained by diluting 
the denatured protein in 6M GnHCi respectively. 
Figure 2.2 Guanidine hydrochloride denaturation profile of fatted ( • ) and fatty acid free 34 
HSA (O) as monitored by (A) intrinsic fluorescence measurement at 340 nm (B) The 
change in fluorescence intensity monitored by FI 310/350 ratio. The protein (3.5|.i M) 
was excited at 280 nm. The shapes (D) and (A) represent the reversibility points for 
fatted and fatty acid free HSA obtained by diluting the denatured protein in 6M GnHCl 
respectively. 
Figure 2.3 Normalized transition curves for GnHCl induced unfolding of fatted and fatty 36 
acid free HSA as followed by measurements of MRE at 222 nm ( • ) , Intrinsic 




Figure 2.4 Effect of GnHCl concentration on lone Trp-214 fluorescence of fatted HSA 39 
( • ) and fatty acid free HSA (O). (A) Trp-214 fluorescence at 340 nm after exciting the 
protein at 295 nm (B) Normalized transition curves as followed by Trp-214 fluorescence 
at 340 nm. (C) Shows the dependence of free energy change of HSA and fHSA as a 
function of GnHCl concentration shown in (B). 
Figure 2.5 Dependence of free energy changes of (A) fatty acid free HSA and (B) fatted 
HSA on GnHCl concentrations for N ^ I and 1=^ D transitions. 
40 
Figure 2.6 Dependence of free energy changes of (A) fatty acid free and (B) fatted HSA 41 
on GnHCl concentration for N=F^  I and I^ D transitions. 
Figure 2.7 (A) Fluorescence quench titration results of hemin binding to fatted HSA ( • ) .^ 
and fatty acid free HSA (O). (B) Log [(Fo-F)/F] versus log [Q] plots fatted ( • ) and fatty 
acid free (O) conformations of HSA for binding constants and binding sites. 
Figure 2.8 (A) Fluorescence quench titration results of Diazepam binding to fatted HSA .^ 
( • ) and fatty acid free HSA (O). (B) Log [(Fo-F)/F] versus log [Q] plots fatted ( • ) and 
fatty acid free (O) conformations of HSA for binding constants and binding sites. 
Figure 2.9 Relative Fluorescence of Bilirubin bound to fatted HSA ( • ) and fatty acid 45 
free HSA (O). The fluorescence was recorded at 525 nm after exciting the biiirubin-
albumin complex at 466 nm. 
Figure 2.10 A pictorial model representing the structure and different domains of Human 47 
Serum Albumin. The palmitic acid binding site 2 ( • ) , site 6(#), and site 7(A) are 
modeled on the basis of crystal structure of the HSA liganded to fatty acid (Bhattacharya 
et al. 2000). 
Figure 3.1 Melting thermograms of Human Serum Albumin under normal (A and B) and 5^ 
uremic (C and D) conditions at pH 7.0 (A and C) and pH 9.0 (B and D). 
Figure 3.2 Isothermal titration calorimetry of N isomer B and isomers of Human serum 58 
albumin at pH 7.0 (A) and 9.0 (B) respectively at 25°C. In the top panels, the heat 
released per unit time (ncal/sec) was plotted vs time where each peak corresponds to the 
injection of an aliquot of ligand. In the bottom panels, the heat of reaction per injection 
(kcal/mole) was determined by integration of the area under each peak, plotted vs [CTN]/ 
[HSA], and fit using the software provided by Microcal. (C) Comparative distribution of 
AH, TAS and AG at pH 7.0 (dark grey) and pH 9.0 (light grey). 
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Figure 3J FTIR spectra in the region 1800-1400 cm"' at pH 7.0 (A) and pH 9.0 (B) for 60 
the free HSA, free CTN and difference spectra of HSA-CTN complexes (bottom two 
curves) obtained under normal serum (ACR=5) to uremic condition (ACR=0,25) 
(indicated in the figure). 
Figure 3.4 Curve fitted amide I region (1700-1600 cm"') with secondary structure 61 
determination of the free HSA and its toxin adducts in aqueous solution with varying 
ACR molar ratios and SOOuM protein concentrations at pH 7.0 (A) and pH 9.0 (B). 
Figure 3.5 Stem-Volmer (A«fcC) and modified Stem-Volmer (B&D) plots of uremic 64 
toxin creatinine quenching for N (A&B) and B (C&D) isomeric conformations of HSA. 
Each data point was the mean of 3 independent observations (S.D. ranging 0.03-0.4%). 
The Protein was excited at 280 (•) and 295nm (0). 
Figure 3.6 Representative CD and UV spectra obtained following the titration of the 65 
buffer solution of HSA with creatinine at (A) pH 7 and (B) pH 9. Spectral contributions 
of the protein alone were subtracted from the spectra of the toxin-protein mixture ([HSA] 
= lOO^M, T = 25°C). Asmax values calculated on the basis of the total ligand 
concentrations are displayed at the different molar ratios (L/P). Arrows denote increasing 
concentration of uremic toxin CTN. 
Figure 3.7 Results of CD displacement experiments performed with warfarin, 66 
phenylbutazone, ibuprofen and diazepam on HSA-CTN complex at (A) pH 7.0 and (B) 
pH 9.0 (1=1 cm, T=25°C). Displacers were added as ^1 aliquots of stock solutions. 
Positive induced CD values measured at 278 nm were plotted against displacer/creatinine 
molar ratios. 
Figure 3.8 (A) Molecular surface representations of HSA showing site I specific markers 68 
[warfarin (limegreen); phenylbutazone (yellow)] and the toxin CTN (red) at binding site 
1. (B) One hydrogen bond (as highlighted by the yellow dashed line) was formed between 
CTN and Arg257 of HSA. The hydrogen bond length was represented in yellow colour 
(C) Other site I amino acid residues of HSA interacting with CTN within 5 A distance. 
Figure 3.9 (A) Molecular surface representations of HSA showing site II specific 69 
markers [ibuprofen (light orange); diazepam (magenta)] and the toxin CTN (red) at 
binding site II. (B) The toxin molecule forming repulsive interaction (white colour) with 
Phe488 of HSA (as highlighted by the white dashed line). (C) Other site II amino acid 
residues of HSA interacting with CTN within 5 A distance. 
Figure 4.1 (A) Fluorescence Emission spectra of HSA in the presence of increasing 86 
concentrations of Ganciclovir. (T = 298 K, lex = 295 nm). Concentration of HSA = 5 
^M; concentration of GA2 (10"" nM) varies, A-I: 0, 0.8, 1.6, 2.4, 3.2, 4.0, 4.8, 5.6, and 
6.4, respectively; curve J (dashed line) shows the emission spectrum of drug only. 
(B) Corresponds to the modified Stem-Volmer plot for drug -protein complex. 
VII 
Figures 
Figure 4.2 Linear Van't Hoff Plots for determining the binding constant, K, of HSA- 88 
ganciclovir (X.ex = 295 nm, X,em=340 nm, pH=7.4, concentration of HSA = 7.5x10"' ^M, 
ganciclovir = 8.02x1 Q-^ nM) at 298K {filled circles); 308 K (squares); 318 K (filled 
triangles) and 328 K (diamonds). (B) Variation of In K as a function of 1/T. 
Figure 4.3 (Upper panel) Raw data for the titration of 8.02x10" |^iM ganciclovir with 12.3 90 
\iM HSA at pH 7.4 and 298K, showing the calorimetric response as successive injections 
of the ligand are added to the sample cell. (Lower panel) Integrated heat profile of the 
calorimetric titration shown in upper panel. The solid line represents the best nonlinear 
least-squares fit to a single binding- site model. 
Figure 4.4 Binding isotherms for the titration of 8.02x10'^ pM ganciclovir with 12.3|iM ^1 
HSA at pH 7.4 and various temperatures: 298K (•), 308K (•), 318K (A) and 328 K (•). 
Figure 4.5 (A) Plot of enthalpy against temperature (B) Enthalpy-entropy compensation 
plot for the binding of ganciclovir to HSA at pH 7.4 and 298K 
Figure 4.6 (A) Schematic representation of HSA, with its corresponding domains and 
subdomains. The enlarged area corresponds to the Sudlow site I binding region showing 
predicted binding site for ganciclovir on HSA. This figure was prepared by using Pymol. 
(B) Graphical representation of HSA showing GA2 docked in the binding pocket of HSA 
using GOLD v3.1, depicted in stick model (centre) and HSA, represented in solid with 
ray model. LIGPLOT of the intermolecular interaction of the complex between 
ganciclovir and HSA showing hydrogen bonding between Arg 222 of HSA and GA2. 
Polar contacts are shown with dashed lines, and hydrophobic contacts are indicated by 
arcs with radiating spokes. Carbon, nitrogen and oxygen atoms are shown in black, blue 
and red, respectively. 
Figure 4.7 Effect of metal ions on the UV absorption of HSA in absence (A) and 
presence of ganciclovir (B). The concentration of HSA was fixed at 12nM. Curve I is the "" 
spectrum of native HSA (A) and HSA complexed with ganciclovir (8.02x1 0"VM) (B). 
Curve 2 to 6 corresponds to the spectra of arsenic, selenium, lead, cadmium and zinc 
respectively in absence (A) and presence of ganciclovir (B) at their maximum saturating 
concentrations. 
Figure 4.8 Effect of metal ions on the far UV CD spectra of HSA in absence (A) and 
presence of ganciclovir (B). The concentration of HSA was fixed at 6(iM. Curve 1 is the 
spectrum of native HSA (A) and HSA complexed with ganciclovir (8.02x10"''|iM) (B). 
Curve 2 to 6 corresponds to the spectra of arsenic, selenium, lead, cadmium and zinc 






Figure 4.9 (A) Far UV CD spectra of HSA (6nM) bound with Cd^l HSA was treated 98 
with Cd*^  at varying increasing concentrations at the molar ratio ([HSA]: [Cd* ]^) of 
curves (1) 1: 0 (2) 1:5 (3) 1:10 (4) 1:15 (5) 1:20 (6) 1:25 (7) 1:30 (8) 1:40 (9) 1:45 (10) 
1:50 after appropriate incubation at 298K in 20mM Tris-HCl buffer at pH 7.4. (B) The 
plot of ellipticity at 208 nm (•) and 222 nm (o) versus the molar ratio of cadmium to 
HSA. 
Figure 4.10 (A) Far UV CD spectra of HSA (6nM) bound with ganciclovir (8.02x10" 99 
''nM). HSA: GA2 complex was further treated with Cd*^  at varying increasing 
concentrations at the molar ratio ([HSA]: [GA2]:[Cd^^]) of curves (1) 1:1:0 (2) 1:1:5 (3) 
1:1:10(4) 1:1:15(5) 1:1:20(6) 1:1:25(7) 1:1:30(8) 1:1:40(9) 1:1:45(10) 1:1:50 after 
appropriate incubation at 298K in 20mM Tris-HCl buffer at pH 7.4. (B) The plot of 
ellipticity at 208 nm (•) and 222 nm (o) versus the molar ratio of cadmium to HSA-GA2 
complex. 
Figure 4.11 (A) Far UV CD spectra of HSA (6^M) bound with Zn^^ HSA was treated 100 
with Cd"^ ^ at varying increasing concentrations at the molar ratio ([HSA]: [Zn"^]) of 
curves (1) 1: 0 (2) 1:5 (3) 1:10 (4) 1:15 (5) 1:20 (6) 1:25 (7) 1:30 (8) 1:40 (9) 1.45 (10) 
1:50 after appropriate incubation at 298K in 20mM Tris-HCl buffer at pH 7.4. (B) The 
plot of ellipticity at 208 nm (•) and 222 nm (o) versus the molar ratio of cadmium to 
HSA. 
Figure 4.12 (A) Far UV CD spectra of HSA (6nM) bound with ganciclovir (8.02x10 101 
^^M). HSA: GA2 complex was further treated with Zn*^  at varying increasing 
concentrations at the molar ratio ([HSA]: [GA2]:[Zn*^]) of curves (1) 1:1:0 (2) 1:1:5 (3) 
1:1:10 (4) 1:1:15 (5) 1:1:20 (6) 1:1:25 (7) 1:1:30 (8) 1:1.40 (9) 1:1:45 (10) 1:1:50 after 
appropriate incubation at 298K in 20mM Tris-HCl buffer at pH 7.4. (B) The plot of 
ellipticity at 208 nm (•) and 222 nm (o) versus the molar ratio of cadmium to HSA-GA2 
complex. 
Figure 4.13 FT-IR spectra showing Amide 1 and Amide II bands in the region of 1800- 103 
1400 cm"' of hydrated films (pH 7.4) for free HSA, and difference spectra of metal 
complexes obtained after 1 hr incubation time in Tris-HCl buffer, pH 7.4 solution. 
Figure 4.14 FT-IR spectra showing Amide I and Amide II bands in the region of 1800-
1400 cm' of hydrated films (pH 7.4) for HSA complexed with ganciclovir, and 104 
difference spectra of metal complexes obtained after Ihr incubation time in Tris-HCl 
buffer, pH 7.4 solution. 
Figure 4.15 Fourier Self deconvulated spectra in amide I region of Free HSA and its 106 
metal complexes in Tris HCl Buffer solution in absence of ganciclovir. The secondary 
structure determination by curve fitting procedure is indicated. 
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Figure 4.16 Fourier Self deconvulated spectra in amide 1 region of HSA and its metal 107 
complexes in Tris-HCl Buffer solution in presence of ganciclovir. The secondary 
structure determination by curve fitting procedure is indicated. 
Figure 4.17 Proposed Cd^ ^ and Zn*^  site in HSA. (A) Domain structure of albumin (PDB 110 
ID code 1A06): domain I is colored red (residues 1-181); domain II is blue (residues 
188-373); domain III is green (residues 380-571), and connecting helices are the same 
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U6AND BINDIN6 STRAT£ei£S OF 
HUMAN S£RUM ALBUMIN: 
HOW CAN TH£ CAR60 fi£ UTUJZ£D? 
Ligand binding Strategies of Human Serum Albumin 
I luman serum albumin (HSA) is an abundant, multifunctional and non-
-*--"glycosylated, negatively charged plasma protein, with ascribed ligand-binding 
and transport properties, antioxidant functions, and enzymatic activities (Peters 1996). The 
protein is a monomer of 585 amino acid residue having three homologous a-helical 
domains, named domain I, domain II and domain III (He and Carter 1992). Each domain 
contains ten helices and is divided into antiparallel six-helix and four-helix sub-domains (A 
and B). Albumin is the most abundant serum protein that serves as a transport vehicle for 
several endogenous compounds including fatty acids (FA), hemin, bilirubin, and 
tryptophan, all of which bind with high affinity (Dockal et al. 2000; Dill and Shortie 1991). 
For a long time, albumin has attracted the attention of the pharmaceutical industry because 
of its ability to bind a wide variety of drug molecules and alter their pharmacokinetic 
parameters (Simard et al. 2005). Although most ligands for albumin are hydrophobic or 
anionic but heavy metals are also known to bind to the protein (Dockal et al. 2000; Dill and 
Shortie 1991; Simard et al. 2005; Flora et al. 1998; Wallevik 1973). Very few cationic 
drugs are also known to bind with HSA. This versatility, which arises from the presence of 
multiple binding sites, which are dependent on various environmental factors like pH, 
temperature and ionic strength, makes it far from trivial to obtain detailed information on 
ligand binding. It has been especially difficult to assess the interactions between different 
ligands for the protein even though it is a key for our understanding of the role of human 
serum albumin in vivo. Simultaneous binding of several ligands to HSA molecule is a 
complex situation in which the protein recognizes individual ligands by specific and 
nonspecific interactions. This recognition is in turn strongly dependent on the 
microenvironment of the protein as it changes its conformation in-vivo. In physiological 
condition the protein experienced various environments like pH, varying ionic strength, 
etc., which induces considerable changes in the native protein structure. Under such 
condition how it recognizes different drug/ligand molecules is a challenging field of 
investigation. Various binding and denaturation studies have shown to be a rapid and 
effective tool for the characterization of albumin binding sites and their enantioselectivity, 
and for the study of the changes in the binding properties of the protein arising by 
interaction between different ligands. 
Llgand binding Strategies of Human Serum Albumin 
1.1 Historical Perspective 
The name albumin evolved from the more general term, albumen, the early German word 
for protein. Its origin was Latin, albus (white), the colour of that part of an egg surrounding 
the yolk when it is cooked. Albumen is used for the white of an egg, for the secretion of the 
snail, and for urinary proteins as a group, whereas the in-ending refers to the specific 
protein from blood plasma or to a protein with similar properties. Albumin, hemoglobin, 
and fibrin were probably the first proteins of the body to be studied. The Greek physician 
Hippocrates noted in his Aphorisms that foamy urine, in all likelihood caused by the 
presence of albumin, indicates chronic kidney disease. Harvey in 1616 described the 
circulation of the blood serum as the fluid that extrudes from clotted blood as it contracts 
on standing. They recognized that serum contained protein, or "albumen". Several 
reviewers have cited that "albumen is doubtless one of the most important of the animal 
proximate principles; it is found not only in the serum of the blood but in lymph, chyle, in 
the exhalation from surfaces, in the fluid of cellular tissue, in the aqueous and vitreous 
(humors) of the eye. Howe in 1921 published a procedure for serum protein assay; the ratio 
of soluble to precipitated protein became the albumin/globulin ratio, or A/G ratio, which is 
still used as a rough index of health. Table 1.1 lists the chronology of events related to our 
current knowledge of the albumin molecule. It touches on structure, genetics, metabolism, 
clinical applications, and commercial production, topics that are expanded in the 
succeeding chapters. The greatest impetus to the preparation of albumin as a pure protein 
came during World War II. It was selected in 1940 as a blood substitutes on transfusion as 
being more stable, less antigenic, and less viscous than whole plasma. Subsequent studies 
have shown that many of the functions performed by albumin can be assumed by other 
plasma proteins, but there remain disturbances of lipid metabolism in its absence, and there 
may be unrecognized physiological roles of the trace amounts of albumin that are 
invariably present. There is much that we understand about albumin biochemistr}: the 
basis for its flexibility and stability (presumably inherent in its triple domain structure with 
numerous disulfide bonds), the location of some of its binding sites, the steps of its 
biosynthesis, and the cause of the rare and intriguing condition under diseased states. 
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Table 1.1 Chronological Achievements of Human Serum Albumin 
Year Comments Reference 
1940 Prepared bovine and then human albumin for intravenous use 
1947 Crystallized human albumin mercury dimer 
1960 Studied isomeric forms: proposed "domain" type of structure 
1971 Studied cyanogens bromide fragments of human albumin 
1975 Deduced amino acid sequence of human albumin 
1979 Isolated gene for human albumin 
1986 Reported complete gene sequence of human albumin 
1989 Molecular defects in genetic variants of HSA 
1992 Found heart like crystal structure of human albumin 
1999 Crystal structure of human serum albumin at 2.5A 
2004 Albumin fusion technology 
2005 The detection and measurement of microalbuminuria 
2008 Type 2 Diabetic Nephropathy and Microalbuminuria 
2008 Hypoalbuminaemia~a marker of cardiovascular disease 
2009 Water soluble metabolites in blood and urine 
2009 HSA and Alzheimer's disease 
2009 HSA for cell therapy and in-vitro diagnostics 
2009 HSA, suppressing Delayed-type hypersensitivity 
2009 Albumin nanoparticles in stimulation of new bone formation 
2009 HSA and Hemophilia A 
2009 Release of albumin derived mRNA 
2009 Albumin dialysis with MARS and SPAD 
2009 HSA in Endotoxic Shock 
2009 Serum tumor markers for colorectal cancer 
2009 Albumin in treatment of breast cancer 
2009 Multidrug Resistance and serum albumin 
2009 Albumin in Ischemic Disorders 
2009 Heme-HSA structure-function relationships 
2009 Serum biomarkers for detection of ovarian cancer 
2009 Transformation of HSA to blood clot component 
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2009 Hermann Senator and albuminuria Gansevoort and Ritz 2009 
2009 Plasma albumin mRNA in liver pathologies Chan et al. 2009 
2010 ARG: A new member of albumin gene family Naidu e/ a/. 2010 
1.2 The Albumin Molecule: Its sequence and crystal structure 
The complete amino acid sequence of albumin was determined by Meloun et al. (1975), 
and its covaJent structure exists to be a single peptide chain grouped into a series of nine 
disulfide-bonded loops involving adjacent half-cystine residues from the amino terminus, 
differing in ligand-binding functions. In its repeating-loop structure albumin bears a 
resemblance to the second most prominent extracellular protein, immunoglobulin G (IgG). 
The longer double loops in albumin contain about 55 residues; the loops of IgG contain 
about 60. These two proteins are the most long lived of the proteins in plasma, with 
biological half-lives of about 20 days for albumin and 27 days for IgG, longevities that are 
probably attributable in large measure to the stability and flexibility afforded by their loop 
structures in contending with the constant trauma of the circulation. Sequences and 
disulfide bonding patterns of human serum albumin were shown in one letter amino acid 
code in Scheme 1.1. The biosynthesis of albumin has been found to involve a precursor 
form, termed "prealbumin", in which a basic hexapeptide (Arg-Gly-Phe-Val-Arg-Arg) is 
attached to the amino end of the chain. The need for a protective peptide is readily 
appreciated to keep this powerful enzyme inactive until it reaches the gut. HSA, however, 
is able to form disulfide bridges unaided, and has no major known enzymatic activity that 
might need to be suppressed. Perhaps a critical ligand-binding activity must be prevented 
while the albumin is within the cell; the cleaved hexapeptide may serve as regulator of 
albumin synthesis. Based on sequence data analysis of peptide fragments, an hydrodynamic 
measurements a partial domain structure was proposed. The three helical domains of HSA 
are arranged in a heart shaped molecule. Each domain contains ten helices but is evident 
composed of two subdomains (A and B) containing six and four helices respectively linked 
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by a stretch of extended polypeptide. This grouping had functional significance that is 
apparent in the X-ray-derived structure. Many crystal structures of HSA both alone and 
complexed with fatty acids and/or drugs or drug-like molecules have been determined. 
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Potential Glucosylation Sites 
Disulfides 
50 / lOOX 150\ 200 250 JOO 350 400 450 500 550 600 
Domain 1 \ \ Domain 2 
Pliosphoserine Phosphotyrosine 
Domain 3 
Table 1.2 gathers the recent structures of HSA currently present in the Protein Data Bank 
together with the ligand(s) in each structure, the resolution, original reference and year of 
deployment. In all these structures a three lobed, heart-shaped molecule is observed with an 
approximate size of 80x80x30A. The phosphorescence depolarization- hydrodynamic 
modeling study proposed that the overall conformation of HSA in neutral solution is very 
similar to that observed in the crystal form. X-ray diffraction has also shown that the 
protein has three homologous domains (1—111), and that each of these is comprised of two 
subdomains (A and B). The A and B subdomains have six and four a -helices, respectively, 
connected by flexible loops. All but one (34Cys) of the 35 cysteine residues are involved in 
the formation of stabilizing disulfide bonds. 
Table 1.2: Crystal structure of HSA currently present in the Protein data Bank 
Year PDB ID Resolution Human Serum Albumin 
(A) complexes with Ligands 
Reference 
1998 lUOR 2.80 
1998 IA06 2.50 
1998 1BJ5 2.50 
1999 IBKE 3.15 
1999 IBMO 2.50 
2000 1E71 2.70 
2000 1E7F 2.43 
Recombinant human serum albumin 
Human serum albumin 
Myristic acid 
Myristic acid and Tri-iodobenzoic acid 
Human serum albumin 
Octadecanoic acid (Stearic acid) 
Dodecanoic acid (Laurie acid) 
He and Carter 1992 
Sugioera/. 1999 
Curry ef a/. 1998 
Curry era/. 1998 
Sugioe/a/. 1999 
Bhattacharya et al. 2000a 
Bhattacharya et al. 2000a 
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2000 1E7H 2.43 Hexadecanoic acid (palmitic acid) 
2001 1E7C 2.40 Halolhane 
2001 1HA2 2.50 S-'(-) ennatiomer of Warfarin 
2001 1H9Z 2.50 R-(+) enantiomer of Warfarin 
2002 IGNJ 2.60 Arachidonic Acid 
2002 IGNI 2.40 Oleic acid 
2003 IHKl 2.65 Thyroxine 
2004 ITF 2.70 GA module 
2005 2BXA 3.05 CMPF 
2005 2BXB 2.70 OxyjAenbutazone 
2005 2BXC 3.10 Plienylbutazone 
2005 2BXD 3.20 Warferin 
2005 2BXE 3.10 Diflunisal 
2005 2BXF 3.05 Diazepam 
2005 2BXG 2.95 Ibuprofen 
2005 2BXH 2.25 Indoxyl Sulfate 
2005 2BXI 2.50 Myristate and Azapropazone 
2005 2BXK 2.40 Azapropazone and Indomethacin 
2005 2BXL 2.60 Myristic acid with Diidosalicylic acid 
2005 2BXM 2.50 Myristic acid with Indomethacin 
2005 2BXN 2.65 Myristic acid with lodipamide 
2005 2BX0 2.60 Myristic acid with Oxyphenbutazone 
2005 2BXP 2.30 Phenylbutazone 
2005 2BXQ 2.60 Phenylbutazone and Indomethacin 
2006 2ESG - Immunoglobulin IgAl 
2008 2VDB 2.52 S-Naproxen and GA module 
2008 2VUE 2.42 4Z, 15E-Bilirubin-IX-Alpha 
2008 2VUF 3.05 Fusidic acid 
2009 3CX9 2.80 Lysophosphatidylethanolamine 
Bhattacharya et al. 2000a 
Bhattacharya et al. 2000b 
Petitpas e? a/. 2001a 
Petitpas ef a/. 2001a 
Petitpas er a/. 2001b 
Petitpas er a/. 2001b 
Petitpas et al. 2003 
Lejon et al. 2004 
Ghuman et al. 2005 
Ghuman et al. 2005 
Ghuman et al. 2005 
Ghuman et al. 2005 
Ghuman et al. 2005 
Ghuman et al. 2005 
Ghuman et al. 2005 
Ghuman et al 2005 
Ghuman et al. 2005 
Ghuman et al. 2005 
Ghuman et al. 2005 
Ghuman et al. 2005 
Ghuman et al. 2005 
Ghuman et al. 2005 
Ghuman et al. 2005 
Ghuman et al. 2005 
Almogren et al. 2006 
he'ion etal 2008 
Zunszain et al. 2008 
Zunszain et al. 2008 
Guo et al. 2009 
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1.3 Ligand Binding by Human Serum Albumin 
Among its fellow proteins albumin is best known for its ability to bind smaller molecules of 
many types. This willingness to take on a varied cargo causes albumin to be likened to a 
sponge or to a "tramp steamer" of the circulation. The flexibility of the albumin structure 
adapts it readily to ligands, and its three domain design provides a variety of sites. Serum 
albumin possesses a unique capability to bind, covalently or reversibly, a great number of 
various endogenous and exogenous compounds. Several different transport proteins exist in 
blood plasma but albumin only is able to bind a wide diversity of ligands reversibly with 
high affinity. As conformational adaptability of HSA extends well beyond the immediate 
vicinity of the binding site(s), cooperativity and allosteric modulation arise among binding 
sites; this makes HSA similar to a multimeric protein. However, it is important to address 
this issue in order to obtain a fuller description of the ligand-binding properties. Albumin 
has a strong negative charge, but binds weakly and reversibly to both cations and anions. It 
therefore functions as a circulating depot and transports molecules for a large number of 
metabolites including fatty acids, ions, thyroxine, bilirubin and amino acids. More recent 
crystallographic studies of a variety of drugs and biomolecules complexes with HSA 
revealed the number and location of their binding sites on the protein. To date, the binding 
sites for FA, (He and Carter 1992; Sugio et al. 1999; Bhattacharya et al. 2000a; Curry et al. 
1998, 1999) hemin (Petitpas et al. 2001a; Wardell et al. 2002; Zunszain et al. 2003), 
thyroxine (Petitpas et al. 2003) and a wide array of drugs (Holford and Benet 1998; Lindup 
1987) have been identified. In recent years high-resolution structural studies, coupled with 
the development of recombinant methods for expressing HSA in yeast, have stimulated 
renewed interest in the protein. A detailed characterization of its binding properties is 
necessary not only for understanding its key physiological ftinctions but also to help control 
its impact on drug delivery and, most recently to facilitate development as a designed 
delivery vehicle for a range of therapeutic and diagnostic reagents. In particular, studies 
with albumin mutants and crystal lographic studies of albumin-ligand complexes have given 
much new information about the location and structure of binding sites and about potential 
ligand interactions. 









































2°: Indoxyl sulfate 
3 ' : Diflunisal 
Figure 1.1 Summary of the ligand binding capacity of HSA as defined by crystallographic studies 
to date. The domains are colour coded as follows: 1. magenta; II, green; 111. blue. The 
A and B subdomains are depicted in light and dark shades, respectively. Inset shows 
binding location of prototypical ligands (bilirubin, PDB ID, 2VUE; thyroxine, PDB 
ID, IHKI; diazepam, PDB ID, 2BXF and propofol, PDB ID, 1E7A) on respective 
domains (Ghuman et al. 2005). 
Fig. 1.1 shows the primary ligands. binding on HSA which are highly adaptable further 
divided into distinct sub-compartments. These reveal a range of specific binding sites 
distributed widely across the protein (Inset: highlighting the binding geometry of 
prototypical ligands). 
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1.3.1 Fatty acid binding 
Binding of a non-binding compound to albumin can be achieved by coupling the 
compound to a ligand, such as a fatty acid. High-resolution crystal structures of Fatty 
acid/HSA complexes revealed a total of seven binding sites distributed heterogeneously 
throughout the protein and shared by medium-chain fatty acids and saturated, 
monounsaturated or polyunsaturated long-chain fatty acids (Holford and Benet 1998; 
Lindup 1987). The binding sites in HSA are compact and most specifically designed for 
fatty acids. The problem of deciphering the affinities of different binding sites is most 
acute for ligands such as Fatty acid, which bind to several different sites on the protein 
(Fig. 1.1). In our previous work, we analyzed the effects of fatty acid on binding of ligands 
and correlated the effect of ligand binding on the unfolding of HSA (Varshney et al. 2008). 
Single binding of ligands to serum albumin is usually described as high-affinity binding to 
one or two sites and weaker binding to a larger number of sites. It is important to note that 
the numbering of these sites in the crystal structure (fatty acid sites 1-7) was arbitrary and 
not based on affinity for fatty acid. Although the binding pockets appear well adapted to 
accommodate fatty acid, most of the binding sites are capable of binding other ligand 
molecules. In particular, drug site I (subdomain IIA) overlaps with fatty acid site 7 and 
shares at least two amino acid side-chains with fatty acid site 2; and drug site II 
(subdomain IIIA) overlaps with fatty acid sites 3 and 4. Elsewhere on the protein, fatty 
acid site I also acts as the primary site for binding hemin, while fatty acid site 5 is a 
secondary site for propofol and thyroxine. Fatty acid site 6 is a secondary site for ibuprofen 
and diflunisal. Despite the repeating domain structure of the protein, the fatty acid binding 
sites display a surprisingly asymmetric distribution. A large number of articles have been 
written on the nature and location of these binding sites and, although a definitive 
consensus has not been reached. Here (Fig. 1.2A-C), we have focused on the interactions 
of the protein with its primary class of ligand and how HSA binds a variety of fatty acid 
molecules. The structures of the three HSA-fatty acid complexes (namely myristic 
complexed with thyroxine; C14 [PDB ID, 1HK4]; Stearic; C16 [PDB ID, 1E7I] and 
palmitic acids, C18 [PDB ID, 1E7H]) permit an extensive and highly detailed survey of 
acids with the protein. 
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Figure 1.2 Crystal Structures of HSA complexed with three different fatty acids. Bound fatty acids 
are shown in yellow colour space filling representation. This colour scheme is 
maintained throughout. (A) myristic acid complexed with thyroxine (blue colour) [PDB 
ID, 1HK4] (Petitpas et al. 2003); (B) stearic acid [PDB ID, 1E7I] (Bhattacharya et al. 
2000); (C) palmitic acid [PDB ID, 1E7H] (Bhattacharya et al. 2000a); (D) the protein 
secondary structure is shown schematically with the domains colour-coded as follows: 
1, magenta; II, green; III, blue. The dashed line shows GA module binding site at 
domain IIA (Cramer et al. 2007; Lejon et al. 2004). All Figures were prepared using 
Pymol software (version 0.99). 
Fig. 1.2A shows allosteric effect of thyroxine binding to HSA-myristic complex only at 
domain IIA. Using crystallographic analyses four binding sites for thyroxine on HSA have 
been distributed in subdomain IIA, IIIA and IIIB (Petitpas et al. 2003). The structural 
observations depicts that HSA retains a higii-affinity site for thyroxine in the presence of 
excess fatty acid at IIA (drug site I) and IIIA (drug site II) mainly. The number and location 
11 
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of binding sites for thyroxine are not well defined although a consensus of most recent 
studies indicates that there are likely to be high affinity binding site for the thyroxine 
binding to serum albumin. For a more complete understanding of thyroxine binding to HSA 
in vivo conditions where fatty acids are invariably present, the interplay between these two 
types of ligand needs to be characterized. Fig. 1.2B shows the binding of medium chain 
fatty acid i.e. stearic acid (CI 8) to HSA. Both of these complexes in one way covers I-A, 1-
B and II-A while in other way covers II-A, II-B and III-A subdomains. Fig. 1.2C includes 
one of the most physiologically important fatty acid ligands known to bind to HSA in vivo: 
palmitic acid (CI6). Overall, we can conclude that there exist five to seven principal 
binding sites for fatty acids ranging in chain length from 14 to 18 carbon atoms (Curry et al. 
1998; 1999; Petitpas et al. 2001b). 
1.3.2 Drug binding 
HSA interacts reversibly with a broad spectrum of therapeutic agents. Binding to HSA 
controls the free, active concentration of a drug, provides a reservoir for a long duration of 
action, and ultimately affects drug absorption, metabolism, distribution and excretion. 
Usually, drugs bind to one or very few high-affinity sites with typical association constants 
in the range of lO''—10^ M"' (Table 1.3 and 1.4). In addition to the primary site(s), several 
sites of lower or of very low affinity often exist. In the following, attention focuses on high-
affinity drug binding, because the in vivo concentration of administered drugs is almost 
always much lower than that of HSA (about 0.6mM). The free concentration of a drug can 
also be affected by interaction with co-administered drugs or by pathological conditions that 
can modify to a significant extent the binding properties of the carrier, resulting in important 
clinical impacts for drugs that have a relatively narrow therapeutic index. The clinical 
consequences of drug- albumin interactions are now well understood. Dosage schedules that 
have been empirically devised for highly albumin-bound drugs are based on normal 
concentrations and drug-binding behaviour of albumin. HSA has a limited number of 
binding sites for endogenous and exogenous ligands (Table 1.3 and 1.4), so that drug 
binding to the protein may be affected by a variety of factors. The effects on 
12 
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pharmacokinetic of drug-drug competition for the same site on HSA are generally held to be 
of little clinical importance (Petersen et al. 2000; Ghuman et al. 2005). 





Copper (II) 1.5x10'^ 1 Masuoka er a/. 1993 
Hematin 1.1 xlO' 1 Adams and Berman 1980 
Long-chain fatty acids Zinc (II) (1-69) xlO' 1 Richieri e/a/. 1993 
Zinc(II) 3.4x10' 1 MasuokaeM/. 1993 
Bilirubin 9.5 X 10' 1 Brodersen 1982 
Thyroxine 1.6x10* 1 Kragh-Hansen 1981 
Eicosanoids 7x10' 2 Unger1972 
Tryptophan I.OxlO' 1 Mcmenamy and Oncleyl958 
Vitamin D3 SxlO' 1 Bikle 1986 
Bile Acids (3-200) X 10' 3 Roda1982 
Steroids (3.2-5) xIO' 1 -
Calcium 6.5 x 10^  3 Kragh-Hansen and Vorum 1993 
Magnesium 1x10^ 12 Pedersen 1972 
Chloride 7.2x10^ 1 Scatchard and Yap 1964 
Adapted from Varshney et al. 2010b 
Physiological or diseased states that cause variations in the plasma levels of albumin or its 
primary endogenous ligands can influence drug binding and may require dosages to be 
closely monitored. Added to this, genetic polymorphisms in HSA can also alter drug 
binding and may further complicate the clinical picture (Beljaars et al. 2000; Tsuchida et al. 
2000). To understand the molecular basis of these effects, structural information is required 
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to fully delineate the binding sites for drugs and endogenous ligands. Such information will 
also be invaluable to efforts to exploit the carrier properties of HSA in the development of 
novel therapeutic reagents for drug targeting (Sudlow et al. 1975) or oxygen transport 
(S]oho\m etal. 1979). 
*TabIe 1.4 Binding of Drugs and other Exogenous Compounds 
Association 
Compound Constant n Reference 
Site I (Subdomain II A): 1.4x10^ 1 Monteroera/. 1986 
Indomethacin 1.5x10* 3 Bjerrum 1968 
Bromphenoi blue 1.9x10' 1 Kragh-Hansen 1988 
Salicylate 3.3x10' 1 Pinkerton and Koeplinger 1990 
Warfarin 7.0x10' 1 Kragh-Hansen 1988 
Digitoxin 0.4x10' 1 Kragh-Hansen 1981 
Furosenamide 2.6 x 10^  1.6 Vianiefa/. 1991 
Phenytoin 6x10^ 6 Schoenemann et al. 1973 
Chlorpropamide 3.3 X 10' 1 Kragh-Hansen 1988 
Benzylpenicillin 1.2x10^ 1 JOGS and Hall 1968 
Evans blue 4.0x10' 14 Freedman and Johnson 1969 
Site II (Subdomain III A): 
Diazepam 3.8x10' 1 Kragh-Hansen 1991 
Ibuprofen 2.7x10* 1 Kragh-Hansen 1981 
Naproxen 1.2x10* 1 Honore and Brodersen 1984 
Clofibrate 7.6x10' 1 Meisner and Meet 1978 
Chiorpromazine 2.0x10' - Kragh-Hansen 1981 
Imipramine 2.5 x 10' - Kragh-Hansen 1981 
Quinidine 1.6x10^ - Kragh-Hansen 1981 
Adapted from Varshney et al. 2010b 
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Structural studies have mapped the locations of the fatty acid binding sites (Bhattacharya et 
al. 2000a; Fehske et al. 1982) and the primary drug binding sites on the protein as shown in 
Fig. 1.1 (Kragh-Hansen 1988). The fatty acid binding sites are distributed throughout the 
protein and involve all six subdomains; by contrast many drugs bind to one of the two 
primary binding sites on the protein, known as Sudlow's sites 1 and II (Scatchard and Yap 
1964; Bhattacharya et al. 2000b). Although examples of drugs binding elsewhere on the 
protein have been documented (Bhattacharya et al. 2000a; Curry et al. 1999), most work 
has focused on the primary drug sites. These investigations have largely employed 
competitive binding methods to investigate the selectivity of the primary drug binding sites. 
Both sites comprise largely apolar cavities with defined polar features and entrances framed 
by helices 1, 2 and 6 of the sub-domain. However, the similarity ends there. For a start the 
two sites have different "packing environments" with respect to the rest of the protein. 
Whereas the entrance to subdomain IIA faces sub-domain IIIA, the entrance to site II is 
completely open to solvent. 
Sndlow Site I UmiSi 
SuSow tilt 11 
(SkaJrd rimf 
Figure 1.3 (a) Sudlow Site 1 binding cavity (HSA), (b) hydrophobic cavity (CAV-1) inside site 1, 
(c) hydrophilic cavity (CAV-2) located inside site I, (d) Sudlow Site II. 
15 
Ligand binding Strategies of Human Serum Albumin 
Moreover, site I is more complex in its construction: three subdomains, IB. IIB and iilA, 
all contribute to the architecture of drug site I: the polypeptide that leads into helix 3 of 
sub-domain IB (residues 148-153) closes off the top of the site (Fig. 1.3) and in addition, 
there is an extension of site I. stabilized by residues from sub-domains IIB and IIIA. Drug 
site I, where warfarin binds, has been characterized as a conformationally adaptable region 
with up to three sub domains (Yamasaki et al. 1996). In addition, numerous subsequent 
studies have shown that the presence of fetty acids has unpredictable effects on drug 
binding, and both cooperative and competitive interactions have been observed. In contrast 
drug site II where diazepam binds, only benefits from some close contacts near the pocket 
entrance with sub-domain IIB. In particular salt-bridges from Glu 450 and Arg 485 (in 
IIIA) to Arg 348 and Glu 383 respectively (in IIB) serve to stabilize one end of the binding 
site. 
In most cases, the mechanisms of interaction of these Sadlow Site n O ^ 
ligands with HSA and the relative importance of the r ^ / Vj^4ff' 
different domains and subdomains of HSA for ligand 
binding remain incompletely clarified. Therefore, the 
existence of the sites does not, in itself, provide a 
complete explanation for the unique and complex 
ligand-bindine properties of HSA. 
1.3.3 Stereoselective binding of drugs 
Stereoselective plasma protein binding of chiral drug molecules administered in racemic 
form results in uneven enantiomeric composition of the unbound molecules. Besides 
quantitative differences the enantiomers may take part in different kinds of binding 
interactions during simultaneous binding with other drugs or endogenous ligands. In this 
situation, the single enantiomers act as distinct compounds, their metabolism, distribution, 
and elimination differing in principle. This accounts for the growing interest in the 
molecular mechanisms involved in stereo discrimination by serum proteins. Because of its 
rather exceptional enantioselectivity, comparable to that displayed by a specific drug target, 
HSA has also been regarded as a "silent receptor". The different pharmacokinetics profile 
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of the drug bimoclomol enantiomers found in humans is in accordance with the 
stereoselective high affinity, and low capacity plasma protein binding (Fehske et al. 1982). 
Fitos et al. (2002) found that, binding of (S)-warfarin involves mainly acetonyl group 
located at the basic mouth of the binding pocket where polar interactions occurs. The 
multiple effect of ibuprofen on lorazepam hemisuccinate showed competitive displacement 
for the common primary site in which the ionic interaction plays vital role, accompanied by 
induced binding of the benzodiazepine due to allosteric modification of the protein 
conformation (Visy et al. 2002). 
1.3.4 Bacterial Protein and albumin Association 
A very interesting example of a protein-protein interaction involving HSA was reported by 
Lejon and colleagues, who solved the crystal structure of HSA complexed with the small 
GA domain from the PAB (Peptostreptococcal albumin-binding Protein) surface protein of 
the anaerobic bacterium Finegoldia magna (Lejon et al. 2004). The triple helical bacterial 
GA domain adheres to an exterior flank of domain II, making polar and apolar contacts 
with both A and B sub-domains. In the complex molecular interplay between a pathogen 
and its human host, bacterial binding association plays important roles. 
Figure 1.4 Electrostatic potential surface representations of GA binding interfaces. Red indicates 
negatively charged surface areas and blue indicates positively charged surface areas. 
Key interface residues are indicated with text. The binding surfaces are marked with 
yellow borders. (A) Chain A of the crystal GA dimer. (B) Chain B of the crystal GA 
dimer. (C) The binding site for HSA on the GA module. (D) The GA-binding surface 
on HSA. 
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GA (protein G-like albumin binding module) is found in a family of surface proteins of 
different bacterial species. It has been reported that the GA module binds close to a cleft at 
a site in domain IIA and domain IIIB of the albumin molecule (Fitos et al. 1999; 2002) and 
involves a single site consisting of a segment spanning residues 330-548 (Fig. 1.2D). This 
module binding to HSA might prove useful, especially in the context of minimizing the 
HSA affinity of drug molecules by structure-based drug design. The analysis shows here is 
one main interface, consisting of two protein binding surfaces located on two different 
parts of the GA module (Fig. 1.4 A&B). The interactions are observed in the binding 
surface of the HSA-bound GA module (Fig. 1.4C), where Phe27 is buried in a hydrophobic 
pocket on the surface of domain JIB in HSA (Phe209, Phe326 and Met329 in Fig. 1.4D), 
flanked by an adjacent hydrogen bond network, involving GA residues Tyr28 and Glu47, 
among others. The three key residues pinpointed by the current analysis, Phe27, Tyr28 and 
Glu47, were confirmed by a recent NMR study of GA modules (He et al. 2006), as 
necessary residues for binding HSA and for conferring species specificity. Nevertheless, 
the mode of binding of GA is unchanged even when albumin is deliberately loaded with 
this mediimi chain fatty acid and adopts a conformation very similar to that observed for 
other HSA-fatty acid complexes (Lejon et al. 2008). 
HSA also interacts with other proteins as part of its daily roimd through the circulation. 
These mclude albondin (or gp60), the receptor believed to mediate transcytotic movement 
of the protein across the endothelial barrier and the MHC-related receptor for IgG (FcRn), 
which helps to rescue albimiin from lysosomal degradation, thus prolonging its lifetime 
(Chaudhury et al. 2006) However, structures of the complexes of HSA with these proteins 
have yet to be reported. Co-crystallisation of HSA v^ dth FcRn Crystal Structures of HSA 
351 presents particular challenges since the interaction is greatest at a pH 5.5 or less, 
(Andersen et al. 2006) a regime that is known to involve structural change in albumin. 
1.3.5 Metal Binding 
Acute and chronic toxicoses caused by heavy metal ions mainly involving zinc, cadmium, 
mercury and lead are known for all forms of life (Hu 2005; Kosnett 2007). Moreover, 
cadmium and very likely lead are carcinogens in humans (Waisberg et al. 2003), and may 
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also induce neurodegenerative diseases (Bolin et al. 2006; Monnet-Tschudi et al. 2006). 
Human serum albumin is useful as a model system for studying the metal binding 
properties of other vertebrate serum proteins. A large effort has been devoted to the study 
of the metal-binding sites of albumin, but a detailed discussion of this particular binding 
property of the albumins is beyond the scope of this work. It suffices to say that N terminal 
portion of HSA (N-Asp-Ala-His-Lys-) possess high affinity for Cu(II), Ni(II), Hg(II), 
Au(I), and Ag(II) with weaker affinities for Ca(II) and Zn(II). The particular importance for 
the binding of metals is Cys34 (site V) and the N terminus of the protein (site VI). Copper 
(II) and nickel (II) deserve special consideration (region 4) among the metals because most 
mammalian albumins bind them more tightly and more specifically than they do other 
cations. HSA has also been reported to possess a relatively weak, non-specific; latent iron-
binding capacity (Loban et al. 1997). This is, however, unlikely to be of significance under 
normal circumstances in plasma, because the specific, high affinity, iron binding protein 
transferrin binds all low-molecular-mass ferric ions. 
13.6 Allosteric Interactions 
Allosteric effects occur when the interaction of one substance with a binding agent alters the 
interactions of a second substance at a different region on the same agent. Such effects can 
occur during target-receptor and drug-protein binding (Visy et al. 2002; Christopoulos and 
Kenakin 2002). The globular domain structural organization of monomeric HSA is at the 
root of its allosteric properties which are reminiscent of those of multimeric proteins. 
Information about competitive and synergistic influences of ligands is important, because 
alteration in protein binding may alter the volume of distribution, clearance, and elimination 
of a drug and may modulate its therapeutic effect. 
Drug-drug Interactions: Allosteric interactions have been observed between a numbers of 
drugs as they bind to HSA. Drug-drug interactions at the protein-binding level are usually 
regarded as problematic secondary effects but useful for therapeutic purposes (Kragh-
Hansen 2002). Binding of drugs to plasma proteins is an important determinant for their 
biological efficacy since it modulates drug availability to the intended target. 
Benzodiazepines bind to several HSA clefts depending on their conformation and 
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Benzodiazepines bind to several HSA clefts depending on their conformation and 
substitution. The most remarkable allosteric effect could be observed in the simultaneous 
binding of (S)-lorazepam acetate (Fitos et a/. 1986) clonazepam and (S)-uxepam (Fitos and 
Simonyi 1988). These drugs selectively increase the binding of (S)-warfarin to HSA. 
Drug-non drug interactions: At higher relative concentrations, the medium chain fatty 
acid anions often displace site II drugs by competition while the displacing effect in site 1 
drugs is probably very small. The improving effect of long-chain fatty acid anions on the 
binding of certain site I ligands was originally explained by induction of conformational 
changes in the albumin molecule rendering site I more suitable for ligand binding. For 
example consider binding of 2, 3, 5-triiodobenzoate (TIB) at sites I and II in absence of 
myristic acid (He and Carter 1992). In the presence of myristate, TIB becomes displaced 
from site II but rebinds at a new, myristate-induced binding site in subdomain IB (Curry et 
al. 1998). Remarkably, Arg2I8-His and Arg2I8-Pro mutations within subdomain IIA 
greatly enhance the affinity for thyroxine and causes the elevated serum total thyroxine 
levels associated with familial dysalbuminemic hyperthyroxinemia (Petitpas et al. 2003). 
Myristate not only competitively binds to FAl, but allosterically modulates the affinity of 
the Mn (III) heme label to FAl in a complex way; interestingly, the myristate affinity for 
the modulatory site is allosterically modulated by a third FA binding site (Fanali et al. 
2005). The ferric heme allosterically regulates inhibition of drug binding to HSA sudlow's 
site I. In turn, drugs impair allosterically heme binding to HSA by the same extent, in 
agreement with spectroscopically and conformationally linked functions (Ascenzi et al. 
2005). The increase in plasmatic levels of ferric heme under pathological conditions (e.g. 
hemolytic anemia) may induce a massive release of drugs with concomitant intoxication of 
the patient. Newborns are suggested to be tested against bilirubin-displacing properties 
since strong displacing drugs such as valproate, sulfisoxazole, phenylbutazone, 
glibenclamide, tolbutamide and furosemide should be avoided under high conditions of 
kemicterus (Ascenzi et al. 2005). Human Serum Albumin is widely used as a model 
multidomain protein to investigate how interdomain interactions affect the global 
folding/unfolding process. The binding affinity of HSA is highly dependent on its 
conformational changes. Under such conditions how it recognizes different drug/Iigand 
molecules is a challenging field of investigation. 
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1.4 Conformational Changes Affecting Ligand Binding 
The structure and dynamics of HSA are known to be influenced by different environmental 
conditions, which on the other hand depend on several factors like, temperature (Sinha et al. 
2008), pH (Ahmad et al. 2006), ionic strength (Bikle et al. 1986), surfactants (Gull et al. 
2008; Bordbar et al. 2008), and chemical denaturants (Ahmad et al. 2005a; b; Ahmad et al. 
2004a; b; Carter and Ho 1994; Sabelko et al. 1999; Kama! et al. 2004) yielding basic 
information about possible hydrophobic and electrostatic interactions, contributing to the 
overall binding affinity. In several disease states, such as bacterial infection, diabetes 
mellitus, and stress, the fatty acid levels are found to increase remarkably. Under such 
circumstances, the fatty acid modulates the ligand binding properties of HSA by inducing 
conformational changes in the binding sites I and II (Ghuman et al. 2005). 
A schematic model represented the spatial relationships among drug site I, Trp- 214, and 
Cys-34 along with the palmitic acid as probes. The instantaneous loss in the binding 
properties of environmental sensitive probe, prodan on denaturation supports the idea that 
the unfolding of HSA occurs with an initial separation of domain I and domain II resulting 
in the expanded form of the protein followed by complete unfolding of the domains 
(Krishnakumar and Panda 2002). HSA acts as an effective plasma buffer due to the 
presence of many charged residues. At physiological pH, albumin has a net charge of 
negative 19. It is responsible for about half of the normal anion gap. A reduction in plasma 
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HSA undergoes several transitions in dependence of pH, the N'*-*? transition between pH 5.0 
and 3.5, the F<-^ E transition (acid expansion) below pH 3.5, and the N'<->B transition between 
pH 7.0 and 9.0. HSA is known to exist as Neutral 'N' (pH~7) and basic 'B' isomeric forms 
under equilibrium conditions (Fig. 1.5). This N-B transition has physiological significance 
and is suggested by the fact that, under increased Ca^ ^ ions concentration in blood plasma, 
the B isomer predominates. Moreover, it is believed that the transport function of albumin is 
controlled through this transition or akin to it (Ahmad et al. 2006). The N<->B isomerization 
is interpreted to be "a structural fluctuation, a loosening of the molecule with higher 
configurational adaptability". Warfarin and ibuprofen binding stabilizes heme-HSA in both 
N and B states (Fanali et al. 2007). 
Complexation of HSA with amphiphilic antidepressant drug amitriptyline (Leis et al. 2002) 
and penicillin (Ruso et al. 2001) at pH above, below and isoelectric point of the protein, 
evidenced saturation below CMC (critical micellar concentration) and conformational 
change above CMC. Pedersen et al. (1990; 1995) showed that the binding strength of the 
fatty acids does not change much in the acid to neutral pH region, but becomes stronger 
when moving towards alkaline region. The recent advancement in the field of nanoscience 
requires the preparation of bioactive nanoparticles under different temperatures using protein 
molecules as templates (Liang et al. 2005; Mitra et al. 2007; Sarkar et al. 2007; Narayanan et 
al. 2007). The single-residue mutations could modify the stability of albumin and that the 
effects are more pronounced for mutations in sub domain IIA (sudlow site I) than for 
mutations in sub domain IIIA (sudlow site 11). Similar approach was being made to 
characterize the simultaneous binding of the ligands in various temperature-dependent folded 
states of HSA for revealing the nature of binding of ligands. A portion of the cationic probe 
NB (Nile blue), which resides in subdomain IIB at room temperature, was expelled from its 
original location at higher temperatures due to melting of subdomain at elevated 
temperatures (Sudarson et al. 2008). Reversible thermal dentauration of genetic variants of 
HSA especially in domains I and III provides more insights into both protein chemical 
relevance and of clinical interest, because they could be useful when designing stable, 
recombinant HSA for clinical application (Kragh-Hansen et al. 2005). 
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1.5 Practical Aspects: How can the Cargo Be Utilized Further? 
Medically, a generous concentration of albumin in the blood stream is a measure of the 
"Quality of Life" (Kobayashi et al. 1991). Binding of exogenous/endogenous ligands and 
unfolding/refolding of human serum albumin appears to be relevant in drug therapy and 
management. The usual paradigm is that ligand binding induces a change in the 
conformation of the target protein that, in turn, produces a given response. In one hand, 
albumin can carry almost all chemical entity present in the blood including drugs, and in 
the other hand its structure can be engineered to different extents with the help of cheap 
and easily available chemical entities. It is well known that protein stability is modified 
by ligand binding due to the coupling between two mutual processes under equilibrium: 
binding and unfolding (Shrake and Ross 1990; 1992). Some improvements in existing 
methodologies, new applications of experimental techniques, and development of new 
approaches aimed have presented here: 
1. Human serum albumin can be used to clear the body of endogenous toxins. For 
example we can design an albumin based extracorporeal detoxifier (the previous 
known one is MARS; molecular adsorbent recirculating system) (Mitzner et al. 2001). 
Technically speaking, depending on the binding affinity with endogenous ligand, an 
albumin-containing dialysis that can recirculate and regenerate online by dialysis 
against buffered solutions, followed by passage through adsorbent (like charcoal) and 
an ion-exchanger columns. This method of removing albumin-binding toxins and 
water-soluble substances would result in hepatic-encephalopathy and in 
improvements in kidney and liver function (Novelli et al. 2001; Kreymann et al. 
1999). 
2. HSA is widely distributed in the plasma compartment and easily related to the 
immune system. The formation of acyl glucuronides is a major metabolic pathway for 
many compounds with a carboxylic acid function. This type of metabolite is a reactive 
electrophilic species and can therefore, in addition to reversible binding react 
covalently with HSA both in vitro and in vivo. Several drugs become glucuronidated 
and interact covalently with HSA, include mainly NSAIDs like tolmetin (Benet et al. 
1993) and furosemide (Ding et al. 1995). Binding of these drugs may predict the 
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degree to which the corresponding acyl glucuronides form covalent adducts that 
probably/possibly leads to toxicity. This information could be a useful adjunct in drug 
design. 
3. Enantiomeric forms of a drug can differ in potency, toxicity, and behavior in 
biological systems. Therefore, many chiral analytical and preparative methods have 
been developed for the separation of drug enantiomers (Domenici et al. 1990; Ascoli 
et al. 1998; Hage 2002; Noctor et al. 1992; Wainer 1994; Mallik et al. 2004). 
Immobilized albumins have used as chiral selector to separate enantiomers of 
tryptophan (Tao and Gilpin 2001; Zhang et al. 2002), several organic compounds 
including drugs [oxazepam (Millot et al. 1997), arylcarboxylic acids (Andrisano et al. 
1997) and warfarin (Zhang et al. 2000)] ethacrynic acid (Bertucci and Wainer 1997; 
Bertucci et al. 2000) and neoglycoproteins (Zhang et al. 2002). The ability of 
immobilized albumin to separate drug enantiomers has also been used in affinity 
capillary electrophoresis to separate racemic drugs (Haginaka 2000). 
4. Apart from its vital role in transporting drugs and endogenous compounds, HSA is 
also involved in the inactivation of a small group of compounds resulting in 
enzymatic activity. HSA acts like thioestearse because it has a free sulfhydryl group at 
cys (Montero et al. 1986). For example, the protein can degrade drug disulfiram 
(Antabuse), a clinically important process (Agarwal et al. 1986). HSA can catalyze 
dehydration of prostaglandin D2 (Fitzpatrick and Wynalda 1983) and E2 (Fitzpatrick 
et al. 1984) Members of the penem group of antibiotics binds irreversibly to albumin 
through acetylation of a s-lysine to amino acid residues of site 1, with the R-isomer 
being degraded much faster that the S-isomer (Fleury et al. 1997). Penicillin allergy 
has been linked to irreversible coupling of penicilloyl groups to these lysine groups 
(Diaz et al. 2001). The resulting complex may be clinically significant. 
5. HSA accounted for about 40% of the total plasma activity, and the esterase like 
domain was assigned to subdomain IIIA of which Tyr'*" should be important. This 
domain on isolation can be used to detoxify cyanides by forming binding conjugates 
of albumin with sulfur forming thiocyanates (Jarabak and Westley 1991), p-
nitrophenyl acetate (Diaz et al. 2001; Sakurai et al. 2004) and several N-
carbobenzoxy-DS (L)-alanine-p-nitrophenyl esterase (Kurono et al. 1992) . A new 
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acetanilide substrate, o-nitrotrifluoroacetanilide (o-NTFNAC), was found to be more 
reactive than the classical o-nitroacetanilide, thereby possessing aryl acyiamidase 
activity of fatty-acid free HSA (Masson et al. 2007). From the pharmaceutical and 
clinical points of view it is interesting that the esterase like activity of HSA can be 
used to activate prodrugs such as olmesartan medoxomil to the active drug olmesartan 
(Ikeda 2001). However, this kind of prodrug activation can be clinically relevant, 
because although the enzymatic activity of a single HSA molecule is low, the 
concentration of the protein in the circulation is very high. 
6. Free human serum albumin could be used as a useful noncovalently bound vehicle for 
the highly insoluble and toxic zinc phthalocyanine, a second-generation photo 
sensitizer for the photodynamic therapy of cancer (Larroque et al. 1996). This could 
provide a simpler alternative for liposome incorporated zinc phthalocyanine which in 
turn appeared to effectively control tumour growth in a human colon carcinoma. 
T380. 
7. Since chemotherapeutics agents are notorious for their side effects. Human serum 
albumin is a marvelous binder of therapeutical drugs. For effective therapy of 
disseminated malignant diseases, it can be used as a shielding membrane around 
target organs so that disease can not spread and side effects can be minimized. 
8. The big advantage of albumin is the compatibility with human blood, plasma, and 
body components. Thus, HSA can be used as a cargo for immobilization of hormones 
covalently coupled to the endogenous ligands in vivo such as fatty acids. A strategy 
can be designed to optimize the pharmacokinetics of insulin and especially the 
glucose disposal curve elicited by insulin. The hormone was covalently coupled to 
fatty acids, which bind to serum albumin in vivo. This appeared to result in favorable 
pharmacokinetics but especially in improved glucose disposal curve (Larroque et al. 
1996; Markussen et al. 1996; Hoffman and Ziv 1997; Kurtzhals et al. 1997; Hamilton 
etal. 1999). 
9. With the advancement of Bioinformatics, the survey of the albumin binding 
characteristics of major pharmaceutical compounds could lead to the discovery of 
previously unidentified drug binding sites and possible binding mechanisms, creating 
major opportunities for designing safer and more effective drugs. This sort of research 
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required the cloning and expression of several species of albumins, albumin fragments 
and albumin mutants as well as antibodies to these molecules. 
10. Furthermore, successful production of recombinant HSA (rHSA) by secretion from 
yeast cells (Carter and Ho 1994) both in S. cerevisiae (Katoh et al. 1995) and K. lactis 
(Blondeau et al. 1994) with no apparent loss of binding properties could be utilized 
for further mutagenesis studies to check the role and importance of the residues 
proposed above in the binding process. 
11. Successful designing of the human serum albumin micro spheres could be used for 
the delivery of cytostatic agents such as doxorubicin and 5-fluorouracil to tumors in 
the liver, breast, and lungs, rendering the albumin-bound drugs more effective than 
free drug (Gupta and Hung 1989). Albumin-propylene glycol alginate-coated covalent 
network offers a better resistance to the microspheres towards freezing, lyophilization 
and sterilization (Callewaert et al. 2007). A composite collagen hydrogel containing 
protein encapsulated alginate microspheres was also developed for ocular applications 
(Liu et al 2008). 
Unlike many other plasma proteins that exhibit polymorphisms and mutations, some of 
which are harmful, genetic variants of human albumin are rare and benign; hence, until 
recently there was little study of albumin mutations. How can the very rare persons who 
essentially lack albumin exhibit only minor symptoms when it has been shown that such 
important properties as maintenance of blood volume and binding and transport of 
metabolites and drugs are prototypical properties of albumin? 
The modem albumin research has progressed from the mere determination of binding site 
number and corresponding association constants to the development and characterization 
of albumin isoforms and albumin-ligand complexes with new therapeutic or diagnostic 
functions. 
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Comparative studies of unfolding and binding ofligands in presence of fatty acid 
2.1 Introduction 
Hiunan serum albumin (HSA) is a highly abundant serum protein (0.6 mM) that comprises 
50-60% of the total plasma protein in humans. In the bloodstream and tissue fluids, HSA 
serves as a vehicle for the transport of several endogenous compounds including unesterified 
fatty acids (FA), hemin, bilirubin and diazepam, all of which bind with high affinity (Carter 
and Ho 1994; Peters 1996). 
Albumin is the primary transporter for delivering FA to and from the tissues according to 
metabolic demands and possesses at least seven binding sites for this ligand. High-resolution 
crystal structures of FA/HSA complexes revealed a total of seven binding sites distributed 
heterogeneously throughout the protein and shared by medium-chain fatty acids and 
saturated, monounsaturated or polyunsaturated long-chain fatty acids (Bhattacharya et al. 
2000a; Curry et al. 1999; Petitpas et al. 2001b). Under normal physiological conditions, 
HSA carries around 0.1-2 mol of fatty acid per mole protein although the molar ratio of 
FA/HSA can rise to much higher levels in the microvasculature during fasting or extreme 
exercise (Brodersen et al. 1990; Spector 1975; Bahr et a/.1991; Wolfe et al. 1990; El-Sayed 
et al. 1996). Albumin also binds a variety of drug molecules; a property that can have 
profound effects on their pharmacokinetics and pharmacodynamics and has long been of 
interest to the pharmaceutical industry (Buchholz et al. 2002; Hodgson 2001; Rich et al. 
2001; Valko et al. 2003; Kratochwil et al. 2002). 
The presence of multiple binding sites on HSA for FA and other endogenous and exogenous 
small molecules makes it difficult to assess interactions, whether competitive or cooperative, 
between different ligands bound to the protein. However, it is important to address this issue 
in order to obtain a fuller description of the ligand-binding properties of HSA. 
Crystallographic analyses of HSA revealed that the 585 amino acid residue monomer is a 
heart-shaped molecule containing three structurally homologous a-helical domains (Sugio et 
al. 1999; Curry et al. 1999; He and Carter 1992). In several disease states, such as bacterial 
infection, diabetes mellitus, and stress, the fatty acid levels are found to increase remarkably. 
Under such circumstances, the fatty acid modulates the ligand binding properties of HSA by 
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inducing conformational changes in the binding site I and II. Thereby, understanding HSA-
fatty acid interactions is of major clinical and pharmaceutical importance. 
HSA undergoes a two-step denaturation transition in the presence of pH as well as by 
chemical denaturants (Hilak et al. 1974; Khan 1986; 1987). The two-step transition and 
formation of intermediate has been attributed to denaturation and/or separation of domain III 
(Khan 1986; Khan and Salahuddin 1984). In more recent studies on the heat denaturation of 
human serum albumin (HSA) it has been found that, at sub saturating levels, bound fatty 
acids redistribute during the denaturation process and produce heterogeneous albumin 
populations (Shrake and Ross 1988; 1990; 1992). In order to determine the role of bound 
fatty acids in HSA denaturation, we now aim to GnHCl-induced denaturation of completely 
defatted HSA (fatty acid free) and HSA containing six-mol palmitic acid/mol HSA (fatted). 
In order to advance our understanding of the ligand binding properties of HSA, the protein 
was explored with circular dichroism, intrinsic fluorescence spectroscopic technique and 
ligand binding studies in the absence and presence of FA. On the basis of results obtained, 
the present study revealed how binding of fatty acids modulates the binding of diazepam (an 
anesthetic), bilirubin (increased concentration in jaundice) and hemin (a product of 
bilirubin). 
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2.2 Experimental 
2.2.1 Materials 
Human serum albumin (HSA) essentially fatty acid free, lot no. 90K7604; guanidine 
hydrochloride, lot no. G3272, Palmitic acid and hemin were obtained from Sigma Chemical 
Co. USA. Bilirubin was purchased from Sisco Research Laboratories, India. Diazepam was 
a product of Ranbaxy Laboratories Ltd., India. All the other reagents were of analytical 
grade. HSA was freed from dimmers and higher-mers by passing through Sephacryl-S 100 
(HR) (76x 1.8 cm) gel filtration column. 
2.2.2 Determination of Protein concentration 
1% 
Protein concentration was determined spectrophotometrically using E icm of 5.30 at 280 nm 
(Wallevik 1973) on a Hitachi spectrophotometer, model U-1500 or alternately by the method 
of Lowry et al. (1951). Bilirubin concentration was also determined spectrophotometrically 
using a molar absorption coefficient of 47,500 M ' cm"' at 440 nm (Jacobsen and Wennberg 
1974). 
2.2.3 Preparation of fatty acid free and fatted HSA 
From commercially prepared fatty acid free HSA the monomeric form of HSA was prepared 
by size-exclusion chromatography on a Sephacryl S-100 column. The purified homogeneous 
HSA monomer was then used for preparing fatted HSA using six-mol palmitic acid/mo 1 
protein as described by Brodersen et al. (1988). 
2.2.4 CD Measurements 
CD measurements were carried out with a Jasco spectropolarimeter, model J-720 equipped 
with a microcomputer. The instrument was calibrated with d-10- camphorsulphonic acid. All 
the CD measurements were made at 25°C with a thermostatically controlled cell holder 
attached to Neslab's RTE-110 water bath with an accuracy of T 0.1°C. Spectra were 
collected with scan speed of 20 nm/min and response time of Is. Each spectrum was the 
average of four scans. Far UV CD spectra were taken at protein concentrations of 1.8-2.0 
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HM with a 1-mm path length cell. The results were expressed as MRE (Mean Residue 
EUipticity) in deg cm^ dmol"' which is defined as 
MRE = eobs/[lO X n X 1 X Cp] (i) 
where Gobs is the CD in milli-degree, n is the number of amino acid residues (585), 1 is the 
path length of the cell and Cp is mole fraction. Helical content was calculated from the MRE 
values at 222 nm using the following equation as described by Chen (Chen et al. 1972). 
%a-helix = [(MRE222 nm -2340)730300] x 100 (ii) 
2.2.5 Fluorescence Measurements 
Fluorescence measurements were performed on Shimadzu spectrofluorimeter, model RF-
540 equipped with a data recorder DR-3. The fluorescence spectra were measured at 25 ± 0.1 
°C with a 1-cm path length cell. The excitation and emission slits were set at 5 and 10 nm, 
respectively. Intrinsic fluorescence was measured by exciting the protein solution at 280 nm 
and emission spectra were recorded in the range of 300—400 nm. 
2.2.6 Denaturation Studies 
Samples of varying GnHCl concentration were prepared by combining different ratios of 
denaturant stock solution and 0.06 M sodium phosphate buffer of pH 7.4. The final solution 
mixture (3.0 ml) was incubated with different GnHCl concentration for 10-12 hr at room 
temperature before optical measurements. The denaturation was followed by monitoring the 
spectral changes by fluorescence spectroscopy and circular dichroism techniques. The 
denaturation data obtained by the two techniques were converted into the fraction denatured 
FD, using the equations (i) and (ii). 
For renaturation experiments, to a stock protein solutions (fatty acid free HSA and/or fatted 
HSA), different volumes of concentrated denaturant solution were added first and mixture 
was incubated for 10-12 h and finally buffer was added to get desired denaturant 
concentration. The final solution mixture for renaturation experiment was further incubated 
for 12 h before optical measurements. 
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2.2.7 Data analysis 
Data were expressed in term of fraction unfolded (FD) calculated from the equation (Athar ei 
al 1999). 
FD = [ ( Y - Y N ) / ( Y D - Y N ) ] (iii) 
where Y is the observed variable parameter and YN and YD are the values of the variable 
characteristics of the folded and unfolded conformations. The difference in free energy 
between the folded and unfolded states, AG was calculated by the following equation: 
AG = -RTlnK = -RTln[FD/(l-FD)] (iv) 
where K is the equilibrium constant, R is the gas constant (1.987 Cal deg"' mol"') and T is the 
absolute temperature. A least square analysis of the equations (1) and (2) as a function of 
denaturant concentration, [D] was used to fit the data to the following equation for the 
determination of delta G "^^'the free energy change in the absence of GnHCl. 
AG = AG"^°-m[D] (v) 
2.2.8 Bilirubin Binding 
Bilirubin solution was prepared by dissolving 5 mg of solid bilirubin in 0.5 N NaOH 
containing 1 mM EDTA and immediately diluting it to the desired volume of 50 mM sodium 
phosphate buffer, pH 7.4. The binding of bilirubin to fatty acid free and fatted HSA was 
studied using fluorescence enhancement technique (Chen et al. 1974; Athar et al. 1999). To a 
fixed volume of stock protein solution (3.5 i^M), increasing volumes of stock bilirubin 
solution was added to achieve different bilirubin/albumin molar ratios. The fluorescence was 
measured at 525 nm after exciting the bilirubin-albumin complex at 466 nm. The spectra 
were recorded in dark after 15-20 min of the addition of bilirubin to protein solution. The 
data were plotted as relative fluorescence against bilirubin/albumin ratio. 
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2.2.9 Diazepam Binding 
To study the binding of diazepam to fatty acid free and fatted HSA, stock protein solution 
(3.5 |aM) was titrated with increasing diazepam concentrations to get different 
diazepam/protein molar ratios. The solution was excited at 280 nm after 30^0 min 
incubation at room temperature and the fluorescence emission was measured at 340 nm. The 
data were plotted as relative fluorescence vs. diazepam/ protein molar ratio. 
2.2.10 Hemin Binding 
Immediately prior to use, hemin was dissolved in 10.0 mM NaOH to obtain a stock 
concentration of 4.0 mM. To a fixed volume of stock protein solution (3.5 i^M), increasing 
volumes of stock hemin solution were added to achieve different hemin/albumin molar ratios 
and the fluorescence was measured at 340 nm after exciting the solution at 280 nm. The 
spectra were recorded after 15- 20 min of the addition of hemin to protein solution. The data 
were plotted as relative fluorescence against hemin/ albumin ratio. 
2.2.11 Binding constant (K), Binding capacity (n) and Binding energy (AGo Binding) 
As discussed above, fatty acid induced fluorescence quenching of HSA was a static 
quenching process. Florescence quenching data of fatted and defatted HSA were analyzed to 
obtain various binding parameters. The binding consteint (K) and binding affinity was 
calculated according using equation (Kang et al. 2004). 
Log [(Fo-F)/F] - log K + n log [Q] (vi) 
where FQ and F are the florescence intensity without and with the ligand respectively. 
Aplotoflog[(Fo-F)/F] versus log [Q] gave a straight line using least squares analysis whose 
slope was equal to n (binding affinity) and the intercept on Y-axis to log K (K= binding 
constant). The binding constant (K) thus obtained was used to calculate the standard free 
energy change AGoof the ligand binding to HSA from the relafionship: 
AGo binding = -2.303RT log K (vii) 
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2.3 Results and Discussion 
Fig.2.1 show GnHCl induced unfolding transitions of fatted (fHSA) and fatty acid free 
human serum albumin (HSA) as monitored by the measurement of MRE at 222 nm. HSA is 
a predominantly a-helical protein contains around -60% a-helix (and no P-sheet) (Chen et al. 
1972). A change in the MRE at 222 nm is a useful probe for monitoring varying a-helical 
content. As shown in Fig. 2.1 GnHCl induced unfolding transitions of fHSA started at higher 
concentration of GnHCl (2.0 M) compared to HSA (1.6 M). Fatted HSA shows a sharp 
transition between 2.0 M and 2.8 M and fatty acid free HSA between 1.6 M and 2.4 M 
GnHCl concentrations with almost equal loss of a-helices (-30%). 
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Figure 2.1 Guanidine hydrochloride denaturation profile of fatted ( • ) and fatty acid free HSA (O) 
as monitored by measurements of MRE at 222 nm. The shapes (n) and (A) represent 
the reversibility points for fatted and fatty acid free HSA obtained by diluting the 
denatured protein in 6M GnHCl respectively. 
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Figure 2.2 Guanidine hydrochloride denaturation profile of fatted ( • ) and fatty acid free HSA (O) 
as monitored by (A) intrinsic fluorescence measurement at 340 nm (B) The change in 
fluorescence intensity monitored by FI 310/350 ratio. The protein (3.5)i M) was excited 
at 280 nm. The shapes (n) and (A) represent the reversibility points for fatted and f2tt> 
acid free HSA obtained by diluting the denatured protein in 6M GnHCl respectively. 
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The transitions between these GnHCl concentrations are found to be highly cooperative. 
Above these GnHCl concentrations the transition proceeds with low cooperativity thereby 
indicating the involvement of intermediate states. Both fatted and fatty acid free HSA 
showed almost complete loss of a-helical content at 6M GnHCl. However, compared to 
MRE value of HSA (-1130 deg.cm^ dmol"') denatured in 6M GnHCl solutions, the tHSA 
showed higher MRE (-2000 deg.cm^ dmol'') value at 222 nm. Similar result has been 
reported by Ahmad et al (2005a; b) for fatty acid free HSA. 
Fig. 2.2A and 2.2B shows the GnHCl induced unfolding transition as monitored by intrinsic 
fluorescence intensity at 340 nm due to the tryptophan and fluorescence intensity at 310/350 
ratio energy transfer due to tyrosyl residues, after exciting the protein at 280 rmi. Since HSA 
harbors 18 tyrosyl residues distributed among all domains of HSA, tyrosyl fluorescence (FI 
310/350 nm) and fluorescence intensity at 340 nm can be used to monitor tertiary structural 
changes in the protein. GnHCl induced unfolding transitions monitored by these probes 
found to be highly cooperative processes without £iny detectable change, unlike transition 
curve probed by MRE at 222 nm. Difference in GnHCl induced unfolding transition curves 
of HSA as monitored by secondary and tertiary structural probes indicates the accumulation 
of intermediate state in the unfolding reaction of HSA. Several studies on GnHCl induced 
unfolding of fatty acid free HSA have been reported (Muzammil et al. 2000; Chmelik et al. 
1988; Tayyab et al. 1995; Krishnakumar and Panda 2002; Flora et al. 1998). Most of the 
studies referred that unfolding of HSA by GnHCl occur through a highly cooperative two 
state process (Muzammil et al. 2000). Some recent studies suggest that GnHCl unfolding of 
HSA occurs in multiple steps (Wallevik 1973; Flora et al. 1998). Moreover, intermediate 
state in GnHCl induced unfolding pathway of HSA remains controversial. On the other hand, 
effect of fatty acid (which is plentiful in blood plasma) on the unfolding pathway and 
stability is uncovered. In view of these results we have attempted to determine the unfolding 
mechanisms of fatty acid free HSA and fatted HSA. The unfolding transition was monitored 
by measurements of MRE at 222 nm, intrinsic fluorescence measurement at 340 nm, and FI 
310/350 ratio were compared by converting tlie data to the plot of fraction denatured as a 
function of GnHCl concentration (Fig. 2.3). 
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Figure 2.3 Normalized transition curves for GnHCI induced unfolding of fatted and fatty acid free 
HSA as followed by measurements of MRE at 222 nm ( • ) , Intrinsic fluorescence at 
340 nm (A), and FI 310 / 350 ratio ( • ) after exciting the protein at 280 nm. 
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As shown in Fig. 2.3A and 2.3B, fo analyzed by both secondary and tertiary structural probes 
was found to be non-overlapping, providing evidence that GnHCl induced unfolding is a 
multistep process. Such non-coincidental transitions indicate the probable existence of 
intermediate in the unfolding pathway of proteins (Flora et al. 1998). Fig. 2.3A and 2.3B 
shows that large fraction of far UV-CD in the transition region (above 3.2 M for HSA and 
above 3.6 M GnHCl for fHSA) does not originate from native state but from a species that 
has lost its tertiary contact completely. The unfolding transition of both fatted and fatty acid 
free HSA was found to be completely reversible for all the transitions studied by different 
probes (Fig. 2.1 & 2.2). Therefore, it appears that the fatty acid free and fatted HSA are in 
intermediate state around 3.2 and 3.6 M GnHCl concentration respectively. Hence, the 
unfolding mechanism may be represented as: 
N (Fath^ acid free HSA) 
N (Fatted HSA) 
^•2 M GnHCl) 
"^  I ^ ri 
(3.6 M GnHCl) 
I* = = = ^ D 
Scheme 2.1 Unfolding mechanism of fatty acid free and fatted HSA transitions in presence of 
GnHCl 
where N, I, I* and D are the native, intermediate and denatured state of HSA. The I state 
retained almost equal amount of a-helix (-30 %) compared to -54% and -58% found in 
native fatted and defatted HSA as calculated from MRE value at 222 run. On the other hand, 
intermediate states (I* and I) did not possess any specific tertiary contact and melt non-
cooperatively as mentioned in far UV-CD section. Such intermediate state possessing 
significant amount of secondary structure without tertiary structure has been identified as 
intermediate of molten globule type. Similarly we have reported earlier the urea induced 
unfolding of HSA is also a two-step three state process with accumulation of MG like 
intermediate state around 4.8 - 5.2 M urea concentration. It is interesting to point out that 
urea induced and GnHCl induced molten globule like intermediate contains almost similar 
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amount of a-helical contents (Ahmad et al. 2005). From these results it seems that this state 
might be a specific folding intermediate of HSA. Identification of this state by kinetic 
refolding of unfolded HSA wall provide great insight into the folding mechanism of 
multidomain protein like HSA. 
2.3.1 Effect of fatty acid binding on unfolding transition of domain II 
Structural perturbations in domain II can be examined by tryptophanyl fluorescence, since the 
lone Trp-214 residue is located almost centrally in helix-2 of domain II. In Fig. 2.4A, the 
unfolding transition occurs between 0.8 and 2.8 M GnHCl. As discussed above intermediate 
state of HSA was detected at around 3.4 M GnHCl and was characterized by retention of 
-30% of a-helices and almost complete disruption of tertiary structure. These results together 
with our recent report (Ahmad et al. 2005b) indicates that accumulation of MG state is due to 
unfolding of domain II and III and loss of tertiary contact of domain 1. Normalized transition 
curve of domain II of fatted and fatty acid free HSA and the dependence of free energy 
change on GnHCl concentration is shown in fig. 2.4B and 2.4C. The free energy of unfolding 
of domain II was calculated to be 2800 Cal mof" for fHSA while 3399 Cal mol"' for HSA 
respectively. Small difference in free energy of unfolding and Cm value for fHSA (2.0) and 
HSA (1.8) indicated a small perturbation in the vmfolding of HSA due to fatty acid binding. 
2.3.2 Thermodynamic induced stabilization of fatty acid free and fatted HSA 
Thermodynamic parameters for N=?il and I^D processes were calculated according to the 
procedure described in data analysis (Materials and methods). The dependence of free energy 
change on denaturant concentration of these transitions are shown in Fig. 2.5 & 2.6, the value 
of AGi*, AGi and AGD"^° and their respective values are shown in Table 2.1. Since the 
intermediate state possesses only helical content, the second transition (I^I*^D) was 
monitored by measurement of MRE at 222 rmi. 
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Figure 2.4 Effect of GnHCI concentration on lone Trp-214 fluorescence of fatted HSA ( • ) and 
fatty acid free HSA (O). (A) Trp-214 fluorescence at 340 nm after exciting the protein 
at 295 nm (B) Normalized transition curves as followed by Trp-214 fluorescence at 
340 nm. (C) Shows the dependence of free energy change of HSA and fHSA as a 
function of GnHCI concentration shown in (B). 
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As listed in Table 2.1, AGi*, and AGi were found to be 4.9 and 4.3 kcal mol"' respectively and 
the total free energy change of unfolding for HSA (AGD"^°) and f HSA (AGD"^^*) were 













GnHCI |M| GnHCI |M| 
Figure 2.5 Dependence of free energy changes of (A) fatty acid free HSA and (B) fatted HSA on 
GnHCI concentrations forN^ 1 and I^ D transitions. 
The values of AGi are similar; it is not identical for the first transition i.e. whether observed 
by different tertiary structural probes or helical structural probes. These also suggest the 
existence of intermediate state -3.0 M GnHCI concentration. The AGD"^° associated with 
the transformation of 'N' to T' and finally to 'D' state was found to be 5.5 Kcal mol"' and 
6.4 Kcal mol'' respectively. The free energy of stabilization AGD"^°*, i.e. the free energy 
change of imfolding of HSA due to fatty acid binding, was found to be 900 Cal mol'. These 
results suggested that binding of fatty acid to HSA markedly stabilized the protein stability 
and its conformation. 
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Figure 2.6 Dependence of free energy changes of (A) fatty acid free and (B) fatted HSA on GnHCl 
concentration for N5=i I and I^ D transitions. 
Table 2.1 Thermo dynamical parameters of fatty acid free and fatted HSA 
Variables xr-i, H O AG*D 2 AG*N^i AG*,^D 
HSA fHSA HSA fHSA HSA fHSA 
MRE 222 nm a, t 4.3 4.9 1.2 1.5 5.5 6.4 
Ex. =280nm 
RFI 340 nm 3.7 4.9 
FI 310/350 nm 2.4 2.3 
' MRE= deg.cm' dmol"' 
'' Fluorescence of native protein was taken as 100% 
* AG= Kcal M ' 
^The mean value of 3 individual experiments with the standard deviation of ±0.3 to ±0.\% 
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2.3.3 Effect of fatty acid binding on the binding properties of Domain I 
X-ray crystal structure of HSA-hemin complex has shown a single binding site for hemin on 
domain I (Kratochwil et al. 2002; Kang et al. 2004). Hemin is a large planar molecule that 
sterically displace fatty acids from fatty acids site I therefore it can be used as a probe for 
monitoring the effect of fatty acid on the binding properties of domain I. Fig. 2.7 A shows 
the binding isotherm of hemin obtained with HSA as well as fatty acid free HSA. It is 
apparent from the fig. that equilibration of HSA with hemin caused concentration dependent 
quenching in the intrinsic fluorescence intensity, which is suggestive of hemin binding to 
HSA. Hemin induced fluorescence quenching data of fatted and fatty acid free HSA were 
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Figure 2.7 (A) Fluorescence quench titration results of hemin binding to fatted HSA ( • ) and fatty 
acid free HSA (O). (B) Log [(Fo-F)/F] versus log [Q] plots fatted ( • ) and fatty acid free 
(O) conformations of HSA for binding constants and binding sites. 
42 
Comparative studies of unfolding and binding ofligands in presence of fatty acid 
The value of binding constant, binding capacity and change in binding energy thus determine 
were listed in Table 2.2. As can be seen from the table, approximately 5 times decrease in 
association constant was observed in fatted HSA compared to fatty acid free HSA. On the 
other hand, number of binding sites 'n' remains almost unaffected. This indicates decreased 
stability of fatted HSA-hemin complex (K=9.46, AG°=10.94 Kcal mol"') compared to fatty 
acid free HSA-hemin complex (K^43.02, AG°=11.85 Kcal mol"'). These results suggest that 
fatty acid (Palmitic acid) influences the binding of domain I where heme like ligand binds. 
2.3.4 Effect of fatty acid binding on the binding properties of Domain III 
Accumulating evidences suggests that the primary diazepam-binding site is located in HSA 
domain 111 (Kang et al 2004; Dockal et al. 1999). We therefore, examined effect of fatty acid 
on domain III of HSA by measuring it's binding to increasing molar ratio of diazepam. 
10 15 
Diazepam |ftM| 
20 25 -68 -bl -66 -65 -64 -6.1 
log (Diazepamj -t,: 
Figure 2.8 (A) Fluorescence quench titration results of Diazepam binding to fatted HSA (•) and 
fatty acid free HSA (O). (B) Log [(Fo-F)/F] versus log [Q] plots fatted (•) and fatty 
acid free (O) conformations of HSA for binding constants and binding sites. 
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Fig. 2.8 A shows the binding isotherms of diazepam with HSA both in absence and presence 
of fatty acid. The binding isotherms show that diazepam induced quenching of intrinsic 
fluorescence intensity becomes constant at higher concentration of ligand. Fig.2.8 B shows 
the diazepam induced quenching data of fatted and fatty acid free HSA to obtain various 
binding parameters. The values of binding constant, binding capacity and change in binding 
energy thus determined are hsted in Table 2.2. We observe almost 14 times decrease in the 
binding constant of fatted HSA as compared to fatty acid free HSA while no significant 
change in binding site is being noticed. This indicates decreased stability of fatted HSA-
diazepam complex (K= 0.12 x 10 ,^ AG°= 5.60 Kcal mol"') as compared to fatty acid free 
HSA-diazepam complex (K=1.6 x 10 '^ AG°= 7.14 kcal mol"'). These results suggest that the 
binding of diazepam at domain III is affected by the presence and absence of fatty acids. 
Table 2.2 Ligand binding parameters of fatty acid free and fatted HSA 
^ * J binding 
(Kcal M') 
LIGAND K^ 
(xlO^ M ' ) 
n 
Hemin 
HSA 43.02 L83 
fHSA 9.46 1.67 
Diazepam 
HSA 0.016 0.88 





The mean value of 4 individual experiments with standard deviation ± 0.06 to ±0.11%. 
44 
Comparative studies of unfolding and binding ofligands in presence of fatty acid 
2.3.5 Effect of fatty acid binding on the separation of domain I from domain II 
To study the effect of fatty acid binding in the bilirubin cavity of HSA formed by loop4 of 
domain II A and loop3 of domain IB (Carter and Ho 1994), binding of bilirubin to fatted and 
fatty acid free HSA was investigated. Fig.2.9 shows the binding isotherm of bilirubin with 
fatted and fatty acid free HSA monitored by fluorescence enhancement technique (Chen 
1974; Athar et al. 1999). We observe an increase in the fluorescence intensity of bilirubin, 
when HSA bounds to fatty acid. Enhancement in binding of bilirubin to fatted HSA can be 
due to non-specific interaction of bilirubin with fatty acid, while we do not observe any 
fluorescence of free bilirubin in the presence of fatty acid. Since the occurrence of bilirubin 
fluorescence is acquisition of helicity in the pigment upon binding to albumin, thus significant 
increase in bilirubin fluorescence upon binding to fatted HSA suggests that the rearrangement 
of domain I and II occurs in such a way so as to allow the bound bilirubin pigment to acquire 
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Figure 2.9 Relative Fluorescence of Bilirubin bound to fatted HSA (•) and fatty acid free HSA (O). 
The fluorescence was recorded at 525 nm after exciting the bilirubin-albumin complex at 
466 nm. 
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2.4 Conclusion 
In the present studies we have used two well defined albumin preparations, namely fatted and 
fatty acid free HSA, and have conclusively shown the occurrence of their respective 
denaturation intermediates. The relationships among domain specific ligands and FA have 
been used to study the GnHCl induced unfolding and interactions of palmitic acid with HSA. 
To estimate more strictly how modulation of ligand binding by fatty acids would affect the 
physiological function of HSA, simulation studies over longer time are preferable. 
2.4.1 Unfolding Studies 
Since the strong fatty acid binding sites reside in domain III (Reed 1986), this domain is the 
most likely candidate for stabilization towards GnHCl denaturation. Thus, the present study 
unraveled possible conformational changes caused by the binding of fatty acid molecules to 
HSA. In this study, we found that GnHCI-induced denaturation of HSA is a multistep process 
with accumulation of intermediates at 3.2 M GnHCl in absence and 3.6 M GnHCl in presence 
of fatty acid. This difference reflects the multistep unfolding of domain II preceding the 
unfolding of the tryptophan environment. The data suggest that a part of domain IIA that 
corresponds to the environment of Trp-214 might be a specific folding intermediate of HSA. 
Identification of this state by kinetic refolding of unfolded HSA will provide great insight into 
the folding mechanism of multidomain protein like HSA. 
2.4.2 Binding of Fatty acid on HSA 
The crystal structure of HSA complexed with palmitate revealed the presence of seven fatty 
acid binding sites on HSA (Bhattacharya et al. 2000a; Curry et al. 1998). Although FA 
interactions with HSA have been studied for many years, the multiplicity of binding sites on 
the protein, along with the fact that FA binding is accompanied by gross conformational 
changes, make it exceptionally challenging system to study. Our results indicate the allosteric 
interaction between fatty acid and domain specific ligands as site markers in displacement 
studies of palmitic acid. The palmitic acid induces local conformational changes that perturb 
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the immediate enviromnent of Trp-214.These observations suggest that the fatty acid binding 
site is located in the interior of domain II. 
On the basis of above discussed results a pictorial model showing the structure and different 
domains of HSA has been formulated (Fig. 2.10). Nevertheless, the present study successfully 
provides insights on the secondary and tertiary structure of HSA-FA complex as a step 
towards elucidating HSA under normal physiologic conditions. Specifically, the present study 
makes an important contribution to understanding the effect of the binding of fatty acids on 








Binding site Dom-IIA 
Dom-IIB 
Figure 2.10 A pictorial model representing the structure and different domains of Human Serum 
Albumin. The palmitic acid binding site 2 (•), site 6(#), and site 7(A) are modeled 
on the basis of crystal structure of the HSA liganded to fatty acid (Bhattacharya et al. 
2000). 
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Elimination of Endogenous toxin Creatinine from Blood Plasma 
3.1 Introduction 
The uremic syndrome is attributed to the progressive retention of a large number of 
biologically/biochemically active endogenous solutes called "uremic toxins", which under 
normal conditions are excreted by the healthy kidneys (Vanholder et al. 1994; Vanholder et 
al. 2001). The accumulation of these human metabolic products in blood has been implicated 
in a number of toxic effects in uremic patients, including cardio-vascular damage, 
progressive loss of glomerular filtration, bleeding tendencies from platelet dysfunction, 
hypertension, neuropathy, irregularities in thyroid function, and defective protein binding of 
medicinal preparations (Vanholder et al. 2005; Van Biesen et al. 2007; Mingrone et al. 
1997). 
Among the highly increased uremic guanidino compounds (GCs) Creatinine (CTN; 2-
Amino-l-methyl-5H-imidazol-4-one, C4H7N3O), is the most typical example of small water-
soluble breakdown waste product generated from muscle metabolism which can easily be 
removed by any dialysis strategy (Vanholder et al. 2003a;b). CTN have been used as a 
conventional biomarker that predicts several important health outcomes, to diagnose acute 
kidney injury involving the measurement of levels of serum creatinine, blood urea nitrogen, 
and urinary enzymes, all of which are elevated after substantial kidney function is lost 
(Vaidya et al. 2009). Its concentration for a healthy person is in the range of 35-106^M 
whereas for a person with uremia reaches upto 2000 |xM (Vanholder et al. 2003a). The 
normal level of albumin-to-creatinine ratio (ACR) in blood depends highly on sex, body 
muscle mass, age, racial/ethnic groups (Mattix et al. 2002) and diseased states. ACR predicts 
several health outcomes such as neurotoxicity (De Deyn et al. 2009), hypertension 
(Kestenbaum et al. 2008; Brantsma et al. 2006), vascular damage due to leukocyte activation 
(Glorieux et al. 2004), kidney failure (Peterson et al. 1995), cardiovascular events, (Gerstein 
et al. 2001) and microalbuminuria (Forman et al. 2006). In renal diseases, the 
pharmacokinetics of many drugs are altered even when the primary route of elimination is 
not renal, due to changes in protein binding, volume of distribution, and/or acid-base 
disturbance (Pema et al. 2004). 
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We elucidate the interaction of CTN during the pH dependent structural transition, often 
referred to as the N-B transition (Ahmad et al 2006; Kosa et al. 2007) of Human serum 
albumin (HSA) which regulates the volume of circulating plasma; therefore, albumin must be 
conserved by the body (Varshney et al. 2010b). pH varies widely among normal human body 
fluids, for example, a pH of 2 in gastric fluid, pH 4-7 in sweat, pH 4.5 in vaginal fluid, pH 5-
7 in urine and pH 7.4 in blood. The structural transitions and toxin binding properties were 
evaluated by means of calorimetric and, spectroscopic approaches using typical site-specific 
bound drugs (wjirfarin, phenylbutazone, ibuprofen eind diazepeim). Any compound that binds 
to a protein, enzyme, gene, or other biomacromolecule will affect its structure and function to 
a greater or lesser extent. For example, a drug binding to HSA in the blood may be 
transported to the focus of disease for therapeutic effect, but binding of a toxin may impede 
the transport of endogenous as well as exogenous substances (Varshney et al. 2010b). The 
elimination of such toxins from the blood stream of CRP patients, an important therapeutic 
goal was found to be dependent on albumin conformation. Here, we attempts to determine 
the high affinity binding site of CTN on HSA using displacement, molecular docking and 
surface accessibility. It has been revealed that the primary binding site was located in the 
vicinity of Arg 257 or near to loop 4 and 6 in subdomain IIA which corresponds 
approximately to amino acid position of 190-300, one of the two principal sites on HSA for 
small Hgands (Varshney et al. 2010b). Thus, binding of CTN to its high affinity (site I) and 
low affinity (site II) sites indirectly displaces drugs from albumin and increases the 
transiently liberated toxin molecules leading to impaired drug binding. 
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3.2 Experimental 
3.2.1 Materials 
Human serum albumin (lot No. A1887; essentially fatty acid free and globulin), creatinine 
(lot No. C4255), warfarin (lot No. A2250), ibuprofen (lot No. 14883) and phenylbutazone (lot 
No. P8386) were purchased from Sigma. Diazepam was a product from Ranbaxy 
Laboratories Ltd., India. All of the other reagents were of analytical grade. 
3.2.2 Preparation ofHSA Isomers and Creatinine solutions 
The protein and toxin solutions were prepared in pH 7.0 (60 mM sodium phosphate) and pH 
9.0 (10 mM glycine-NaOH) buffer solutions. The protein concentration used was similar to 
that of albumin concentration present in blood i.e. 500^M and was determined 
¥"'1% 
spectrophotometrically using -c^ icm of 5.31 (Ahmad et al. 2005b) at 279 nm on a Hitachi 
spectrophotometer, model U-1500. The concentration of creatinine (Mw = 113.12) used 
varies accordingly from normal serum creatinine (106|iM) to uremic conditions (2000|iM) as 
previously analyzed in a survey of patients suffering from uremic disorders (Vanholder et al. 
2003a). For all measurements we have used HSA/CTN ratio similar to that of invivo 
conditions i.e. ACR=5 (normal condition) and ACR=0.25 (maximal uremic condition). 
3.2.3 Differential Scanning Calorimetry (DSC) 
The thermal denaturation of the proteins was carried out on a VP-DSC microcalorimeter 
(MicroCal Inc., Northampton, MA). The thermograms were obtained in the temperature 
range of 30-90 °C at a scanning rate of 0.5 K/min. Before being loaded into the cells, the 
sample (HSA or HSA-CTN) and the reference (buffer or buffer-CTN) solutions were 
degassed by stirring in an evacuated chamber at room temperature. The solution with the vial 
was weighed before and after degassing, and the appropriate amount of degassed deionized 
water was added to make up for any loss of water thus evaporated. The solutions were then 
immediately loaded into the respective cells. The calorimetric reversibility of the thermal 
transitions was determined by heating the sample to a temperature that was a little over the 
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transition maximum, cooling immediately, and then reheating. The reversible non-two-state 
denaturation model provides the temperatvire where the area under the transition curve is half 
complete (ATm), van't Hoff (AHVH) and calorimetric (AHm) enthalpies depicting actual heat 
absorption during protein unfolding. The cooperative unit is defined by the ratio AHm/AHvH 
(Celej etal. 2005). 
3.2.4 Isothermal Titration Calorimetry (ITC) 
The energetic of the binding of Creatinine to HSA were measured using a VP-ITC titration 
microcalorimeter (MicroCal Inc., Northampton, MA). All the solutions were thoroughly 
degassed before loading, and the consequent water loss was compensated using degassed 
deionized water. The sample cell was loaded with the buffer or 500|aM protein solution. A 
250|iL autopipet was filled with the respective toxin solution (2000|aM creatinine) and its 
stirring speed was fixed at 300 rpm. Sequential titrations were performed to ensure full 
occupancy of the binding sites by loading and titrating with the same ligand without 
removing the samples from the cell until the titration signal was essentially constant. To 
correct for the dilution effect by the injection of toxin solution, two controls were obtained: 
titration of HSA solution by the buffer to account for HSA dilution and titration of buffer 
solution by creatinine solution to account for toxin dilution effect. The heats of dilution were, 
therefore, subtracted from experimental toxin onto protein titrations, and the data were 
plotted as integrated quantities. Experiments were repeated two or more times to get a 
reproducibility of better than 3%. The data were analyzed with a single set of identical 
binding sites model using the Origin 7 software provided by MicroCal. The ITC profiles 
were best fitted to a single set of identical binding sites model. After subtraction of the heat 
of dilution, a nonlinear least squares algorithm and the concentrations of the titrant and 
sample were used to fit (minimization of x )^ the heat flow per aliquot, providing best fit 
values of the stoichiometry (n), changes in enthalpy (AH), entropy (AS), and binding 
constants (K). The other thermodynamic parameters were calculated according to the 
formulas (Cheema et al. 2007; Gao et al. 2008): 
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AG = -RTlnK =AU-TAS ...m 
a ^' 
Where T is the absolute temperature (298K) and R=8.3151 J mol"' K"' 
3.2.5 Fluorescence Measurements 
The intrinsic fluorescence properties of the protein were studied on a Hitachi 
spectrophotometer, model F-4500. The fluorescence spectra were measured at 25 ± 0.1 °C 
with a 1 cm path length cell. The excitation and emission slits were set at 10 and 20 run, 
respectively. Intrinsic fluorescence was measured by exciting the protein solution at 280 eind 
295 nm to selectively excite the chromophoric molecules, and the emission spectra were 
monitored in the wavelength range 300-500 nm. The emission spectra of the protein-toxin 
solutions were subtracted from the buffer-toxin blanks, and an average of three accumulated 
scans was recorded as the final graph. The fluorescence data were Einalyzed according to 
linear and modified stem-volmer equations as (Ahmad et al. 2005b; Varshney et al. 2008): 
% = i + ^ svL^J (ii) V = 1 + KSJQ]. 
log 1^ 0 F j / =iogK+nIog[Q] (iii) 
3.2.6 FT-IR Spectroscopic Measurements 
Infrared spectra were recorded on a Nicolet Magna 750 FT-IR spectrophotometer (DTGS 
detector, Ni-chrome source and KBr beamsplitter) with a total of 100 scans and resolution of 
16 cm" , using AgBr windows at room temperature. The concentration of HSA was 500 ^M. 
The difference spectra [(protein solution) - (protein solution + ligand solution)] were 
collected after 1 h of incubation of HSA. The protein FT-IR spectra were processed as the 
procedures reported previously by Kang et al. (2004). 
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3.2.7 Determination of the Protein Secondary Structure 
The protein secondary structure was determined from the shape of the amide I band, located 
around 1650-1660 cm'\ The FT-IR spectra were smoothed, and their baselines were 
corrected automatically using the built-in software of the spectrophotometer (OMNIC 
version 3.1). Thus, the root mean square (RMS) noise of every spectrum was calculated. By 
means of the second derivative in the spectral region 1600-1700 cm"', major peaks for HSA 
and the complexes were resolved. The above spectral region was deconvoluted by the curve-
fitting method with the Gaussian-Lorentzian algorithm, and the peaks corresponding to a-
helix (1656-1658 cm''), p-sheet (1614-1638 cm"'), turn (1660-1677 cm"'), random coil 
(1640-1648 cm"'), and P-antiparallel (1680-1692 cm"') were adjusted and the area was 
measured with the Gaussian function. The area of all the component bands assigned to a 
given conformation were then summed up and divided by the total area (Kanakis et al. 2007). 
3.2.8 CD and UVspectroscopic measurements 
CD and UV spectra were recorded on a Jasco J-715 spectropolarimeter, equipped at 
25±0.2°C in a rectangular cuvette with 1 cm pathlength. All spectra were accumulated three 
times with a bandwidth of 1.0 run and resolution of 0.2 nm, at a scan speed of 20 nm/min. 
Induced CD spectra were obtained as the difference between the spectra of CTN-HSA 
mixtxire and those of the HSA protein solution alone. EUipticities values were converted to 
Ae = 9/(33982cl) where, AE is the molar circular dichroic absorption coefficient expressed in 
M"'cm"', c is the concentration of the sample expressed in mol/L, and 1 is the pathlength 
through the cell expressed in cm. The ligand (L) was added in small aliquots to HSA 
solutions (P), and the L/P ratio was recorded. 
3.2.9 Molecular Docking Studies 
The crystal structure of HSA site I markers (warfarin, PDB ID: 1H9Z; phenylbutazone, PDB 
ID: 2BXC) and the site II markers (diazepam, PDB ID: 2BXF; ibuprofen, PDB ID: 2BXG) 
were derived Irom Protein Data Bank. The residues falling within 5 A distance of the marker 
were extracted and combined to define the binding site. The two dimensional (2D) structures 
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of ligands were extracted from Pubchem database in SDF (Structure Data File) format. The 
three dimensional structures were generated with CORINA version 2.6 (Tetko el at. 2005). 
Molecular docking simulations of uremic toxin and site specific probes were carried out 
using the GOLD version 3.1.4 program (Genetic Optimization Ligand Docking) (Jones et al. 
1997) software which uses a genetic algorithm to calculate the possible conformations of the 
toxin that binds to the protein. The ligands were docked to active site of HSA using standard 
set parameters of GOLD throughout the simulations. For each of the 100 independent genetic 
algorithm runs, a selection pressure of operations were set to terminate after a maximum of 
2,500,000 energy evaluations. Lowest energy complex geometries and the corresponding free 
energy of binding were calculated. Top 20 poses were saved for each ligand and best score 
values were used to correlate with experimental data. The binding energies of docked 
molecules were also calculated using X-score (Wang et al. 2003). The hydrogen bonding 
(cutoff distance of 2.8-3.2A between donor and acceptor) and hydrophobic interactions 
between ligand and protein were calculated using Getneares, a program available with 
DOCK version 3.1.4 (Ewing et al. 2001). PyMol version 0.99 (DeLano 2002) and chimera 
version 1.3 (Pettersen et al. 2004) were used for visualization and measurement of distances 
between the ligand and the receptor. 
The Accessible Surface Area (ASA) of uncomplexed HSA and complexes of ligands with 
HSA were calculated using NACCESS version 2.1.1 (Hubbard and Thornton 1993). The 
structure of the ligands corresponding to the final docked conformation was chosen and 
composite coordinates were generated to form the docked complex. The change in ASA 
(A AS A) of the i'*" residue was calculated using the expression: 
AASA = AS AHS'^ - A S A " ^ ' ^ " ^'^"^^ ,,., 
1 1 1 ^'^'' 
If a residue lost more than 10 A^ ASA on going from the uncomplexed to the complexed 
state, it was considered as being involved in interaction (Ghosh et al. 2009). 
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3.3 Results 
3.3.1 Thermal denaturation of N and B isomer ofHSA in presence of creatinine 
The representative differential scanning calorimetric profiles of thermal denaturation of N 
and B isomers of HSA in absence and presence of creatinine were performed under normal 
and uremic condition as shown in Fig. 3.1 (for simplicity we have only shown data for native 
protein at pH 7.0 (A) pH 9.0 (B) and maximal uremic conditions at pH 7.0 (C) and 9.0 (D) 
respectively. The corresponding thermodynamic parameters accompcinying the transitions 
were reported in Table 3.1. In the absence of toxin, N isomer of HSA unfolds with reversible 
endotherm at transition temperatures of 59-64°C and an average calorimetric enthalpy of 
14.2-35.2 kcal/mol. Almost similar value of the transition temperature of N and B isomeric 
forms (in absence of toxin) indicates the extent of the interactions of positive charge of 
amino acid residues participating in the molecular mechanism of this equilibrium. 
Table 3.1 Thermodynamic parameters accompanying thermal unfolding of HSA complexes 
with Creatinine at a scan rate of 0.5K/min 
Condition T„ [Kl AH„ [Kcal/mol] 
j,\a rj,2a .TT^b 
^m 
A 59.84±0.63 64.59±0.: 14.2±0.52 35.2±0.54 
B 61.01±0.51 65.83±0.: 26.2±0.38 13.2±0.38 
C 59.93±0.02 80.27±0.( 143.00±0.52 39.31±0.09 
D 65.06±0.12 80.31±0.( 110.30±0.96 58.69±0.15 
Condition A: N Isomer of HSA at pH 7.0 
Condition B: B Isomer of HSA at pH 9.0 
Condition C: N Isomer of HSA at pH 7.0 + CTN 
Condition D: B Isomer of HSA at pH 9.0 + CTN 
^ Midpoint denaturation temperature; *" Calorimetric enthalpy; Superscripts 1 and 2 refer to the low 
and high unfolding transition, respectively (see text for details) 
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However, a little difference in the cooperativity ratio P was found to be 1.02±0.01 (data not 
shown), indicating that the thermal unfolding of the protein in the presence of toxin even at 
higher concentrations was a reversible process. These values were in concurrence with those 
reported in the literature (Samatskaya et al. 2002). 
30 40 50 60 70 80 
Temperature ["C] Temperature fC] 
Figure 3.1 Melting thermograms of Human Serum Albumin under normal (A and B) and uremic 
(C and D) conditions at pH 7.0 (A and C) and pH 9.0 (B and D), 
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The melting curve of uremic plasma (albumin complexed with creatinine) shows a different 
shape without any reversal in amplitude of the two peaks but a slight shift to the right at 
higher temperature. The toxin renders the strongest influence on the endotherms (more 
pronounce for basic isomer of HSA, Fig. 3.ID) by transforming the unimodal curve of its 
melting to a bimodal one. As it follows from Fig. 3.1, during uremic condition, the melting 
curve was practically identical to that for the complex "albumin-nonconjugated bilirubin" 
(Samatskaya et al. 2007). 
3.3.2 Isothermal Titration Calorimetry ofNandB isomer of HSA in presence of creatinine 
In order to determine thermodynamic parameters for binding we performed isothermal 
titration calorimetry of creatinine with neutral and basic isomer of HSA. A representative 
calorimetric titration profile of ACR at molar ratio of 1:4 (HSA in normal serum: HSA 
complexed with creatinine under uremic conditions) at pH 7 (A) and pH 9 (B) were shown in 
Fig. 3.2. Each peak in the binding isotherms (Fig. 3.2, upper panels) represents a single 
injection of creatinine. The negative deflections from the baseline on addition of creatinine 
indicate that heat was evolved (an exothermic process). The enthalpy change associated with 
each injection of ligand was plotted versus the [CTN]/ [HSA] molar ratio (Fig. 3.2, lower 
panel), and the AH, Ka, the free energy change (AG) associated with binding were 
determined from the plots. The thermodynamic data derived from the model fitting were 
summarized in Table 3.2. The 1:4 binding stoichiometry of CTN to basic isomer of HSA 
with a binding constant of 2.69 xlO^ M"' indicates a strong and specific interaction. This 
binding constant was of larger order of magnitude than that of neutral form (8.92 xlO^ M''). 
Furthermore, the heat released during the CTN-HSA reaction increases with increasing pH, 
i.e., the ion pair attraction and H-bonds between CTN and HSA were weakened. This 
indicates that the number of H-bonds formed by CTN was lower at pH 7.0. In contrast, AS 
become more negative with increasing pH. This indicates that CTN binding destroyed the 
internal hydrophobic interactions in HSA at pH 9.0, replacing them with ion pair attraction 
and H-bonds. Comparison of the AG, AH, and TAS values suggests that the CTN-HSA 
interaction was amphipathic and H-bonds and ion pair binding were both major contributors, 
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i.e., the interaction of CTN with HSA depends on a combination of ion pair attraction and H-
bonds (Fig. 3.2C,Table 3.2). 
Time (min) 
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Figure 3.2 Isothermal titration 
B isomers of 
albumin at pH 
respectively at 
panels, the heat 
time (jical/sec) 
where each -2^ 
calorimetry of N and 
Human serum 
7.0 (A) and 9.0 (B) 
25°C. In the top 
released per unit 
was plotted vs time 
peak corresponds to 
the injection of an aliquot of ligand. In the bottom panels, the heat of reaction per 
injection (kcal/mole) was determined by integration of the area under each peak, 
plotted vs [CTN]/ [HSA], and fit using the software provided by Microcal. (C) 
Comparative distribution of AH, TAS and AG at pH 7.0 (dark grey) and pH 9 0 (light 
grey). 
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Table 3.2 Association constants and thermodynamic data for binding of Creatinine to 
HSA 
-h 
KallNT] n AG^ AH 
Condition ITC" Spec'' ITC" Spec'' 
AS" 
[Kcal/mol] [Kcal/mol] [cal/moI/K] 
8.92x10" '1.15x10" 0.98 *0.94 -6.75 -0.017±0.91 22.6 
"2.92x10" "1.07 
B 2.69x10' V^""^^!, ^-^"^ #'-^! -23.03 -15.53±0.79 -25.2 
*1.36xl0' *1.17 
Condition A: N Isomer of HSA at pH 7.0 + CTN 
Condition B: B Isomer of HSA at pH 9.0 + CTN 
^ Constants determined by Isothermal Titration Calorimetry 
*" Constants determined by Fluorescence spectroscopy (Xxciiation=280nm; *A.excitation=295nm) 
3.3.3 Analysis of secondary structure o/N and B isomer of HSA in presence of creatinine 
To investigate the effects of the uremic toxin creatinine on the secondary structure of albumin, 
we analyzed regions of IR spectra caused by vibrations of polypeptide backbone, viz., the 
Amide I (1700-1600 cm'', mainly C=0 stretch) band and the Amide II (1500-1600 cm"', C-N 
stretching coupled with N-H bending modes) band. The Amide I band of free HSA (Fig. 3.3) 
had a major maximum around 1654 cm'' for native and 1657 cm'' for basic isomer, 
characteristic of the a-helical conformation (Hubbard and Thornton 1993). Similarly, the 
infrared self-deconvulation and curve fitting procedures were used to determine the protein 
secondary structure under normal and uremic conditions both at pH 7.0 and 9.0 (Fig. 3.4, 
Table 3.3). Positions and relative intensities of the components in presence of toxin (i.e. 
uremic condition) did not differ significantly from those of normal HSA (free HSA without 
toxin). Though quantitative analysis of the Amide I (Table 3.3) revealed a substantial decrease 
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Figure 3.3 FTIR spectra in the region 1800-1400 cm"' at pH 7.0 (A) and pH 9.0 (B) for the free 
HSA, free CTN and difference spectra of HSA-CTN complexes (bottom two curves) 
obtained under normal serum (ACR=5) to uremic condition (ACR=0.25) (indicated 
in the figure). 
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Figure 3,4 Curve fitted amide I region (1700-1600 cm"') with secondary structure determination 
of the free HSA and its CTN adducts in aqueous solution with varying ACR molar 
ratios and SOO^ iM protein concentrations at pH 7.0 (A) and pH 9.0 (B). 
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Table 3.3 FT-IR/ATR detennination of secondary structure percentages of N and B 




Free HSA Normal Uremic 
(%) (%) 
B isomer 








Random coil 6i:l 
(1637-1645 cm"') 
P-sheets 17±1 


























'Normal condition: HSA complexed with creatinine under normal serum condition 
Uremic condition: HSA complexed with creatinine under maximal uremic condition 
These complexes were obtained incubating uremic toxin with 500|iM of HSA for Ihr at room 
temperature. Data represent average obtained from two independent replicates, standard error is 
indicated 
The decrease in the intensity of Amide I and amide II bands, mainly C=0 and C-N vibrations, 
compared to low toxin concentration (normal condition) suggests major protein 
conformational changes upon HSA-toxin interaction possibly caused by a reorganization of 
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intra- and intermolecular hydrogen bonding. The CTN-HSA complexation suggests partial 
protein unfolding more pronounced at higher molar ratio (uremic condition) i.e. similar to 
uremic diseased state and for basic isomeric form of HSA. The IR spectra of uremic HSA 
(HSA complexed with CTN) at higher molar ratios for both isomers showed appearance of 
some new components for amide II band (Fig. 3.3). This band was caused by vibrations of 
the peptide N-H groups and by motions of Glu, Asp, Tyr, Lys and His side chains. We 
observed main aherations in the range 1652-1695 cm' that were basically associated with 
that of arginine environment. Because the appearance of this component in the IR spectra 
of uHSA was accompanied by no changes in the peptide C=0 absorption, it likely reflects 
alterations in the environment of Glu and Asp side chains in uHSA molecules (Ivanov et al. 
2002). 
3.3.4 Fluorescence spectroscopy ofN and B isomer of HSA in presence of creatinine 
Both the intensity and the position of the fluorescence emission spectrum of tryptophan were 
sensitive to changes in the fluorescence environment and consequently to the protein 
conformation. Hence, to understand the influence of creatinine binding on the neutral and 
basic form of HSA we studied the changes in the intrinsic fluorescence of the protein. Fig. 3.5 
shows the fluorescence spectra of HSA in the presence of increasing concentration of 
creatinine. The fluorescence quenching data were analyzed according to the Linear (Fig. 3.5A 
& C) and modified Stem-Volmer equation (Fig.3.5 B & D) (Ahmad et al. 2006; Varshney et 
al. 2008) after exciting the protein at 280 and 295 nm. We observed, quenching of albumin 
fluorescence was less influenced by the binding strength of tryptophan fluorescence as 
compared to the tyrosine fluorescence for both N and B isomeric forms (Fig. 3.5, Table 3.2). 
This may be so because binding of uremic toxin was not exactly at the site where tryptophan 
resides but it could be somewhere near to it as it mainly affects tyrosine fluorescence. These 
results are comparable with that of our ITC results and are presented in Table 3.2, further 
confirming that association constant Ka of uremic toxin depends on conformation of HSA 
underwent N-B transitions (Table 3.2). 
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Figure 3.5 Stem-Volmer (A&C) and modified Stem-Volmer (B&D) plots of uremic toxin creatinine 
quenching for N (A&B) and B (C&D) isomeric conformations of HSA. Each data point 
was the mean of 3 independent observations (S.D. ranging 0.03-0.4%). The Protein was 
excited at 280 (•) and 295nm (0). 
3.3.5 Dependence on alkalization of the Optical properties of creatinine-HSA solution 
The conjugated double bond system of creatinine constitutes the light absorbing chromophore 
that has no element of chirality, it does not show CD activity. The toxin gives the weak 
absorption band associated with an electronic dipole allowed A-A* transition which becomes 
optically active upon binding to the asymmetric environment of HSA and an induced CD 
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Figure 3.6 Representative CD and UV spectra obtained following the titration of the buffer 
solution of HSA with creatinine at (A) pH 7 and (B) pH 9. Spectral contributions of 
the protein alone were subtracted from the spectra of the toxin-protein mixture 
([HSA] = lOOuM, T = 25°C). Ae^ ax values calculated on the basis of the total ligand 
concentrations are displayed at the different molar ratios (L/P). Arrows denote 
increasing concentration of uremic toxin CTN. 
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spectrum emerges a weak positive A-A* CD band between 250-350 nm (Fig. 3.6). Regarding 
the interaction of toxin with the albumin binding site, it has to be noted that dissociated ligand 
molecules lose their hydrogen donor properties but at the same time, they become more 
powerful proton acceptors ready to form H bonds with basic residues of HSA. Upon 
increasing pH value, the CD signals and absorption curves of HSA-CTN complex enhances; 
triggered by the protonation of histidine residues, toxin flips away at neutral and alkaline pH 
values and the cavity becomes accessible for the ligand molecule. The spectra obtained by 
toxin titration experiment (Fig. 3.6A) clearly demonstrate that the protein microenvironment 
at pH 7.0 was less favourable to accommodate toxin as a chiral conformer. 
3.3.6 Probing the binding site of Creatinine on HSA by Ligand Displacement experiments 
Further spectroscopic experiments were undertaken to obtain information on the potential 
location of the HSA binding site of CTN. 
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Figure 3.7 Results of CD displacement experiments performed with warfarin, phenylbutazone, 
ibuprofen and diazepam on HSA-CTN complex at (A) pH 7.0 and (B) pH 9.0 (1=1 cm, 
T=25°C). Displacers were added as nl aliquots of stock solutions. Positive induced CD 
values measured at 278 nm are plotted against dispiacer/creatinine molar ratios (for 
further details see Materials and methods). 
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Albumin possesses two main drug binding sites, sites I and II, which are located in 
hydrophobic cavities of subdomains IIA and IIIA, respectively (Varshney ei al. 2010b). In 
the presence of a compound having the same binding site as creatinine, amplitudes of the 
induced cotton effects should decrease due to competition. Therefore, CD displacement 
experiments were performed using four marker ligands warfarin and phenylbutazone for site 
I whereas ibuprofen and the benzodiazepine agent diazepam for site II. Addition of the above 
ligands to sample solutions containing creatinine and HSA decreased the magnitudes of the 
induced CD bands for both isomers of HSA but more steep at pH 9.0 (Fig. 3.7). These 
markers especially phenylbutazone followed by warfarin reduced the positive induced CD 
band of ACR complex to almost zero. These spectral changes strongly suggested the direct 
competition between site I markers and creatinine for the binding site, with displacement of 
the uremic toxin from the probable common binding site. Notably, nearly complete 
extinction of the CD signal was achieved for both isomeric forms of HSA suggesting that the 
binding site was not affected by the protonation of albumin molecules. 
3.3.7 Molecular modeling study of uremic toxin creatinine-HSA interaction 
The locations of uremic toxin creatinine in the active sites (site I and site II) of HSA was 
explored by conducting docking simulations using GOLD (Jones et al. 1997) as presented in 
Fig. 3.8 and 3.9. The principal regions of ligand binding to HSA were located in hydrophobic 
cavities in subdomains IIA and IIIA, which are consistent with site I and site II, respectively 
(Varshney et al. 2010b). The Creatinine, site I markers (phenylbutazone and warfarin) were 
docked to HSA and the results have been shown in Table 3.4 and 3.5. The Gold Fitness 
Score, measure of binding affinity was found to be low for CTN at both of the sites when 
compared to respective markers used in this study; however specificity was higher for site 1 
as evident from the presence of hydrogen bond and hydrophobic interactions. The 
spectroscopic experimental results were substantiated by docking results which shows that 
high and low affinity binding sites of toxin on plasma protein are located within the binding 
pocket of subdomain IIA and IIIA. The creatinine binds deep inside the cavity at site I 
(Fig.3.8) whereas in site II (Fig. 3.9), it binds at peripheral side of the cavity. 
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Figure 3.8 (A) Molecular surface representations of HSA showing site I specific markers [warfarin 
(limegreen); phenylbutazone (yellow)] and the toxin CTN (red) at binding site I. (B) One 
hydrogen bond (as highlighted by the yellow dashed line) was formed between CTN and 
Arg257 of HSA. The hydrogen bond length was represented in yellow colour (C) Other 
site I amino acid residues of HSA interacting with CTN within 5 A distance. 
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Figure 3.9 (A) Molecular surface representations of HSA showing site II specific markers 
[ibuprofen (light orange); diazepam (magenta)] and the toxin CTN (red) at binding 
site n. (B) The toxin molecule forming repulsive interaction (white colour) with 
Phe488 of HSA (as highlighted by the white dashed line). (C) Other site H amino 
acid residues of HSA interacting with CTN within 5 A distance. 
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Table 3.4 Change in Accessible surface area and binding interactions of the site I amino acid 
residues of HSA with uremic toxin Creatinine 
Ligands Amino AASA Location Electrostatic Number of GOLD X-score 
acid 
residue 






Creatinine Arg257 17.96 IIa-h4 Hvdrogen bond 10 28.16 -5.68 












































































15 41.62 -8.05 
The inside wall of the pocket was lined by hydrophobic side chains whereas the entrance to the 
pocket was surrounded by several non-polar residues (Leu238, Val241, Ala258, Leu260, 
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Ala261, Ile264, Ile290, Ala291); one polar (Ser287) and few charged residues (His242, 
Arg257) in the proximity distance of 5A of the bound toxin (Fig. 3.8, Table 3.4). 
Table 3.5 Change in Accessible surface area and binding interactions of the site II amino 
acid residues of HSA with uremic toxin Creatinine 
Ligands Amino AASA Location Electrostatic Number of GOLD X-score 
acid 
residue 






Creatinine Tyr411 35.66 na-h2 Repulsive force 7 29.14 -5.55 
Phe 488 26.38 nia-h6 C=O...N' 
Glu 489 10.27 HIa-h4 Phe488(2.62A) 
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13 42.74 -7.29 
Although the involvement of non polar residues makes the interactions to be hydrophobic in 
nature but the strong intermolecular hydrogen bond between carbonyl oxygen atom of Arg257 
and N2 atom of Creatinine (2.85 A, 124.36°), makes the electrostatic interaction as the primary 
binding force responsible for the retention of toxin in the plasma. The hydrogen bond residue 
of site I (Arg 257) was part of helix 4 and 6 of subdomain IIA (represented as lla-h4 & Ila-h6. 
Table 3.4). While at site II, the complex was stabilized by hydrophobic interactions without 
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involvement of any hydrogen bond. Additionally, electrostatic repulsive force between oxygen 
atom of Phe488 with N3 of Creatinine (2.62 A) destabilizes the complex (Fig. 3.9, Table 3.5). 
To further identify the residues taking part in the interaction, we have calculated the accessible 
surface area (ASA) of the amino acid residues. The changes in ASA of the interacting residues 
are presented in Table 3.4 and 3.5 
3.4 Discussion 
The melting thermograms for HSA were shown in Fig. 3.1 attributes to an excessive load of 
hydrophobic uremic toxin bound to the albumin molecule. The uremic plasma under 
physiological conditions have a different shape with a shift to the right at higher temperatures 
and increase in the height above baseline which was also reflected in the values of the melting 
enthalpy (Table 3.1). This was attributed to a higher thermoresistance of the albumin 
component, most probably because of the binding of uremic toxin to HSA. An increase in the 
number of intramolecular bonds increases the thermal stability of the protein molecule and 
more pronounced at pH 9.0. Therefore, binding of toxin increases the cooperativity of the 
melting process and depends on its affinity for the albumin molecule. Comparison of 
thermodynamic parameters with the spectroscopic method (Table 3.2) shows that the two 
measurements yield similar 'n' values at both pH (7.0 & 9.0). Because AH was much less than 
60Kcal/mol (Yang 1998), the CTN-HSA interaction was non-covalent: it involves H-bonds, 
ion-pair attraction, hydrophobic interaction, and van der waals forces. It can be observed that, 
at physiological pH, the binding affinity decreases. This was reflected in the high negative 
values of enthalpy of binding, AHITC, and in a larger affinity binding constant, Kuc (Table 3.2). 
Our finding that the secondary structure of serum albumin from conditions similar to uremic 
patients remains intact was consistent with circular dichroism data on the uHSA conformation 
in solution as determined previously (Ivanov et al. 2008). Likewise, modification of IR spectra 
indicating alterations in structure of uHSA agrees well with published data about the 
physicochemical peculiarities of albumin in chronic uremia. We do not observe any significant 
changes in the secondary environment of protein on complexation with the toxin. On the other 
hand, number of binding sites 'n' remained almost unaffected. This indicates increased 
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Stability of HSA-CTN complex at pH 9.0. Since under increased Ca^* concentration in the 
blood plasma, the B isomer predominates, it is suggested that N-B conformational changes 
have physiological significance (Varshney et al. 2010b, Ahmad et al. 2006). 
The question arises which binding sites on the albumin molecule were usually affected by 
creatinine? Data for the binding ability of albumin before and after its loading with uremic 
toxin with marker ligand specific for sites I and II were represented by displacement 
experiments as shown in Fig. 3.7. The site 1 markers at pH 7 and 9 reduces the induced CD 
signal to almost zero. The association constant of phenylbutazone was Ka7xlO^M"',n=l and 
warfarin was Ka-3.3xlO^ M'', n=l (Varshney et al. 2010b) and that for CTN (after exciting the 
protein at 280 nm) was Ka=1.4xl0^ M'', n~l (Table 3.2) the site I markers can displace CTN 
from its binding site on albumin. The association constant for diazepam (Ka =3.8x10^ M'', n=l) 
and ibuprofen (Ka= 2.7x10^ M"', n=l) (Varshney et al. 2010b) was slightly higher than that for 
CTN but lower than site I markers. Site II markers were, therefore, likely to weak inhibitors of 
the binding of CTN. Thus, fluorescence quenching and induced CD spectrums were utilized to 
achieve three goals (i) calculating the association constant (Ka) (ii) determining the dependence 
of toxin binding on albumin conformation and (iii) probing the location of uremic toxin 
binding site on HSA. Furthermore, CTN possess two pKa values of 4.88 for protonation 
(Berge-Lefranc et al. 2009) and 12.7-13.4 for deprotonation of the exocyclic amino group. This 
suggests that CTN predominantly occurs in aqueous solution and in blood plasma at pH 7.4 in 
neutral form. Its acido-basic equilibrium may be written as: 
111 aqueous soixitioixs tliis 
taut oilier exit<tc! 
When analyzing the accessible surface area we found main involvement of arginine residues 
in the toxin complexation with albumin (Table 3.4). This change seemed to be caused by His 
residues because most of the pKa values of His residues are within this pH region i.e. 6.4. 
These His residues results in conformational changes which involved Arg residues and leads 
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to higher complexation of toxin at basic pH. Thus, during alkalization of HSA, the affinity of 
CTN increases. On the onset of pH 9, the Arg residues involved in binding protonate (pKa of 
Arg = 9.04 (NH "^^ ) and 12.04 (side chain)), and then may interact favorably with the toxin. 
Whilst at pH 7, deprotonation weakens the interaction with the cation. 
What actually happens under in vivo conditions during CRF when urine eliminates from the 
body? The glomerulus is a selective filtration membrane. The filtration barrier of body 
composed of three layers that allow for the filtration of solutes (eg. blood urea nitrogen, 
creatinine, electrolytes) and water, but prevent the loss of blood components and plasma 
proteins. Two mechanisms act to prevent albumin from being lost from the body by filtration 
through the glomerular membrane. The first relates to the glomerular membrane pore size, 
which is small compared to the size and shape of albumin. The second mechanism involves 
the negatively charged sialo-protein-rich electrical charge on the siuface of endothelial cells 
covering the iimer surface of the basement membrane. Since albumin has a net negative 
charge, it is electrostatically repulsed by the glomerular membrane. As a result, it has been 
estimated that only about 2 g of albumin was filtered each day across the glomerular capillary 
wall. Creatinine, on the other hand, lacks electrical cheirges at physiological pH and hence is 
able to escape across the muscle cell membrane. It is found that highly alkaline urine occurs 
in CRF. Thus, we can correlate our in vitro results with this fact i.e. under alkaline conditions 
interaction of toxins enhances due to increased affinity with HSA. Thus, elimination of toxin 
would be more feasible at physiological pH. 
Furthermore, the major changes in ASA occur for the residues (role in binding) belonging to 
the hydrophobic pocket of site I. These residues were overlapping to those of site 1 markers 
(Table 3.4) thereby again supporting the results of site I displacement. Whereas, the residues 
involved in binding of CTN to site II (Table 3.5) were non overlapping to those of respective 
markers, moreover the number of such residues was less than that for site I. 
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Sliaded area depicts 
the coniinon amino 
acid residues spaiuiiiig 
CTN and specific drug 
site I markers of HSA 
Curry et al. (1998) have determined the crystal structure of HSA complexed with five 
molecules of fatty acid at 2.5A resolution (Varshney et al. 2010b). Arg 257 was found to 
interact with myristate bound to subdomain llA. Similar interaction we observed with HSA-
CTN complexation. It was noteworthy that the single tryptophan residue of HSA (Trp 214) 
was not in the immediate environment of the docked toxin molecule as proved by our 
spectroscopic resuhs and was further confirmed by computational mapping approaches. 
Guanidino compounds are generated in vivo as a result of protein and amino acid metaboHsm. 
In general the GCs acquire the guanidino group from arginine, with subsequent methylation to 
creatine and further metabolization to creatinine (Taes et al. 2008). In patients with renal 
impairment, several-fold increases in specific guanidino compounds were observed due to the 
impaired renal function and altered metabolism (Vanholder et al. 2003a). Most drugs are 
bound to serum proteins to a various degree. Only unbound or free drug is pharmacologically 
active. There is equilibrium between bound and free drugs, and concentration of fi"ee drug can 
be predicted from total drug concentration. However, under uremic conditions this equilibrium 
is disturbed and the measured free drug concentration can be significantly higher than expected 
from total drug concentrations, especially for strongly protein-bound drugs. In such case a 
patient may experience drug toxicity. Furthermore, creatinine is removed by hemodialytic 
strategies (Samatskaya et al. 1998) but under diseased states uremic compounds of low 
molecular mass can displace strongly albumin-bound drugs from binding sites responsible for 
the binding defect of various drugs in uremic sera. To account for the mechanisms that govern 
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such specificity in inhibitory potency, we carefully examined the relationship between the drug 
binding site(s) and the uremic toxin binding sites. In summary, accumulation of creatinine in 
patients with renal failure appears to account for a substantial portion of the impaired serum 
protein binding of drug especially at site I. Consequently, interactions of toxin and drug with 
respect to serum protein binding and renal excretion may increase the free fraction of drug in 
serum of patients with renal insufficiency (Sun et al. 2006). These findings lend further 
support to the hypothesis that a retained ligand(s) was responsible for impaired plasma binding 
associated with uremia and suggests a role for CTN icnown to accumulate in renal failure. 
Site I bound uremic toxin 
Site II bound uremic toxin 
Site I bound drug 





Scheme 3.1 Mechanism showing possible cascade displacement mode! in uremic toxin- drug system 
depicts allosteric effect of toxin when binding to site I and site II. Red colour: CTN 
binding to its high-affinity site, site I as shown by solid arrows: blue colour: CTN 
binding to its low-affinity site, site II as shown by dashed arrows. Hemodialytic reaction 
occurring within the blood plasma has been shown in red box. 
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3.5 Conclusion 
Renal failure not only alters the renal elimination but also the non renal elimination disposition 
of drugs that Eire extensively metabolized by the liver. Clearance of CTN from the blood 
depends on intramuscular CTN levels, hormone levels, muscle mass, and kidney 
function/glomerular filtration rate. Creatinine is representative for small uremic toxins, 
important in clinical analytic domain for it is used as a probe to evidence muscular 
dysfunction. Consequently, accumulation of uremic toxin and slight increase of pH may cause 
increase of the free fraction of drug through either direct interaction (competitive 
displacement) or indirect interaction (allosteric interaction or site-site interaction) of toxin in 
patients with renal failure. Thus, accumulation of uremic toxin in body can be due to 
conformational change caused by neutral to basic transition which in turn may affect the site-
site interactions between domain IIA and domain IIIA such that site interactions between 
domains will disappear. The findings obtained here will provide useful information for 
elucidating the complicated mechanism of drug and toxin disposition in renal disease state. 
This is the current interest of the pharmaceutical companies. This is extremely important for 
various diseases such as muscular dystrophy and diabetes. Most of the future research and 
advances well be spxm off of these clinical studies. 
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Heavy environmental pollutants are carcinogenic 
4.1 Introduction 
Heavy environmental pollutants damage organism at low micromolar levels and at intervals 
as short as minutes. It is believed that they are involved in a number of human health 
problems including neurological problems and myocardial infarction, as well as in the 
development of some kinds of autism, and pose significant risk for genome integrity. Metals 
impart various effects on protein structure and bring about overall structural stability. These 
effects are seen in quartemary, secondary and tertiary structures of the protein. Acute and 
chronic toxicoses caused by heavy metal ions mainly involving zinc, cadmium, selenium, 
arsenic and lead are known for all forms of life (Hu 2005; Kosnett 2007). Moreover, zinc, 
cadmium and very likely lead are carcinogens in humans (Waisberg et al. 2003), and may also 
induce neurodegenerative diseases (Bolin et al. 2006; Monnet-Tschudi et al 2006). 
Characterization of the interactions of heavy metal ion species and human serum albumin 
(HSA) is essential in evaluating the toxicology and detoxification strategies of ions to humans 
as HSA, the most abundant protein in human blood plasma, serves as a depot protein and 
transport protein for numerous endogenous and exogenous compounds and represents the 
most important class of blood components to which metal ions bound after exposure to 
environmental sources (Varshney et al. 2010b). Other than that albumin has been shown to 
bind variety of essential and toxic metals, including Zn(II), Ca(II), Co(II), Ni(Il), Cu(II) and 
Cd(Il) (Haford and Sarkar 1997; Bal et al. 1998). It binds with the metal ions with clear 
specificities, which are achieved by exploiting difference in the coordination chemistries of 
preferred metal ion. The heavy metals interact with albumin through the sulfhydryl group, 
imidazole nitrogen of histidine, N terminal amino group, two deprotonated backbone amide 
nitrogens and carboxylate chain of aspartate (Haford and Sarkar 1997) forming tetragonal or 
square planar coordination complexes. It suffices to say that N terminal portion of HSA (N-
Asp-Ala-His-Lys-) defined as ATCUN (N terminal copper and nickel) binding motif at N 
terminus possess high affinity for Cu(II), Ni(II), Hg(II), Au(I), and Ag(Il) with weaker 
affinities for Ca(II) and Zn(II) (Haford and Sarkar 1997). The so called site A, the primary 
Zn(ll) binding site that can also bind other divalent metal ions (Bal et al. 1998). Site B that 
displays high affinity towards Cd (II), but the location of which is unknown (Giroux and 
78 
Heavy environmental pollutants are carcinogenic 
Schoun 1981; Goumakos et al. 1991, Sadler and Viles 1996). (iiii) the reduced thiol cys34, 
suggested to bind Cd (II) previous studies have demonstrated that apart from the presence of 
imidazole, carboxyl and sulfhydryl groups the fatty acid content of protein is also a 
determining factor in its binding to metal ions (Sadler and Viles 1996). Of particular 
importance for the binding of metals is Cys34 (site V) and the N terminus of the protein (site 
VI). Generally, there are two modes of how proteins are affected by metal ions have been 
described to date: the metal ions either bind to free thiol and other functional groups of certain 
native proteins or replace zinc and other essential metal ions in metal-dependent proteins 
(Frausto and Williams 1993). 
We investigated, the ability of five metal ions namely zinc, cadmium, selenium, arsenic and 
lead to monitor the conformational changes in absence and presence of an antiviral drug 
ganciclovir (GA2). It is an antiviral medication used to treat or prevent cytomegalovirus 
(CMV) infections. Ganciclovir has also been used to study sensitivity of different viruses to 
antiviral treatment (Cannon et al. 1999; Petersen et al. 2002). This interaction is being used to 
study gene therapy in cancer research (Oon et al. 1999; Maatta et al. 2004). The binding of 
ganciclovir to the sudlow site I located in the subdomain IIA involves the alteration of HSA 
structure around Trp 214 and induce conformational changes. Our work attempts to give the 
basis for the understanding of HSA/ GA2/Metal ion interaction which might provide 
significant insights into structural features, critical to biological functions using both 
spectroscopic and calorimetric approaches. Thereby, provides a strategic approach that could 
combat the hazardous and toxic effects of complex formation against environmental 
pollutants. Probing the binding mode of toxic action of heavy metals might not only be 
important in the pathogenesis of classic heavy metal poisoning but also underlie so far 
unknown or inexplicable consequences of the exposure of living organisms to heavy metals, 
including certain protein folding diseases (Bamham et al. 2004; Chiti and Dobson 2006), 
autoimmune responses (Rowley and Monestier 2005), and subtle chronic impairments of 
health that are still undefined (Hu 2005, Cohen et al. 2004). 
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4.2 Experimental 
4.2.1 Materials 
Human serum albumin (A-1887, essentially fatty acid-free) and Ganciclovir (G2526) were 
obtained from Sigma Chemical Company (St. Louis, MO) and used as supplied. In the blood 
plasma metal ions exists in the form of their oxides and chlorides. Thus, high purity metal 
salts: AS2O3, CdCl2, ZnCh, SeOa and PdCh used were obtained from Sigma Aldrich and were 
of analytical grade. 
4.2.2 Protein and ligand-complexes preparation 
The protein, drug and metal ions were dissolved in Tris-HCl buffer of 20mM, pH 7.4. The 
protein concentration used was similar to that of albumin concentration present in blood i.e. 
SOO^M and was determined spectrophotometrically using i^xcm of 5.31 (Varshney et al. 
2008) at 279 nm on a Hitachi spectrophotometer, model U-1500. Different independent 
replicates of HSA solutions, HSA/M^^, and HSAyGA2/M^^ complexes were used. The mean 
stock concentrations of lead, selenium, arsenic, cadmium and zinc were within the normal 
values present in the blood plasma. 
4.2.3 Fluorescence Measurements 
The intrinsic fluorescence properties of the protein were studied on a Hitachi 
spectrophotometer, model F-4500. The fluorescence spectra were measured at 25 ± 0.1 °C 
with a 1 cm path length cell. The excitation and emission slits were set at 10 and 20 nm. 
respectively. Intrinsic fluorescence was measured by exciting the protein solution at 295 nm 
to selectively excite the chromophoric molecules, and the emission spectra were monitored in 
the wavelength range 300-500 nm. The emission spectra of the protein-drug solutions were 
subtracted from the respective buffer-drug blanks, and an average of three accumulated scans 
were recorded for the final graph. The fluorescence data were analyzed according to linear 
and modified stem-volmer equations as (Ahmad et al. 2005b; Varshney et al. 2008): 
80 
Heavy environmental pollutants are carcinogenic 
% =1 + KSV[Q] (i) 
log ^ ^ « " 7 ^ =logK+nlog[Q] (ii) 
4.2.4 Isothermal Titration Calorimetry (ITC) 
The energetic of the binding of ganciclovir to HSA was measured using a VP-ITC titration 
microcalorimeter (MicroCal Inc., Northampton, MA). All the solutions were thoroughly 
degassed before loading, and the consequent water loss was compensated using degassed 
deionized water. The sample cell was loaded with the buffer or 500|j.M protein solution. A 
250|iL autopipet was filled with the respective drug solution (8.02x10'*^M ganciclovir) and its 
stirring speed was fixed at 300 rpm. The volume of each injection was 8^1, and the intervals 
between injections were 400s to allow correct equilibration. Sequential titrations were 
performed to ensure full occupancy of the binding sites by loading and titrating with the same 
ligand without removing the samples from the cell until the titration signal was essentially 
constant. To correct for the dilution effect by the injection of drug solution, two controls were 
obtained: titration of HSA solution by the buffer to account for HSA dilution and titration of 
buffer solution by ligand solution to account for drug dilution effect. The heats of dilution 
were, therefore, subtracted from experimental drug onto protein titrations, and the data were 
plotted as integrated quantities. Experiments were repeated two or more times to get a 
reproducibility of better than 3%. The data were analyzed with a single set of identical 
binding sites model using the Origin 7 software provided by MicroCal. The ITC profiles were 
best fitted to a single set of identical binding sites model. The total heat content Q of the 
solution contained in the active cell volume VO (determined relative to zero for the unligated 
species) at fractional saturation 0 is given by 
Q^neM^AHV^ (iii) 
where A// is the molar heat of ligand binding, Mi the total concentration of the 
macromolecule, and n the number of binding sites in the macromolecule. The heat released 
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from the /th injection for an injection voliune AF/ (Ag(/)) is then given by the following 
equation: 
"Q(i) + Q(i-1)' 
AQ(i) = Q(i)+' '^' 
Vo 2 
-Q( i - l ) (iv) 
The plot of change in enthalpy against temperature was used to calculate the change in heat 
capacity upon binding, according to 
^c,= (v) 
The value of the van't Hoff enthalpy at each temperature was calculated, including ACp 
values, using the following equation: 
. rr(^^ {in(j^(r,)/ic(7;))-(AC/i?)in(r,/r,)+(AC7,//?][(i/r,)-(i/r,)]}x/? 
-^^ ^^ '^ = [(i/r,)-(i/r,)] "^^  
After subtraction of the heat of dilution, a nonlinear least squares algorithm and the 
concentrations of the titrant and sample were used to fit (minimization of x )^ the heat flow per 
aliquot, providing best fit values of the stoichiometry (n), changes in enthalpy (AH), entropy 
(AS), and binding constants (K). The other thermodynamic parameters were calculated 
according to the formulas (Cheema et al. 2007; Gao et al. 2008): 
AG = -RTlnK = A H - r A 5 (vii) 
a ^ ^ 
4.2.5 UV-Visible Spectroscopy 
Absorption measurements were performed at room temperature on a Perkin Elmer UV 
Winlab 2500 spectrophotometer. A fixed concentration of HSA {\l\iM) with increasing 
concentrations of metal ions equivalent to presence of these ions in blood plasma were added 
to the sample cell. An equal concentration of ligand was added to the reference cell 
simultaneously. 
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4.2.6 Circular Dichroism (CD) Spectroscopy 
CD measurements were carried out with a Jasco spectropolarimeter, model J-815 equipped 
with a microcomputer. The instrument was caUbrated with d-10-camphorsulphonic acid. All 
the CD measurements were made at 25°C with a thermostatically controlled cell holder 
attached to Neslab's RTE-110 water bath with an accuracy of T ± 0.1°C. Spectra were 
collected with scan speed of 20 nm/min and response time of Is. Each spectrum was the 
average of four scans. Far UV CD spectra were taken at protein concentrations of 6x10" M 
with a 1-mm path length cell. The resuUs were expressed as MRE (mean residue ellipticity) in 
deg. cm^ dmoP' which is defined as (Varshney et al 2008;2010a) 
Mi?£ = CD[/wdeg]/10xnx/xCp (viii) 
where CD is in the millidegree, n is the number of amino acid residues (585), / is the path 
length of the cell and Cp is mole fraction. Helical content was calculated from the MRE 
values at 222nm using the following equation as described by Chen et al. (1972). 
%ahelix = MRE,,,„„-2340 xlOO (ix) 
30,300 
Circular dichroism data were analyzed by online available softwares, K2d (Andrade et a!. 
1993; Varshney et al. 2010a) and by using CDSSTR, which calculates the different 
assignments of secondary structures by comparison with CD spectra, measured from different 
proteins for which high quality X-ray diffraction data are available (Johnson 1999; Sreerama 
and Woody 2000). The program CDSSTR is provided in CDPro software package, which is 
available at the Web site: http:// lamar.colostate.edu/~sreeram/CDPro. 
4.2.7 FT-IR Spectroscopic Measurements 
Infrared spectra were recorded on a Nicolet Magna 750 FT-IR spectrophotometer (DTGS 
detector, Ni-chrome source and KBr beamsplitter) with a total of 100 scans and resolution of 
16 cm"', using AgBr windows at room temperature. The concentration of HSA was 500 fiM. 
Spectra were collected after a 2 h incubation of BSA with polymer solution at room 
temperature using hydrated films. Interferograms were accumulated over the spectral range 
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4000-600 cm''.The difference spectra [(protein solution) - (protein solution + ligand solution)] 
were collected after 1 h incubation of HSA. The protein FT-IR spectra were processed as the 
procedures reported previously by Kang et al. (2004). Metal salt solutions were added drop 
wise to the HSA solution with constant stirring to ensure the formation of homogeneous 
solution. Spectra of the Tris-HCl buffer were subtracted from protein solution and protein-
metal while spectra of protein-GA2 were subtracted from protein-GA2-metal species prior to 
obtaining the deconvulated spectra in a similar procedure as described in the literature 
(Froehlich et al. 2009). 
4.2.8 Determination of protein secondary structure 
The protein secondary structure was determined from the shape of the amide I band, located 
around 1700-1600 cm"'. The FT-IR spectra were smoothed, and their baselines were corrected 
automatically using the built-in software of the spectrophotometer (OMNIC version 3.1). 
Thus, the root mean square (RMS) noise of every spectrum was calculated. By means of the 
fourier deconvulation in the spectral region 1600-1700 cm'', major peaks for HSA and the 
complexes were resolved. The above spectral region was deconvoluted by the curve-fitting 
method with the Gaussian-Lorentzian algorithm, and the peaks corresponding to a-helix 
(1656-1658 cm''), p-sheet (1614-1638 cm''), turn (1660-1677 cm''), random coil (1640-1648 
cm"'), and P-antiparallel (1680-1692 cm'') were adjusted and the area was measured with the 
Gaussian fiinction. The area of all the component bands assigned to a given conformation 
were then summed up and divided by the total area (Kanakis et al. 2007). 
4.2.9 Molecular Docking 
4.2.9.1 Docking of Ganciclovir with HSA 
A crystal structure of HSA (PDB ID: 1A06) was obtained from the Brookhaven Protein Data 
Bank. A three dimensional structure of ganciclovir was built and the geometry optimized 
using the Insight II/Builder software package. Water molecules and ions were removed and 
hydrogen atoms added at appropriate geometry; groups within the protein were ionized as 
required at physiological pH. The two dimensional (2D) structures of ligands were extracted 
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from Pubchem database in SDF (Structure Data File) format. The three dimensional structures 
were generated with CORINA version 2.6 (Tetko et al. 2005). Molecular docking studies of 
ganciclovir and HSA was carried out using the GOLD version 3.1.4 program (Genetic 
Optimization Ligand Docking), a docking program based on genetic algorithm (Jones et al. 
1997) software which uses a genetic algorithm to calculate the possible conformations of the 
ligand that binds to the protein. The GOLD was applied to calculate the possible binding 
conformations of the drug at the active site. Molecules with a GOLD fitness score 100 were 
selected to analyze interactions in the binding site using LIGPLOT v4.4 (Yennamalli et al. 
2009). The residues falling within SA distance of the marker were extracted and combined to 
define the binding site. During docking process a maximum of 10 different conformations 
were considered for GA2. Among which the best and the similar GOLD fitness score of each 
ligand was selected. 
4.2.9.2 Docking of Metal ions with HSA 
The initial model of Zn/Cd-albumin was based on a published crystal structure of unliganded 
albumin (PDB ID code 1A06) by using Pymol version 0.99. The three dimensional structures 
were generated with CORINA version 2.6 (Tetko et al. 2005). In a first step, the geometry 
around Cd /Zn was optimized by 100 steps of energy minimization, taking into account 
only the Cd^ /^Zn^^ ion. PyMol version 0.99 (DeLano 2002) and chimera version 1.3 
(Pettersen et al. 2004) were used for visualization. 
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4.3 Results 
4.3.1 Interaction of anticancerous drug ganciclovir with HSA 
4.3.1.1 Fluorescence measurements 
HSA contains a single polypeptide of 585 amino acids with only one tryptophan (Trp 214) 
located in subdomain II A. Tryptophan 214 emission dominates HSA fluorescence spectra in 
the UV region. When other molecules interact with HSA, tryptophan fluorescence may 
change depending on the impact of such interaction on the protein conformation, or via direct 
quenching effect. Fig. 4.1 shows the intrinsic fluorescence of the HSA in the presence of 
increasing concentration of ganciclovir. The decrease of fluorescence intensity of HSA has 
been monitored at 340 nm for HSA-drug system. 
0 140 
/ \ A ^ B 
^ 122 [ / ^ ^ -0.2 -
— 104 / M^^^^^^^\ I i' fe ^ 
i 86 i -0 .4 ^ 
to 
a 68 UD 













0.3 0.8 10 330 350 370 390 4 10 -0.2 1 
Wavelength [nm] Log [Q] 
Figure 4.1 Fluorescence emission spectra of HSA in the presence of increasing concentrations of 
Ganciclovir. (T = 298 K, ^ex = 295 nm). Concentration of HSA = 5 nM; concentration 
of GA2 (10"'' ^M) varies, A-I: 0, 0.8, 1.6, 2.4, 3.2, 4.0, 4.8, 5.6, and 6.4, respectively; 
curve J (dashed line) shows the emission spectrum of drug only. (B) Corresponds to the 
modified Stern-Volmer plot for drug -protein complex. 
86 
Heavy environmental pollutants are carcinogenic 
Assuming that the observed changes in fluorescence come from the interaction between drug 
and HSA, the quenching constant can be taken as the binding constant of the complex 
formation. Further increase in drug concentration of the sample solution resulted in the 
appearance of a new absorption band beyond 410 nm, indicating the precipitation of free drug 
molecules (data not shown). Data from the fluorescence experiments were used to determine 
the binding constant of HSA with drug according to the linear and modified Stem-Volmer 
equations as described in materials and methods section. The slope of the plot (Fig. 4.IB) 
yields the number of binding sites (n < 1) and moderate association constant (Ka = 1.92 x 10" 
M''). However, moderate binding constants (10'* to 10^  M"') were also reported for several 
other ligand-protein complexes using fluorescence spectroscopic methods (Nsoukpoe-Kossi et 
al. 2007; Liang et al. 2008). Additionally, we observed the presence of a single high-affinity 
binding site for drug on HSA with no existence of a secondary binding location for 
ganciclovir, and it is revealed that the same HSA-bound molecule is responsible for 
fluorescence quenching. 
4.3.1.2 Binding modes 
Small molecules are bound to macromolecule by four binding modes: H-bonding, Van der 
Waals, electrostatic, and hydrophobic interactions. The thermodynamic parameters, enthalpy 
(A//°) and entropy (AS") of reaction are important for confirming binding modes. For this 
purpose, the temperature-dependence of the binding constant was studied. The temperatures 
chosen were 298, 308, 318 and 328 K so that HSA does not undergo any structural alteration. 
The quenching plots were shown in Fig. 4.2 and Table 4.1. It can be found that there was a 
strong interaction between GA2 and HSA. The interaction was weakened when the 
temperature rose, thus the quenching efficiency of drug to HSA was reduced when the 
experimental temperature rose. The temperature of the sample was maintained by a waterbath 
throughout the experiment. The data thus obtained were analyzed by modified Stem-Volmer 
equation to calculate the binding constants. In order to elucidate the interaction of Ganciclovir 
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where Ka Binding Constant at Temperature T and R is Gas constant. The value of Enthalpy 
change {Atf) and entropy change (AiS") were obtained from linear Van't Hoff plot. The value 
of free energy content (AG") as calculated from the Gibbs-Helmholtz equation: 
AG''=A//'-rA5" (xi) 
The thermodynamic parameters were calculated from the linear relationship between la^ and 
the reciprocal absolute temperature (Table 4.1, Fig.4.2). From this plot, AH and AS of binding 
were estimated to be -10.07 cal /mol and -8.85 cal /mol/K respectively. 
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Figure 4.2 Linear Van't Hoff Plots for determining the binding constant, K, of HSA-ganciclovir 
(A,ex = 295 nm, A.em=340 nm, pH=7.4, concentration of HSA = 7.5x10^ |iM, 
ganciclovir = 8.02x10'^iiM) at 298K {filled circles); 308 K (squares); 318 K (filled 
triangles) and 328 K (diamonds). (B) Variation of In K as a function of 1/T 
The AH for the binding was higher than the total free energy change, AG, indicating that the 
binding was mainly enthalpy driven. Similar values of negative AH and AS were reported for 
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the interaction of curcumin with liposomes and HSA (Began et al. 1999; Barik et al. 2007). 
Such negative values observed in several protein-ligand association reactions, have been 
explained due to introduction of Van der Waals' interactions as a consequence of hydrophobic 
effects (Ross and Subramanian 1981). The results indicated that the decrease of energy was 
due to the hydrophobic interaction and that the increase of entropy was based on the 
destruction of the water structure induced by the hydrophobic interactions. Furthermore, 
specific hydrophobic interactions between ionic species in aqueous solution were 
characterized by negative values of ^S and A// energy changes. Accordingly, it was not 
possible to account for the thermodynamic parameters of HSA-GA2 compound on the basis 
of a single interaction molecular force model. It was more likely that hydrophobic and 
electrostatic interactions were involved in the binding process. Ganciclovir barely dissociates 
under the experimental conditions, so the interaction between ganciclovir and HSA was 
mainly based on the hydrophobic interaction however the possibility of electrostatic 
interaction can also not be excluded (Tanaka et al. 1998). Therefore, the interaction between 
anticancer drug GA2 and HSA was mainly hydrophobic in nature. 
Table 4.1 Modified Stem-Volmer association constants KdL and relative thermodynamic 
parameters of the system of Ganciclovir - HSA complex. 
r(K) KA A^ ^s AG 
(xlO*M~') (cal/mol) (cal/mol/K) (kcal /mol) 
298 5.88 -2.64 
308 3.59 -2.73 
318 2.03 -10.07 -8.85 -2.82 
328 1.93 -2.92 
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4.3.1.3 Isothermal titration colorimetry of the binding of Ganciclovir to HSA at pH 7.4 and 
various temperatures 
A representative calorimetric titration profile of 8.02xlO" |^aM ganciclovir with 12.3nM of 
HSA at pH 7.4 and 298 K was shown in Fig. 4.3. Each peak in the binding isotherm (upper 
panel) represents a single injection of the drug into the protein solution. Lower panel of the 
figure shows the plot of the amount of heat liberated per injection as a function of the molar 
ratio of the drug to the protein. A standard nonlinear least-squares regression binding model, 
involving a single class of noninteracting sites fitted well to the data. The smooth solid line 














N 1.08 ±0.0486 
K 2.44E5 ±7.99E4 





(Upper panel) Raw data for the 
titration of 8.02x1 0"VM 
ganciclovir with 12.3 |iM HSA at 
pH 7.4 and 298K, showing the 
calorimetric response as successive 
injections of the ligand are added to 
the sample cell, 
(Lower panel) Integrated heat 
profile of the calorimetric titration 
shown in upper panel. The solid 
line represents the best nonlinear 
least-squares fit to a single binding-
site model. 
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The binding profiles from 298K to 328K were shown in Fig. 4.4A. The temperature 
dependence of the thermodynamic parameters accompanying the binding of ganciclovir to 
HSA was summarized in Table 4.2. Each value in this table was an average of two to three 
independent experiments. The observed enthalpy was practically the binding enthalpy of the 
drug to the protein. As seen in Fig. 4.3 and 4.4, the ITC titrations of 8.02xlO'^nM ganciclovir 
with 12.3 ^M HSA yielded negative heat deflection, which indicated that the binding was an 
exothermic process with a medium affinity constant ranging from (2.44±7.99) xIO^ M"' at 
298 K to (0.84±6.28) xlO^ M'' at 328K. We do not observe any major thermal transitions with 
increasing temperatures in the thermodynamic profile of ganciclovir with HSA. 
0.5 1.5 2 2.5 
Molar ratio 
3.5 
Figure 4.4 Binding isotherms for the titration of 8.02x10"^ |iM ganciclovir with 12.3nM HSA at pH 
7.4 and various temperatures: 298K (•), 308K (•), 318K (A) and 328 K (•). 
The binding was entropically opposed but enthalpically favored (-17.38 to -18.02 Kcal/Mol) 
in the studied temperature range (Table 4.2). With an increase in temperature from 298K to 
328K, the stoichiometry and the association constant also increase. This could be due to a 
slight expansion of the binding site, to allow more drug molecules to be accommodated on a 
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single set of identical binding sites with increased affinity. The change in enthalpy was 
favorable in all the cases but decreases as the temperature increases. The unfavorable decrease 
in the binding enthalpy was compensated by a slight increase in the entropy values, as 
observed in Table 4.2. Ganciclovir is sodium salt marketed under the trade name of Cytovene 
and Cymevene, negatively charged molecule under physiological conditions. Thus, it was 
expected to bind at the sites that were comprised of the positively charged amino acid residues 
and hydrophobic side chains on the protein. The weak exothermicity as shown by both 
spectroscopic and calorimetric profiles suggests the involvement of both hydrophobic and 
electrostatic type of interactions in the binding process. Generally, the value of the 
stoichiometry of the binding was ~ 1 and there was slight decrease in the number of binding 




298 308 318 
Temperature/ K 
17.5 
328 9.2 9.48 9.76 10.04 10.32 10.6 
-TAS [Kcal /mol] 
Figure 4.5 (A) Plot of enthalpy against temperature (B) Enthalpy-entropy compensation plot for the 
binding of ganciclovir to HSA at pH 7.4 and 298K 
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Furthermore, slight decrease in the entropy of binding with an increase in temperature, 
indicates more restriction of the protein molecule, as a result of binding. The negative value of 
the heat capacity of binding, calculated from a plot of AH against T (Fig. 4.5A) with a 
correlation coefficient of R = 0.9908 indicates that the binding leads to burial of the some 
hydrophobic groups of the protein during the binding process. The slight increase in entropy 
with increase in temperature indicates that the hydrophobic interactions were more dominant 
during the binding process and there was an increase in the degree of freedom upon binding. 
The enthalpy-entropy compensation was observed in the plot of AH against TAS with the 
slope=0.94 and the correlation coefficient R = 0.9997 (Fig. 4.5B). This means that, in the case 
of ganciclovir binding to HSA, only single molecule interact with the protein, which were 
consistent with our conclusions on the equivalence of the van't Hoff and calorimetric 
enthalpy. 
Table 4.2 Binding parameters accompanying the titration of ganciclovir with HSA at pH 7.4 
and various temperatures. 
Temperature n K Change in enthalpy, AH Change in entropy, AS 
T(K) [xio^ivr'i [xlO^Kcal/moI] [cal/mol/K] 
298 1.08 2.44 -17.38 -31.40 
308 1.02 1.32 -17.88 -31.65 
318 1.06 1.02 -17.92 -31.54 
328 1.04 0.84 -18.02 -32.17 
4.3.1.4 Molecular Docking studies 
Computational molecular docking has been employed to improve the understanding of GA2 
and HSA. In the present study, the GOLD v3.1.4, was chosen to examine the binding mode of 
GA2 at active site of HSA. The Fig. 4.6 shows the location of amino acid residues and also 
the binding of drug (Fig. 4.6A & B). 
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Figure 4.6 (A) Schematic representation of HSA, with its corresponding domains and subdomains. 
The enlarged area corresponds to the Sudlow site I binding region showing predicted binding site 
for ganciclovir on HSA. This figure was prepared by using Pymol. 
Domain I 
(Suhdomain lA. IB) 
Domain III 
(Subdomain IIIA. IIIB) 
Domain 
(Suhdomain IIA. IIB) 
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Figure 4.6 (B) Graphical representation of HSA showing GA2 docked in the binding pocket of 
HSA using GOLD v3.l, depicted in stick model (centre) and HSA, represented in solid with ray 
model. LIGPLOT of the intermolecular interaction of the complex between ganciclovir and HSA 
showing hydrogen bonding between Arg 222 of HSA and GA2. Polar contacts are shown with 
dashed lines, and hydrophobic contacts are indicated by arcs with radiating spokes. Carbon, nitrogen 
and oxygen atoms are shown in black, blue and red, respectively. 
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The present study indicates that drug binds within the hydrophobic pocket of subdomain IIA 
(Fig. 4.6B). The complexation of HSA-GA2 was stabilized primarily by only one hydrogen 
bond. The hydrogen bond was formed between GA2 and Arg222 with a bond length of 3.5A 
(inset to Fig. 4.6B, LIGPLOT).The results suggest that the formation of hydrogen bond 
decreased the overall hydrophilicity and increased the hydrophobicity, stabilizing the drug-
HSA complexes (Maiti et al 2008; Bian et al. 2004).The computationally calculated free 
energy change AG for GA2-HSA binding was -4. 60 kcal.mol"', and the GOLD score was 
3.47. These results were very close to the experimentally-measured values of AG = -2.92 
kcal.mol'' as determined by spectroscopy (Table 4.1). Therefore, the molecular docking and 
free energy calculation results suggested that ganciclovir bound to HSA with both 
hydrophobic and hydrogen bond interactions. 
4.3.2 Interaction of Heavy metal ions with HSA in absence and presence of Ganciclovir 
4.3.2.1 UVAbsorption Studies 
The significant interaction of metal ions with HSA were displayed in the UV-Vis showing a 
weak band in the near-UV region with maximum at 278 rmi (Fig. 4.7A, curve 1) and the 
similar maxima was reported when protein was complexed with ganciclovir (Fig. 4.7B, curve 
1) at its saturating concentration i.e. 8.02xl0"^|iM. The mean stock concentrations of lead, 
selenium, arsenic, cadmium and zinc were within the normal values. In our experiments, UV-
Vis spectra of HSA solutions showed the two typical peaks at 220-240 rmi and 280 nm 
assigned to peptide bond and aromatic amino acid side chains (phenylalanine, tryptophan, 
histidine, and tyrosine), respectively (Stoscheck 1990). Binding of divalent metal ions (M^ )^ 
resulted in the increase of absorption of native HSA and HSA complexed with GA2 in the far 
UV-region showing intensity increment in 280 nm band, which was attributed to the burial of 
aromatic residues to water. As can be seen for HSA (Fig.4.7A) and HSA-GA2 complex (Fig. 
4.7B) the absorbance of native HSA and HSA-GA2 complex increased with the addition of 
metal ions. This increase was more prominent for Cd^ ^ and Zn"^ ^ ions (Fig. 4.7, curve 5&6), 
indicating that the peptide strands of protein molecules extended more upon the addition of 
these metal ions to HSA and HSA-GA2 complex. Thus these two metal species, cadmium and 
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zinc seemed to produce more significant perturbations i.e. affecting the microenvironment 
around HSA and HSA-GA2 complexes as compared to other divalent metal ions (arsenic, 
selenium and lead) being monitored. 
Figure 4.7 
Effect of metal ions on the UV 
absorption of HSA in absence (A) 
and presence of ganciclovir (B). 
The concentration of HSA was 
fixed at 12nM. Curve 1 is the 
spectrum of native HSA (A) and 
HSA complexed with ganciclovir 
(8.02x1 Q-^ jiM) (B). Curve 2 to 6 
corresponds to the spectra of 
arsenic, selenium, lead, cadmium 
and zinc respectively in absence 
(A) and presence of ganciclovir 












/ / ^ \ \ 1 HSA 
3 2 HSA: As*''= 1:50 
/ / / '* )loS^  3 
. 4 
HSA: Se*"= 1:50 
HSA: Pd'^ ''^  1:50 
2 A 5 j \ 6 
HSA: Cd^^= 1:50 














M\ ' HSA:GA2=1:1 ihX ^ HSA: GA2:As^*=l: 1:50 j! Vft 3 HSA: GA2:Se''=l: 1:50 
/ ll Mvl "* HSA: GA2:Pd"*=l: 1:50 
1 / A \^ 5 HSA: GA2:Cd""=l: 1:50 
i 1 // \\\ ^ HSA: GA2:Zn'*=l: 1:50 
/ //// \\\ 6 
. ^ ^ 
r. 1 1 — 1 1 ^^ ^ 
220 240 260 280 300 
Wavelength [nm] 
4.3.2.2 CD Spectroscopy 
The effect of metal ions on HSA stability in absence (Fig. 4.8A) and presence of (Fig. 4.8B) 
of ganciclovir was investigated by far UV-CD spectra. A high content of a-helices in HSA 
was revealed by the two minima around 208 and 222 nm (Varshney et al. 2008; 2010b). Both 
bands were attributed to the electron transitions from A-A* and n -A* transitions typical of a-
helical protein. 
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1 HSA 
2 HSA: As^ *= 1:50 
3 HSA: Se*"= 1:50 
4 HSA: Pd*^= 1:50 
5 HSA: Cd^= 1:50 
6 HSA- ZxT- 1:50 
Figure 4.8 
Effect of metal ions on the far UV CD 
spectra of HSA in absence (A) and 
presence of ganciclovir (B). The 
concentration of HSA was fixed at 
6nM. Curve 1 is the spectrum of native 
HSA (A) and HSA complexed with 
ganciclovir (8.02X10"VM) (B) . Curve 2 
to 6 corresponds to the spectra of 
arsenic, selenium, lead, cadmium and 
zinc respectively in absence (A) and 
presence of ganciclovir (B) at their 
maximum saturating concentrations. 
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Examination of CD spectra (Fig.4.8) both in absence and presence of drug indicates that 
among five metal species examined, binding of Cd"^ ^ and Zn^^ induces the major secondary 
structural transitions of HSA (Fig. 4.8A, curve 5 and 6) and HSA-GA2 (Fig. 4.8B, curve 5 
and 6). The molar ellipticities of both the positive and negative bands decrease more markedly 
due to interaction of Cd"*^ ^ and Zn"^ ^ with protein complexes. It is clearly shown that this 
interaction leads to decrease in the a-helical fraction with a concomitant increase of the (3-
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Structures. But this decrease was more prominent in case of Cd"^  and Zn^ . This observation 
reported herein, leads to our speculation that binding of Cd^^  and Zn*^ to the donor atoms (N 
and O) of the amino acid residues in HSA may destabilize the hydrogen bonds between the 
carbonyl and amide in a-helix structure, but somewhat promote the hydrogen bonds 
contributing to the p-structural arrangement. 
Further experiments were performed to study the effect of Cd*^  and Zn"^ ^ concentrations on 
the secondary structure of HSA in absence and presence of ganciclovir with varying 
concentration of metal ions. 
200 210 220 230 240 250 
Wavelength [nm] 
10 20 30 40 50 
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60 
Figure 4.9 (A) Far UV CD spectra of HSA (6^M) bound with Cd^l HSA was treated with Cd'^  at 
varying increasing concentrations at the molar ratio ([HSA]: [Cd"^ ]^) of curves (1) 1: 0 (2) 
1:5 (3) 1:10 (4) 1:15 (5) 1:20 (6) 1:25 (7) 1:30 (8) 1:40 (9) 1:45 (10) 1:50 after 
appropriate incubation at 298K in 20mM Tris-HCl buffer at pH 7.4. (B) The plot of 
ellipticity at 208 nm (•) and 222 nm (o) versus the molar ratio of cadmium ions to HSA. 
Fig. 4.9 shows the changes in the secondary structure content of HSA with increasing 
concentration of Cd"^  . Major perturbation was being observed in the dominating a-helix 
fraction of HSA while increasing the mole fractions of HSA: Cd""^  from 1:0 to 1:50. The 
relative changes in the structural contents were also shown by the CD plots at 208 and 222 nm 
(Fig. 4.9B). On titrating the increasing concentrations of Cd*^  ions with HSA and ganciclovir 
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complex, further decrease in the secondary structural content was observed (Fig. 4.10A). We 
conclude that the presence of drug intensifies the environmental perturbation to more extent 
as compared in absence of drug (Fig. 4.9). An appreciable change in the dominating a-helical 
fraction was observed at the mole ratio of HSA/Cd^^= 1:25, suggesting the secondary 
structural perturbations of microenvironment of native HSA. Further increase in the molar 
ratio of HSA /Cd*^ to 1:50 resulted in an abrupt transformation of the a-helix content into the 
P-structures (Fig. 4.9 & 4.10, curve 10). The similar results have been shown by ellipticity 
plot at 208 and 222 nm (Fig. 4.9 and 4.10). 
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Figure 4.10 (A) Far UV CD spectra of HSA (6nM) bound with ganciclovir (8.02x1 0"VM). HSA: 
GA2 complex was further treated with Cd*^  at varying increasing concentrations at the 
molar ratio ([HSA]: [GA2]:[Cd''^ ]) of curves (1) 1: 1:0 (2) 1:1:5 (3) 1:1:10 (4) 1:1:15 
(5) 1:1:20 (6) 1:1:25 (7) 1:1:30 (8) 1:1:40 (9) 1:1:45 (10) 1:1:50 after appropriate 
incubation at 298K in 20mM Tris-HCl buffer at pH 7.4. (B) The plot of ellipticity at 
208 nm (•) and 222 nm (o) versus the molar ratio of cadmium ions to HSA-GA2 
complex. 
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Figure 4.11 (A) Far UV CD spectra of HSA (6jiM) bound with Zn^l HSA was treated with Zn'" at 
varying increasing concentrations at the molar ratio ([HSA]: [Zn*^ ]) of curves (1) 1: 0 (2) 
1:5 (3) 1:10 (4) 1:15 (5) 1:20 (6) 1:25 (7) 1:30 (8) 1:40 (9) 1:45 (10) 1:50 after 
appropriate incubation at 298 K in 20mM Tris-HCl buffer at pH 7.4. (B) The plot of 
ellipticity at 208 nm (•) and 222 nm (o) versus the molar ratio of zinc ions to HSA. 
These structural transitions were more pronounced when increasing concentrations of Zn^ ^ 
ions were titrated with HSA (Fig. 4.11) and HSA complexed with ganciclovir (Fig. 4.12). 
Thereby, we can assume that ganciclovir alters or induces such conformational changes which 
affects metal ion binding sites and resulted in the reduction of the a-helical content of the 
protein and increase in the P-tums and sheets in return. The CD 208 and 222 nm plots also 
depicted the similar results, major reduction in the helical content of the protein. The molar 
ellipticities of both the positive and negative bands decrease more markedly due to interaction 
of Zn"^  . The result indicates that Zn""^  and Cd^ ^ starts to coordinate with the active donor 
atoms (N and O) of the amino acid residues in stable geometries, which induces the 
development of other structure at the molar ratios below the binding stoichiometry. With 
saturation of Zn"^  and Cd^^ at the binding sites, the a-helix fraction decreases continually and 
^-sheet appears. Then, more loss of a-helix structure with a concomitant increase of P 
structure occurs with increasing concentration of Zn^^ and Cd""^  until two marker bands at 208 
and 222 nm disappear at higher metal ion concentration (r=50:l). 
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Figure 4.12 (A) Far UV CD spectra of HSA (6^M) bound with ganciclovir (8.02x1 O'VM). HSA: 
GA2 complex was further treated with Zn^ ^ at varying increasing concentrations at the 
molar ratio ([HSA]: [GA2]:[Zn^ ]^) of curves (1) 1:1:0(2) 1:1:5(3) 1:1:10(4) 1:1:15(5) 
1:1:20(6) 1:1:25(7) 1:1:30(8) 1:1:40(9) 1:1:45(10) 1:1:50 after appropriate incubation 
at 298 K in 20mM Tris-HCl buffer at pH 7.4. (B) The plot of ellipticity at 208 nm (•) 
and 222 nm (o) versus the molar ratio of zinc ions to HSA-GA2 complex. 
This evidence suggests that excessive inorganic zinc and cadmium interacts with the 
negatively charged HSA molecule due to the electrostatic effect, leading to decomposing a-
helix structure with an enhancement of ^ -sheet and y9-tum which is liable to cause aggregation 
of HSA as noted previously (Romero et al. 2005). As for the far UV CD spectra of HSA 
bound with Se* , As* and Pb* , no appreciable changes were observed even when the metal 
species are in excess in the incubation solution (Fig. 4.8). 
These CD results in correlation with our UV absorption studies evidence shows that, in 
contrast to Zn"^ ^ and Cd"^ ^ these metal species induces little secondary structural transitions in 
HSA when compelxed with drug, which may be attributed to their different binding behavior 
in presence of drug i.e. their binding is not affected or least affected by the presence of 
ganciclovir unlike that of Zn*^  and Cd"^ .^ Furthermore, secondary structure calculations based 
on CD data suggest that free HSA has a high a-helix content, 56%, p-sheet 17%, turn 17%, 
and random coil 10% (Table 4.3), which is consistent with the literature report (Tian et al. 
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2005). Upon metal complexation, a major reduction of a-helix was observed from 54% free 
HSA to 40% in Cd*^  and 32% in Zn"^ .^ This decrease was more prominent in presence of 
ganciclovir i.e. HSA complexed with drug reduces a-helix to 53%, metal complexed with 
drug to 38% (with Cd""^  ) and 30% (with Za^) (Table 4.3). The major decrease in a-helix 
was accompanied by an increase in the P-sheets and random coil structures. The major 
reduction of the a-helix with an increase in the P-sheet and random coil was consistent with 
the FTIR results that showed reduction of a-helix and an increase of random coil and turn 
structure due to a partial protein unfolding (Fig. 4.13 and 4.14). 
Table 4.3 Effect of Cadmium and Zinc on the secondary structures in HSA and HSA 
complexed with geinciclovir 
Secondary structures 
a-helix P-sheet' turns' random coil" 
CDSSTR' K2D"' 
HSA 56% 54% 17% 17% 10% 
HSA-Cd"' 40% 42% 24% 20% 16% 
HSA-Zn*^ 32% 31% 26% 25% 17% 
HSA-GA2 53% 52% 25% 14% 8% 
HSA-GA2-Cd^^ 38% 34% 30% 28% 4% 
HSA-GA2-Zn*^ 30% 28% 37% 32% 1% 
'calculated by CDSSTR software 
' calculated by K2D software 
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4.3.2.3 FTIR Spectroscopy 
Amide I and Amide II bands (1700-1500 cm"') of IR spectra have been extensively used in 
the characterization of chemical composition and conformational studies of proteins. 
Particularly, Amide I (1690-1620 cm'') reflects an almost pure vibrational character, since it 
consists mainly of the carbonyl stretching vibration mode of the peptide bond. Therefore, it 
has a well-recognized potential in protein secondary structure studies (Kang et al. 2004). To 
test whether the interaction of HSA with metal species produces conformational changes in 
the native HSA protein, Amide 1 and II bands of FT-IR/ATR spectra of protein and their 
metal complexes in absence (Fig.4.13) and presence of ganciclovir (Fig.4.14) were analyzed. 
The main spectral features of native HSA was characterized by a strong Amide 1 band at 1654 
























Wavenumber (cm'^ ) 
1500 
Figure 4.13 FT-IR spectra showing Amide I and Amide II bands in the region of 1800-1400 cm' of 
hydrated films (pH 7.4) for HSA, and difference spectra of metal complexes obtained 
after 1 hr incubation time in Tris -HC! buffer, pH 7.4 solution. 
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The location of these bands indicates that HSA secondary structure was dominated, as it has 
previously been reported, by a-helix conformation (Froehlich et al. 2009). The interaction of 
metal species like arsenic, selenium, lead, cadmiimi and zinc with native HSA shows that low 
concentrations of these metal species did not produce significant changes on HSA structure 
(data not shown). The FT-IR spectroscopy studies revealed that under our experimental 
conditions, metal binidng produces detectable spectral changes associated to HSA secondary 
structure. Incubations with metal species under physiological conditions indicated in methods, 
produced small shifts of the typical 1654 cm"' band present in HSA spectrum towards lower 
frequencies (1654 for Cd""^  and 1655 cm'' for Zn^^ As^^ Se^^ and Pb^ )^ (Fig. 4.13). The 
shoulder observed in HSA spectrum at 1547 cm"' appeared at 1548cm'' for Se^ ^ complexes 
and its intensity almost vanishes for As^ ^ and Pb^^ ion compounds. Furthermore, amide II 
band at 1547 cm'' in native HSA shifted to 1544 cm'' for cadmium ions. 
HSA:GA2 
1700 1600 
Wavenumber (cm'^ ) 
1500 
Figure 4.14 FT-IR spectra showing Amide I and Amide H bands in the region of 1800-1400 cm ' of 
hydrated films (pH 7.4) for HSA complexed with ganciclovir, and difference spectra of 
metal complexes obtained after Ihr incubation time in Tris-HCl buffer, pH 7.4 solution. 
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The difference spectra shows several positive and negative derivative features in the amide I 
region (1700-1600 cm'') and amide II region (near 1550 cm"') of the spectra which were 
explored in order to analyze structural variation on Zn"^ ^ and Cd*^  ion complexation and 
binding mode. Fig. 4.13 and 4.14 shows readily identifiable trends (1) there was obvious 
decrease of the intensities of the amide I bands especially in between the 1690-1622 cm'' 
region both in absence and presence of drug and (2) the amide I shifts from lower to higher 
frequency with the addition of Zn^^  and Cd"^ ^ ions. These features indicate that the secondary 
structure of HSA molecule changes upon binding with ganciclovir which further on changes 
due to binding of Zn*^  and Cd"^ ^ ions due to increase in P-sheet and turn structures. These 
results show that the HSA molecule undergoes conformational transitions from a-helix to (3-
sheet and turn species (Fig. 4.13 and 4.14). Therefore, it may be concluded that the Zn^' and 
Cd*^ ion binding occurs mainly through the protein carbonyl groups. We observed emergence 
of positive features for Cd*^  at about 1596, 1573 cm"' (Fig. 4.13) in absence and 1592. 1548 
cm' (Fig. 4.14) in presence of drug. While for Zn these features emerged at 1593, 1577 and 
1555 cm"' in absence (Fig. 4.13) and 1553 cm'' (Fig. 4.14) in presence of drug. These intensity 
variations of amide II band indicates that Zn and Cd ions binding was also through C-N 
groups. The observed decrease in intensity of the amide I band at 1654 in the spectra of the 
metal-protein and metal-drug-protein complexes suggests a major reduction of protein a-
helical structure at high metal concentrations. Similar infrsired spectral changes were also 
observed for protein amide I band in several ligand-HSA complexes, where major protein 
conformational changes occurred (Ahmed et al. 2006) 
Fourier self deconvulation of HSA in Tris-HCl buffer solution and metal complexes FT-IR 
spectra were analyzed in order to perform a quantitative analysis of the corresponding 
secondary structures in Amide I region. Deconvulated spectra of HSA showed a strong peak in 
helical region and other peak positions were being indicated on spectra itself (Fig. 4.15 and 
4.16). The percentages of the different secondary structural elements obtained were in 
agreement with several previously reported studies, using different techniques such as Raman 
spectroscopy (Lippert et al. 1976) circular dichroism (Rawel et al. 2002) and X-ray 
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crystallographic studies (Carter et al. 1989) in which a high percentage of a-helix conformation 
in the native protein was reported. A quantitative analysis of the secondary structure was 
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Figure 4.15 Fourier Self deconvulated spectra in amide I region of HSA and its metal complexes in 
Tris HCl Buffer solution in absence of ganciclovir. The secondary structure determination 
by curve fitting procedure is indicated. 
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Figure 4.16 Fourier Self deconvulated spectra in amide I region of Free HSA and its metal 
complexes in Tris-HCl Buffer solution in presence of ganciclovir. The secondary 
structure determination by curve fitting procedure is indicated. 
The drastic reduction observed in a-helix conformation and the significant enhancement in 
disordered structures and P conformations in relation to HSA native structure were consistent 
with the hypothesis of the existence of a strong interaction between cadmium (Cd^^) and zinc 
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(Zn* )^ species and HSA. The various contributions to the secondary structure were indicated in 
the spectra and were calculated considering the following minimums: 1675 cm"' for P 
antiparallel, 1639 cm'' for random coil and 1616 cm'' for P-sheet structures. It is important to 
note that these latter bands have a minor contribution to the secondary structure of HSA in the 
presence of metal species. Furthermore, the absence of the 1630 cm"' is indicating strong 
structural changes involving the loss of solvated helix and the feasible formation of compact 
hydrophobic cores in HSA-metal complexes. The major reduction of the a-helix with an 
increase in the yff-sheet and random was consistent with the CD results that showed reduction of 
a-helix and an increase of random coil and turn structure due to a partial protein unfolding 
(Tables 4.3). 
4.4 Discussion 
Albumin contains several metal-binding sites with clear specificities for different metal ions. 
HSA has been proposed to be involved in metal ion transport and has a variety of metal sites 
with different specificities (Bal et al. 1998; Martins and Drakenberg 1982). Four different 
binding sites can be readily distinguished (Scheme 4.1). The best-characterized metal site on 
albumin is that for Cu^^ and Ni*^ at the N terminus (Sadler et al. 1994). This motif exists in 
different native peptides and proteins and was dubbed the amino-terminal Cu^ ,^ Ni"*^^ binding 
(ATCUN) motif (Harford and Sarkar 1997). The second binding site is at cys 34 and third and 
fourth metal-binding site are called sites A and B, demonstrating the existence of two strong 
Cd"^ ^ binding sites (Goumakos et al. 1991; Martins and Drakenberg 1982; Sadler and Viles 
1996). As a summary, the different sites are given in Scheme 4.1. We refer to the different 
binding sites as the N-terminal site, site A, site B, and the cysteine-binding site. It was 
remarkable that proposed Cd"^ ^ and Zn^ site lies at the interface of domain I (His-67 and Asn-
99) and II (His-247 and Asp-249) involving small movements of the four ligand residues. His-
67 was situated at the N-terminal end of helix 4 and Asn-99 is at the N terminal end of helix 6. 
His-247 is at the C-terminal end of helix 13, and Asp-249 was situated in the loop connecting 
helices 13 and 14 in domain II (Stewart et al. 2003). 
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Binding site of Cd^ "^  and Zn^ ^ 
at the interface of domain I 
and II 
Scheme 4.1 Scheme of the metal-binding sites in HSA: N terminal site, site A with His 67 as a 
ligand; site B, so far not localized; site with the ligand cys 34. Cd '^ and Zn^ bind to site 
A (high affinity). Cd"^^ also binds at site B (low affinity). 
Previous reports suggested the involvement of His residues, Cys 34 in the binding of Cd^ and 
Zn to albumin (Goumakos et al. 1991; Yongqia et al. 1992; Masuoka et al. 1993; Pettit and 
Pettit 1993). These data suggest strongly that Cd and Zn cause similar protein 
conformational changes on binding and were consistent with them sharing a common His-rich 
binding site. It has been proposed that the metal ion binding site involves at least two histidine 
ligands (Sadler and Viles 1996). HSA possess strong binding sites for Cd^^ and Zn^^ and 
plays a major role in transport of these essential elements especially (Zn^^) in blood and 
delivery to cells and tissues (Peters 1996; Paterson 1991; Bobilya et al. 1993). 
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Domain III 
Domain I 
Cd*^ and Zvt^ binding 
site is located at the 
interface of Domian I 
and II 
Domain 11 
Figure 4.17 Proposed Cd"" and ZvC^ site in HSA. (A) Domain structure of albumin (PDB ID code 
1A06): domain I is colored red (residues 1-181); domain II is blue (residues 188-373); 
domain III is green (residues 380-571), and connecting helices are the same color as the 
preceding domain. The ligand atoms for Cd"^ ^ and Zn^ are highlighted in yellow. 
Here, we have studied metal binding in absence and presence of anticancerous drug 
ganciclovir thereby highlighting the problems associated with cancer causing heavy 
environmental pollutants when they formed complexes with serum albumin. We observed that 
among all the five metals monitored, mostly the conformational changes of Zn^' and Cd^ 
binding sites were altered. The binding site for ganciclovir was at domain IIA i.e. sudlow site 
I and involves mainly hydrophobic amino acid residues. The conformational changes induced 
due to the binding of drug at site I might triggers an alteration in the binding of metal ions 
(Zn^^ and Cd^^) at site A (Fig. 4.17). Thus, we can conclude that binding of ganciclovir to 
HSA could provide a strategy against hazardous effects of metal ions. It will be of interest to 
explore the possible consequences of the interactive binding of Zn^ ,^ Cd^^ and ganciclovir to 
albumin. The proposed alteration of the Zn^^ and Cd^^ binding site in human albumin by 
ganciclovir is an intriguing example of a mutual interaction between a drug and essential 
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might be possible to exploit this interaction in drug design and therapy. The observations 
described above raise the question of the significance of the allosteric relationship between 
metal and drug binding to albumins. 
4.5 Conclusion 
The effect of interactions between heavy environmental pollutants with HSA in presence and 
absence of anticancerous drug ganciclovir provides useftil biochemical basis for further 
understanding of the toxicological effects of metal species. Ganciclovir is considered a 
potential human carcinogen and mutagen. It is also considered likely to cause inhibition of 
spermatogenesis. This drug is known to effective against treatment of prostate cancer. Thus, it 
is used judiciously and handled as a cytotoxic drug in the clinical setting. The heavy metals 
we have explored are well probable human carcinogens as categorized by Internationa! 
agency for research on cancer. Especially arsenic (suppressive influence on spermatogenesis, 
gonadotrophin and testosterone release), lead, cadmium (kidney damage and prostate cancer) 
and zinc (skin cancer) are responsible for carcinogenic response in human body. Our results 
depicted altered conformational changes in the binding of cadmium and zinc at site A in 
presence of HSA-GA2 complex. We speculate that the binding of drug at domain 11 (drug site 
I) induces switch at domain I and II interface which weakens the interaction of cadmium and 
zinc ions. Thus, ganciclovir could provide a combating effect especially against prostate and 
skin cancers as it could shields site A from binding of cadmium and zinc ions (well known 
carcinogens in human body) respectively. Taking these considerations together, we 
hypothesize that the zinc-binding affinity of albumin might be altered during conditions when 
ganciclovir would be supplied externally. This might have functional significance of metal 
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Abstract 
The human serum albumin is known to undergo N ^ F (neutral to fast moving) isomerization between pH 7 and 3.5. The 
N ;=i F isomerization involves unfolding and separation of domain III from rest of the molecule. The urea denaturation of N isomer 
of HSA shows two step three state transition with accumulation of an intermediate state around 4.8-5.2 M urea concentration. 
While urea induced unfolding transition of F isomer of HSA does not show the intermediate state observed during unfolding of 
N isomer. Therefore, it provides direct evidence that the formation of intermediate in the unfolding transition of HSA involves 
unfolding of domain III. Although urea induced unfolding of F isomer of HSA appears to be an one step process, but no coinci-
dence between the equilibrium transitions monitored by tryptophanyl fluorescence, tyrosyl fluorescence, far-UV CD and near-UV 
CD spectroscopic techniques provides decisive evidence that unfolding of F isomer of HSA is not a two state process. An interme-
diate state that retained significant amount of secondary structure but no tertiary structure has been identified (around 4.4 M urea) 
in the unfolding pathway of F isomer. The emission of Trp-214 (located in domain II) and its mode of quenching by acrylamide and 
binding of chloroform indicate that unfolding of F isomer start from domain II (from 0.4 M urea). But at higher urea concentration 
(above 1.6 M) both the domain unfold simultaneously and the protein acquire random coil structure around 8.0 M urea. Further 
much higher K,y of NATA (17.2) than completely denatured F isomer (5.45) of HSA (8.0 M urea) suggests the existence of residual 
tertiary contacts within local regions in random coil conformation (probably around lone Trp-214). 
© 2005 Elsevier Inc. All rights reserved. 
Keywords: N s=: F isomerization; Urea denaturation; Chloroform binding; Multidomain protein; Human serum albumin 
Over the past four decades, much research has been 
focused on two central questions: what are the determi-
nants of the protein structures, and how does a polypep-
tide fold to its unique biologically active state? Folding 
of a protein in in vitro is likely to differ in many details 
from that in the cell. However, one feature, which is 
common in both in vitro and in vivo folding, is the exis-
tence of the intermediate conformational state on the 
folding-unfolding pathway [1,2]. Recent advances in 
biophysical techniques [3,4] have shown the presence 
of stable intermediate conformational states in a number 
Corresponding author. Fax: -1-91 571 2721776. 
E-mail addresses: rizwanhkhan@hotmail.coni, 
yahoo.com (R.H. Khan). 
rizwanhkhanl@ 
of proteins [5-8]. There has been considerable interest in 
characterizing these partially folded states for gaining an 
insight into the possible determinants of the protein 
folds and the mechanism of protein folding [9-14]. The 
folding process is even more complex in multidomain 
proteins where each domain may be capable to un-
fold/refold independently and interdomain interactions 
may affect the overall folding topology of the proteins 
[15-17]. 
Human serum albumin (HSA)' is a monomeric, mul-
ti-domain protein of 66.5 IcDa. It consists of three 
' Abbreviations used: HSA, human serum albumin; MRE, mean 
residue ellipticity; 1 state, intermediate state; 
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Free energy change 
A B S T R A C T 
This stutJy was undertaken to investigate the influence of fatty acid binding on the unfolding of HSA 
and how the fatty acid molecules can influence and/or compete with other ligand molecules bound to 
the protein. The equilibrium unfolding of fatted and fatty acid free HSA was measured by overlapping of 
unfolding transition curves monitored by different probes for secondary and tertiary structure and deter-
mining changes in free energy of unfolding. Proteins stability was studied by fluorescence spectroscopy, 
whereas conformational changes were detected by circular dichroism techniques. We have suggested a 
"molten globule" like intermediate state of HSA at a fairly high concentration of GnHCI (3.2 for fatty acid 
free and 3.6 for fatted). The free energy of stabilization (AC[J'°) in the presence of fatty acid was found to 
be SOOcalmol"'. We also analyze the effects of fatty acid on binding of ligands using spectroscopic tech-
nique and reported the equilibrium constants and free energies obtained from the binding and unfolding 
experiments. 
© 2008 Elsevier B.V. All rights reserved. 
1. Introduction 
Human serum albumin (HSA) is a highly abundant serum pro-
tein (0.6 mM) that comprises 50-60% of the total plasma protein in 
humans. In the bloodstream and tissue fluids, HSA serves as a vehi-
cle for the transport of several endogenous compounds including 
unesterified fatty acids (FA), hemin, bilirubin and diazepam, all of 
which bind with high affinity [1,2). 
Albumin is the primary transporter for delivering FA to and from 
the tissues according to metabolic demands and possesses at least 
seven binding sites for this ligand. High-resolution crystal struc-
tures of FA/HSA complexes revealed a total of seven binding sites 
distributed heterogeneously throughout the protein and shared 
by medium-chain fatty acids and saturated, monounsaturated or 
polyunsaturated long-chain fatty acids [3-5]. Under normal physi-
ological conditions, HSA carries around 0.1 -2 mol of fatty acid per 
mole protein although the molar ratio of FA/HSA can rise to much 
higher levels in the microvasculature during fasting or extreme 
exercise (6-10). Albumin also binds a variety of drug molecules; 
a property that can have profound effects on their pharmacokinet-
ics and pharmacodynamics and has long been of interest to the 
pharmaceutical industry [11-15]. 
* Corresponding author. Tel.: +91 571 2720388: fax: +91 571 2721776. 
E-mail addresses: rizwanhkhaR@hotmail.com, rizwanhkhanl@yahoo.com 
(R.H. Khan). 
0141-8130/J - see front matter C 2008 Elsevier B.V. All rights reserved. 
doi:10.1016/j.ijbiomac.2008.03.004 
The presence of multiple binding sites on HSA for FA and other 
endogenous and exogenous small molecules makes it difficult to 
assess interactions, whether competitive or cooperative, between 
different ligands bound to the protein. However, it is important 
to address this issue in order to obtain a fuller description of 
the ligand-binding properties of HSA. Crystallographic analyses 
of HSA revealed that the 585 amino acid residue monomer is a 
heart-shaped molecule containing three structurally homologous 
a-helical domains [16-18]. In several disease states, such as bac-
terial infection, diabetes mellitus. and stress, the fatty acid levels 
are found to increase remarkably. Under such circumstances, the 
fatty acid modulates the ligand binding properties of HSA by induc-
ing conformational changes in the binding sites I and II. Thereby, 
understanding HSA-fatty acid interactions is of major clinical and 
pharmaceutical importance. 
HSA undergoes a two-step denaturation transition in the pres-
ence of pH as well as by chemical denaturants [19-21 [.The two-step 
transition and formation of intermediate has been attributed to 
denaturation and/or separation of domain 111 [20.22 j . In more recent 
studies on the heat denaturation of human serum albumin (HSA) 
it has been found that, at sub saturating levels, bound fatty acids 
redistribute during the denaturation process and produce hetero-
geneous albumin populations [23-25J. In order to determine the 
role of bound fatty acids in HSA denaturation, we now aim to 
GnHCI-induced denaturation of completely defatted HSA (fatty acid 
free) and HSA containing 6-mol palmitic acid/mol HSA (fatted). In 
order to advance our understanding of the ligand binding prop-
ISSN 0006-2979, Biochemistry (Moscow), 2009, Vol. 74, No. 12, pp. 1337-1343. & Pleiades Hublishing, Ltd., 2009. 
Published in Russian in Biokhlmlya, 2009. Vol. 74. No. 12, pp. 1642-1649. 
Originally published In Biochemistry (Moscow) On-Llne Papers In Press, as Manuscript BM09-098, November S, 2009. 
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Unusual Stability against Urea at Neutral pH 
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Abstract—Equilibrium unfolding of stem bromelain (SB) with urea as a denaturant has been monitored as a function of pH 
using circular dichroism and fluorescence emission spectroscopy. Urea-induced denaturation studies at pH 4.5 showed that 
SB unfolds through a two-state mechanism and yields AC (free energy difference between the fully folded and unfolded 
forms) of-5.0 kcal/mol and C^ (midpoint of the unfolding transition) of-6.5 M at 25°C. \fery high concentration of urea 
(9.5 M) provides unusual stability to the protein with no more structural loss and transition to a completely unfolded state. 
DOI: I0.II34/S0006297909120062 
Key viords: stem bromelain, urea denaturation, protein stability 
Denaturation studies have long been used to eluci-
date the folding-unfolding transitions in proteins. They 
have contributed considerably to the understanding of the 
role of various stabilizing and destabilizing forces that are 
responsible for their unique folded structure in solution 
[1-3]. This helps us to elucidate the molecular mecha-
nism of the spontaneous folding of proteins from a ran-
dom polypeptide chains to a well-ordered native confor-
mation. Results of i/i vitro refolding experiments as well as 
theoretical considerations suggest that folding of large 
proteins is a sequential hierarchical process, in which 
protein folding proceeds according to the established 
hieiBrchy of the native structure, i.e. involving secondary 
and tertiary structures [4, 5]. The partially folded inter-
mediates can be made to accumulate in equilibrium by 
mild concentrations of chemical denaturants, low pH, 
covalent trapping, or by protein engineering [6]. 
Stem bromelain (SB) belongs to the (a + p)-protein 
class as other cysteine proteinases do, and the highly sim-
ilar amino acid sequences of papain [7], actinidin [8], 
proteinase fi [9, 10], chymopapain [11], and SB |12] 
indicate a common fold. This has been confirmed for the 
first three proteinases by detailed X-ray diffraction studies 
113-15]. These proteins are rich in hydrophobic and 
Abbreviations: CD, circular dichroism; D, denatured state; F, 
folded state; I, intermediate state; MRE, mean residue elliptic-
ity; SB, stem bromelain. 
* To whom correspondence should be addressed. 
uncharged amino acid residues and contain only 16-18% 
charged amino acid residues. X-Ray diffraction studies on 
these proteins reveal that the entire polypeptide chain 
folds into two domains, L and R. The domains interact 
with each other through hydrogen bonds, hydrophobic 
interactions, and salt bridges, in which residues from both 
domains participate [12-16]. 
\kTy little information about the general folding 
aspects of plant cysteine proteases is available. Extensive 
studies on the folding of papain [17, 18] as well as other 
cysteine proteases (procerain and ervatamin C) have been 
carried out by the group of Jagannadham [19-26]. They 
have demonstrated that cysteine proteases unfold through 
an intermediate state. On the other hand, the thermal 
denaturation of bromelain, as studied by means of circu-
lar dichroism (CD) and differential scanning calorimetry, 
is completely irreversible and apparently follows a simple 
two-state mechanism of the F -D type (where F is folded 
and D is denatured states) [2]. The SB molecule, when 
exposed to increasing alkalinity, exhibits conformational 
response through at least three different stages leading to 
the ionization of Tyr hydroxyl groups [27]. Folding stud-
ies on more cysteine proteases from different sources 
would certainly help in generalizing the folding behavior 
of cysteine proteases as well as complementing the pro-
posed mechanism. With this view, unfolding studies of SB 
have been initiated. In our eariier studies on the folding of 
SB, a partially folded intermediate was detected at 
pH 2.0, which refolds to molten globule state around 
1337 
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Synopsis 
This is the first report of its kind that welt demonstrates that a lectin from Phytolacca americana [Pa-2 (P. americana 
lectin-2)] can also be intrinsically unordered, based on the results obtained by CD, tryptophan fluorescence, ANS 
{8-anilinonaphthalene-l-sulfonic acid) binding, acrylamide quenching, DLS (dynamic light scattenng) and its amino 
acid composition database analyses. Pa-2 is an acidic monomeric lectin and acquires random coil conformation at 
neutral pH without any regular secondary structure. As confirmed by different spectroscopic techniques, on lowering 
the pH, some secondary structures, predominantly a-helices, are detected by far-UV CD that adopt a marginally 
stable partially folded collapsed conformation possessing the characteristics of a premolten globule state. It is in 
accordance with coil-helix transition that is commonly observed when these intrinsically unordered proteins interact 
with their partner molecules in vivo. 











The complete programme of native conformation is locked in the 
primary sequence of a polypeptide chain and native conformation 
of a protein is the structure with lowest total free energy state. 
The process of minimizing free energy may not be obligatory, as 
some portions of a molecule may be folded in such a manner 
as to be favoured kinetically, but actually not yielding the lowest 
free energy. Native protein or its functional regions can exist in 
any one of the four thermodynamic states: ordered forms, molten 
globules, premolten globules and unordered random coils. In 
this view, a particular function can depend on any one of these 
states [1]. Besides, it has already been discovered that in protein 
some non-structured segments play an important role in its crucial 
function. Therefore those proteins that are functional and natively 
have any other conformation than the regular ordered one are 
known as lUP [intrinsically unordered protein; also known as 
IDP (intrinsically disordered protein) or NUP (natively unfolded 
protein)!. 
In recapitulation, absolute denaturation of an ordered pro-
tein leads to an unordered random coil. Moreover, during this 
denaturation pathway, a transient intermediate or a partially un-
folded state, between ordered and denatured random coil states, 
is observed. This intermediate exhibits side chains with motional 
characteristics more like those of the random coil but with a 
backbone secondary structure like that of the ordered state. Ptit-
syn and Uversky [2] termed it 'molten globule', which represents 
a third thermodynamically stable and functional state for pro-
teins. Hence, the classical structure-function paradigm that 
protein should be ordered in order to be biologically active should 
go-
Broadly speaking, there are ten methods, in practice, to char-
acterize intrinsic disordemess of a given sequence [3]. One is 
N " - H ' heteronuclear NOE (nuclear Overhauser effect) data ana-
lysis, where an amino acid sequence gives positive values for 
ordered regions due to slower tumbling and negative values for 
disordered regions because of more rapid tumbling [4]. Also 
from protein stiiictures determined by X-ray crystallography, 
disordemess at any region in the sequence leads to missing 
t ANS, G-anllinonaphthalene'1-sulfanlc acid; DLS. dynamic light scattering: fn average fractional hellcity: GdmCI. guanidinium chlonde. GRAVY, grand average o( 
hydropathidty; <H>, mean normalized hydroptwtJicity. <H>b. boundary mean hydroptwblcity; lOP intrinsically disordered protein; IPMG. premolten globule-lil<e intermediate state, lUI? 
intrinsically unordered protein; MRE, mean residue elllpticity; NRC. random coil native state; Pa-2, Phytolacca americana lc-'in-2, PWM, pol<ev«eed mitogen, fi^, hydrodynamic rad'i Rs 
Stoi«s radius; RIS, Rayleigh light scattenng, UQ, GdmCMnduced unfolded state. 
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Ligand Binding Strategies of Human Serum Albumin: 
How Can the Cargo be Utilized? 
ANKITA VARSHNEY,' PRIYANKAR SEN.' EJAZ AHMAD,' MOHD. REHAN,^  
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'Interdisciplinary Biotechnology Unit, Aligarh Muslim University, Aligarh. India 
^Centre for Computational Biology & Bioinfiirmatics, School of Information Technology, 
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ABSTRACT Human serum albumin (HSA), being the most abundant carrier protein 
in blood and a modem day clinical tool for drug delivery, attracts high attention among 
biologists. Hence, its unfolding/refolding strategies and exogenous/endogenous ligand 
binding preference are of immense use in therapeutics and clinical biochemistry. 
Among its fellow proteins albumin is known to carry almost every small molecule. 
Thus, it is a potential contender for being a molecular cargo/or nanovehicle for clinical, 
biophysical and industrial purposes. Nonetheless, its structure and fimction are largely 
regulated by various chemical and physical factors to accommodate HSA to its func-
tional purpose. This multifunctional protein also possesses enzymatic properties which 
may be used to convert prodrugs to active therapeutics. This review aims to highlight 
airrent overview on the binding strategies of protein to various ligands that may be 
expected to lead to significant clinical applications. Chirality 22:77-87, 2010. ® 2009 
WileyUss, Lie. 
KEYWORDS: human serum albumin; ligand binding; enantioselectivity; clinical 
applications 
INTRODUCTION 
Human serum albumin (HSA) is an abundant, multifunc-
tional and nonglycosylated, negatively charged plasma 
protein, with ascribed ligand-binding and transport proper-
ties, antioxidant ftinctions, and enzymatic activities.' The 
protein is a monomer of 585 amino acid residue having 
three homologous a-helical domains, named domain I, do-
main II and domain III.^  Each domain contains 10 helices 
and is divided into antiparallel six-helix and four-helix sub-
domains (A and B). Albumin is the most abundant serum 
protein that serves as a transport vehicle for several en-
dogenous compounds including fetty acids (FA), hemin, 
bilirubin, and tryptophan, all of which bind with high affin-
ity."''' For a long time, albumin has attracted the attention 
of the pharmaceutical industry because of its ability to 
bind a wide variety of drug molecules and alter their phar-
macokinetic parameters.'' Although most ligands for albu-
min are hydrophobic or anionic but heavy metals are also 
known to bind to the protein.''"'^  Very few cationic drugs 
are also known to bind with HSA This versatility, which 
arises from the presence of multiple binding sites, which 
are dependent on various environmental factors like pH, 
temperature and ionic strength, makes it far from trivicJ to 
obtain detailed information on ligand binding. It has been 
especially difficult to assess the interactions between dif-
ferent ligands for the protein even though it is a key for 
© 2009 Wiley-Liss. Inc. 
our understanding of the role of HSA in vivo. Simultane-
ous binding of several ligands to HSA molecule is a com-
plex situation in which the protein recognizes individual 
ligands by specific and nonspecific interactions. This rec-
ognition is in turn strongly dependent on the microenvir-
onment of the protein as it changes its conformation 
in vivo. In physiological condition the protein experienced 
various environments like pH, varying ionic strength, etc., 
which induces considerable changes in the native protein 
structure. Under such condition how it recognizes differ-
ent drug/ligand molecules is a challenging field of investi-
gation. Various binding and denaturation studies have 
shown to be a rapid and effective tool for the characteriza-
tion of albumin binding sites and their enantioselectivity, 
and for the study of the changes in the binding properties 
of the protein arising by interaction between different 
ligands. Here, we have reviewed two important aspects of 
serum albumin, binding and various factors affecting con-
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Abstract Keyhole limpet hemocyanin (KLH) is widely 
used as an immune stimulant and hapten carrier derived 
from a marine mollusc Megathura crenulata. To provide 
details of the stability and equilibrium of KLH, different 
intermediate species were investigated with a series of 
biophysical techniques: circular dichroism, binding of 
hydrophobic dye, l-anilino-8-naphthalene sulfonic acid, 
acrylamide-induced fluorescence quenching, thermal sta-
bility and dynamic light scattering. KLH in its native state 
at pH 7.4 exists in the stable didecameric form with, 
hydrodynamic radii (/?h) of 28.22 nm, which is approxi-
mately equal to a molecular mass of 8.8 ± 0.6 MDa. The 
experimental results demonstrated the presence J^ f two 
structurally distinct species in the conformational t r ^ ^ o n 
of KLH under acidic conditions. One s p e c i e s , ^ ^ l ^ ^ 
pH 2.8, characterized as decameric {\^ 
/?h = 22.02 nm), molten globule-like statg,^fiS 
accumulates at pH 1.2 and is characte 
(2.4 ± 0.8 MDa; /?h = 16.47 nm) 






manipulation of the oligomeric ^ t e s ] ^ ^ L ^ has provided 
data that correlate well with the l^^i^^igomeric forms 
obtained from total KLH form^ in vWb and extends our 
understanding of multimerJFormaBon by KLH. The results 
are of particular interest^ jin fi^t of tfte important role of the 
mechanistic pathway of pH-dependent structural changes 
A. Varshney ^j^g^^^Q Rabbani R. H. Khan (Kl) 
Interdiscipliiwy'Bicitechnology Unit, Aligarh Muslim 
University, M|^,"tJ5^202002, India 
e-mail: tizwanhkTO9@h0tmail.com; rizwanhkhanl@gmail.com 
V. Kumar - ^ ^ ^ ^ v 
Department of Biophysics. All India Institute of Medical 
Sciences, Ansari Nagar, New Delhi 110029, India 
of He stability ipt^. biochemical and medical applications 
of these respir^tqiy- proteins. 
Keywords Acidic |)H • Decamer state 
DynaiTUC^^^ scattering • Keyhole limpet hemocyanin 
MuLti^ tenc protein • Tetramer state 
Abbreviations 
AN^'.,, 1 -Anilino-8-naphthalenesulfonate 
CD * Circular dichroism 
DLS Dynamic light scattering 
He Hemocyanin 
KLH Keyhole limpet hemocyanin 
MG Molten globule state 
MRE Mean residue ellipticity 
PFC Packed folded conformational state 
Introduction 
Interest in the molluscan hemocyanins is well established, 
based primarily on the unique immunostimulatory prop-
erties of keyhole limpet hemocyanin (KLH) from the 
marine mollusc Megathura crenulata. These extracellular 
biopolymers are oxygen carrier copper glycoproteins, 
forming freely dissolved aggregates in the hemolymph 
of molluscs with extremely high M^ (comparable in size 
to ribosomes or small viruses) and complex quaternary 
structure (Harris et al. 2000; Sterner and Decker 1994). 
They differ fundamentally from arthropod hemocyanins 
(Martin et al. 2007; Decker et al. 2007) and are extremely 
large proteins (6-7.5 million daltons) that occur either as 
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Stabilization of Folding Intermediate States from Alkaline Induced Un-
folded State of Bovine Serum Fetuin in Trifluoroethanol and Acetonitrile 
Basir Ahmad, Zeyaul Islam, Ankita Varshney and Rizwan Hasan Khan* 
Abstract: The conformation of bovine serum fetuin (BSF) was examined over the pH 7.0-12.9 regions by circular dichro-
ism, intrinsic fluorescence and ANS binding. We observed that at higher pH, BSF exists in alkaline unfolded state. Our 
results provided evidence that correlates simultaneous formation of secondary structure followed by accumulation of hy-
drophobic clusters. 
Keywords: Acetonitrile, alkali denaturation, bovitie serum fetuin, circular dichroism, trifluoroethanol. 
INTRODUCTION 
Over the past four decades, much research has been fo-
cused on two central questions: what are the determinants of 
the protein structures, and how does a polypeptide fold to its 
unique biologically active state? Folding of a protein in vitro 
is likely to differ in many details from that in the cell. How-
ever one feature, which is common in both in vitro and in 
vivo folding, is the existence of the intermediate conforma-
tional state on the folding-unfolding pathway [1, 2]. Recent 
advances in biophysical techniques [3-4] have shown the 
presence of stable intermediate conformational states in a 
number of proteins [5-8]. There has been considerable inter-
est in characterizing these partially folded states for gaining 
an insight into the possible determinants of the protein folds 
and the mechanism of protein folding [9-11]. 
Fetuin is a glycoprotein abundant in calf serum and found 
predominantly during fetal stage. Experiments performed on 
the serum isolated from calves of different ages have shown 
that the amount of this globulin is highest in newly born 
calves and decreases with time. It is associated with the pe-
riod when the greatest building and development of the ani-
mal takes place. The carbohydrate portion of fetuin is made 
up of three branched heteropolysaccharide units. These units 
possess similar monosaccharide composition. The peptide 
portion consists of single chain with six-intrachain disulfide 
bridges [12]. Equivalent of fetuin in other mammalian spe-
cies is alpha 2-HS glycoprotein (AHSG) [13]. Fetuin is 
thought to play an important role in fetal development [13, 
14] and neonatal skeletal development [IS]. It is also impor-
tant for postnatal bone growth, remodeling and contributes to 
insulin resistance during normal pregnancy and gestational 
diabetes [16]. It has been shown that fetuin and various cyto-
kines have a developmentally regulated appearance and ex-
pression in the developing neocortex [13, 15]. A short 19-
amino-acid sequence of the transforming growth factors beta 
(TGF- beta) type-II receptor and in vitro fetuin binds to 
members of the TGF-beta family of cytokines. It has been 
suggested that fetuin is biologically significant antagonist of 
•Address correspondence to this author at the Interdisciplinary Biotechnol-
ogy Unit, Aligarh Muslim University, Aligarh - 202002, India; Tel: 91-
571-2720388; Fax: + 91-571-2721776; 
E-mails: rizwanhkhan@hotmail.com; rizwanhkhanl@yahoo.com 
these cytokines [14]. Thus, fetuin plays an important role in 
the overall development of the fetus. Any misfolding in this 
protein can have adverse effects on its functioning and its 
interaction with cells and other molecules leading to general 
development as well as brain development anomalies. The 
knowledge of its different structural aspects may prove to be 
useful in better understanding of folding pathways of fetuin. 
In the previous report from our lab on fetuin and asialofetuin, 
we have reported that MG state exist at pH 1.8, which has 
substantial amount of secondary structure and significantly 
disordered tertiary structure. This was inferred on the basis 
of circular dichroism spectra taken in the far as well as near 
UV region and fluorescence studies [17, 18] .Thermal stud-
ies in the far UV regions have shown that the secondary 
structure is quite stable and is resistant to high temperature 
while thermal spectra in the near UV region were indicative 
of cooperative unfolding at pH 7.0 and loss of cooperativity 
at pH 1.8, which again suggested the presence of MG state at 
this pH. Based on our previous results on the characteriza-
tion of MG state of BSF at low pH, we report here in a sys-
tematic way the conformational behavior of BSF in the alka-
line region and the effect of co-solvents like TFE and ATN 
on the alkali induced states of the BSF. One of the most well 
studied cosolvents that modify protein structure is alcohol. 
Alcohols are known to weaken non-local hydrophobic inter-
actions while promoting local polar interactions [19, 20]. 
Therefore, in many cases alcohol induced denaturation is 
accompanied by stabilization of the extended helices in 
which hydrophobic side chains are exposed but the polar 
amide groups are shielded from the solvent [21,22]. A recent 
report describes the existence of a native like p structure in 
the partially folded state of tendamistat induced by TFE [23]. 
Moreover alcohols induce significantly higher helical struc-
ture in a partially or completely unfolded protein as com-
pared to folded protein [24]. 
We have identified and characterized various partially 
folded states of BSF to examine the generality of existence 
of intermediate conformation of BSF, which can provide 
significant insight into the nature of protein folding pathway 
and the stability of the protein in alkali and organic condi-
tions. 
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